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ABSTRACT 
The emergence of antibiotic-resistant bacteria necessitates the discovery of new 
classes of antibiotics acting through novel mechanisms. The bacterial sliding clamp, 
also known as the DNA polymerase III β subunit, engages in multiple protein-protein 
interactions by recognizing conserved penta- or hexapeptide motifs in various binding 
partners during DNA replication and repair. The central role of the sliding clamp in 
DNA replication and repair make it an attractive antibiotic target. 
Protein-protein interactions based on linear motif (LM) recognition play roles in 
many cell regulatory processes. The E. coli sliding clamp uses a common surface pocket 
composed of two sub-sites (I and II) to interact with LMs in multiple binding partners. 
A structural and thermodynamic dissection of sliding clamp-LM recognition has been 
performed, providing support for a sequential binding model. According to the model, a 
hydrophobic C-terminal LM dipeptide sub-motif acts as an anchor to establish initial 
contacts within subsite I and this is followed by formation of a stabilizing hydrogen-
bonding network between the flanking LM residues and subsite II. Differential 
solvation/desolvation effects during positioning of the sub-motifs are proposed to act as 
drivers of sequential binding. This model provides general insights into linear motif 
recognition and should guide the design of small-molecule inhibitors of the E. coli 
sliding clamp. 
Following the study of the LM recognition, fragment-based screening against the E. 
coli sliding clamp using X-ray crystallography, was carried out. Screening 352 fragment 
compounds produced hits bound at one of the two LM-binding subsites (subsites I). 
These fragment compounds were estimated to have millimolar binding affinity to the E. 
coli sliding clamp. A number of small-molecule inhibitors were designed based on the 
x 
 
fragment hits, aided by molecular docking, and were found to bind to subsite I and 
inhibit LM-binding by the E. coli sliding clamp. They showed increased affinity at the 
micromolar level. From these, compounds with a tetrahydrocarbazole scaffold were 
chosen for lead development. A lead compound with tetrahydrocarbazole scaffold was 
designed to target both subsite I and subsite II. This work yielded a range of inhibitors 
with low-micromolar affinity with the potential to be a new class of antibiotics. 
This work reveals a sequential binding model of LM recognition by the E. coli 
sliding clamp. Fragment-based inhibitor design was carried out with the aim to find 
novel antibiotics with novel mechanism(s) of action. The inhibitor design improved the 
affinity from millimolar to low-micromolar level, providing a tetrahydrocarbazole 
scaffold with the potential for further optimization.  
xi 
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General Introduction 
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1.1 Antibiotic design targeting the protein-protein interaction network mediated 
by the bacterial sliding clamp  
The emergence of antibiotic-resistant bacteria represents a great challenge to 
medicinal chemistry2 and new classes of antibiotics with novel targets and modes of 
action are desperately needed.3-5 Targeting the bacterial DNA replication machinery is a 
validated strategy for producing clinically useful antibiotics, as evidenced by the highly 
successful quinolones (DNA gyrase inhibitors).6  
DNA replication in the three domains of life involve a ring-shaped clamp-like 
protein that encircles DNA and confers processivity to DNA replication.7-9 This 
mechanism was first discovered in Escherichia coli in which a homodimer, the β-
subunit of DNA polymerase III holoenzyme, was identified as a sliding clamp (SC).10 In 
DNA replication, the SC is loaded onto DNA by the clamp-loader complex (composed 
of Pol III δ, γ/τ and δ’ subunits)11-13 and confers high processivity upon the Pol III α 
subunit (the replicase) by acting as a mobile tether:14,15 The SCis loaded onto the primed 
DNA by the clamp loader complex and is subsequently released. The α subunit binds to 
the SC and catalyzes extension of the primer through incorporation of dNTPs using 
ssDNA as a template.  
The SC is involved in a variety of bacterial cellular events including DNA repair and 
recombination via interactions with DnaA,16 DNA polymerase I,7 II,17 III,18 IV19 and 
V20, DNA ligase7, MutS and MutL7,21, Hda,22 and UmuD23.  
The extensive range of interactions of the SC opens the possibility of targeting it in 
antibiotic development.24 It has been argued that the SC and another critical protein in 
DNA replication, single-stranded DNA binding protein (SSB), represent the most 
promising antibiotics targets in bacterial DNA replication.25 They both mediate complex 
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interaction networks but differ in the mechanism of molecular recognition: the SC 
contains a specific peptide-binding pocket for partner binding, whereas SSB contains a 
peptide motif recognized by its various binding partners. Inhibitor design efforts 
targeting SSB interactions have commenced.26,27 
The binding pocket of the bacterial SC is structurally conserved across bacterial 
species. The eukaryote homolog of the sliding clamp, the proliferating cell nuclear 
antigen (PCNA), shares no significant similarity at the amino acid sequence level, but 
its topology is conserved (see below).7 The high level of structural conservation of the 
SC across diverse organisms attests to the essential nature of the sliding clamp’s 
functions. 
Compounds that disrupt bacterial SC interactions could represent a new broad-
spectrum antibiotic. Development of resistance against such antibiotics is likely to 
present a substantial challenge to bacteria: bypassing this essential protein is unlikely 
and mutations in the binding site are expected to reduce the affinity of the target’s many 
physiological binding partners, rendering mutants non-viable. The work described in the 
thesis is aimed at developing small-molecule inhibitors that disrupt the protein-protein 
interaction mediated by the E. coli sliding clamp.  
1.2 The structure of bacterial sliding clamps 
The first crystal structure of any SC was that from E. coli (β subunit of the DNA 
polymerase III holoenzyme), solved by Kong and co-workers.28 The dimer displays C2 
symmetry, forming a ring with an outer diameter of approximately 80 Å and an inner 
diameter of approximately 35 Å, sufficient to accommodate dsDNA. Each monomer 
contains 3 copies of the “DNA-clamp” domain (domains I, II and III) consisting of two 
anti-parallel, 4-stranded β sheets and two α helices. Thus the clamp displays pseudo 6–
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fold symmetry (Figure 1.1). This architecture allows the SC to encircle duplex DNA 
and slide along it.28 This overall architecture is shared by PCNA although PCNA is a 
homotrimer with each monomer containing two DNA-clamp domains.29 
Burnouf and co-workers30 compared the sequences of bacterial SC homologues and 
found the residues showing over 40% identity, 13 residues are more than 80% 
conserved. Over the last two decades, structures of sliding clamps from various bacterial 
species have been solved (Figure 1.1; Table 1.1) and indeed they show conserved 
topology (Figure 1.1). A sequence alignment of the sliding clamps from nine bacterial 
species (five Gram-negative and four Gram-positive) is shown in Figure 1.2. This 
comparison suggests that the composition of the surface binding pocket is highly 
conserved (See below). 
The tertiary structures of sliding clamps differ slightly between Gram–positive and 
Gram–negative species31. Available SC crystal structures can be categorized into two 
classes: circular and elliptical (Figure 1.1a and b, respectively; Table 1). Escherichia 
coli and Thermotoga maritima are Gram–negative species and their sliding clamps have 
similar circular inner rings, as does Mycobacterium tuberculosis which may be 
considered to be neither Gram-positive nor Gram-negative but is evolutionarily closer to 
the latter.32 Eubacterium rectal, Streptococcus pyogenes and Streptococcus pneumoniae 
are Gram–positive and their sliding clamps both adopt elliptical shapes due to the α-
helices near the dimer interfaces being pulled away from the centre, while those distant 
to the dimer interface are pushed inward (Figure 1.1).  
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Table 1.1 Crystal  structures of bacterial DNA Pol III beta subunit (the sliding clamp). 
 
  
PDB 
code Species 
Space 
Group 
Unit cell 
a, b, c (Å)/α, β, γ (°) Mutation References 
2POL Escherichia coli P21 80.61, 68.35, 82.35/90, 114.26, 90 N/A 28 
2XUR Escherichia coli P21 79.98, 66.49, 81.70/90, 113.75, 90 G157C  33 
3PWE Escherichia coli P21 79.80, 67.36, 80.74/90, 114.16, 90 
R103C, I305C, C260S, 
C333S  
34 
3F1V Escherichia coli P1 40.84, 64.47, 72.11/73.83, 82.72, 83.76  H148A, Q149A, D150A, V151A, R152A  
35 
1MMI Escherichia coli P21 80.01, 66.60, 80.78/90, 114.02, 90 N/A 36 
3P16 Mycobacterium tuberculosis P21 88.05, 132.97, 113.78/90, 109.05, 90 N/A 37 
3T0P Eubacterium rectale C2 127.76, 95.56, 84.01/90, 115.94, 90 N/A To be published 
1VPK Thermotoga maritima P42212 91.70, 91.70, 111.46/90, 90, 90 N/A 
To be 
published 
2AVT Streptococcus pyogenes P21 79.04, 74.67, 82.78/90, 118.57, 90 N/A 31 
2AWA Streptococcus pneumoniae P21 94.06, 70.72, 135.44/90, 91.04, 90 N/A 
To be 
published 
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Figure 1.1 Superimposed crystal structures of the SC of Gram-negative bacteria (Red: E. coli and Yellow: T. maritima and Green: M. 
tuberculosis) (a) and Gram-positive bacteria (Blue: E. rectale, Cyan: S. pyogenes and Pink: S. pneumoniae) (b). The E. coli and S. pyogenes beta 
clamps are superimposed in (c). Arrows indicate the location of the dimer interface. 
  
a b c 
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Figure 1.2. Sequence alignment of sliding clamps from nine bacterial species. Residues comprising the surface binding pocket of the SC are 
highlighted in yellow. Numbering is based on the E. coli SC sequence. 
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1.3 The E. coli SC binding pocket and its interaction with peptidic ligands, binding 
ssDNA and small-molecule inhibitors 
1.3.1 The binding pocket of the E. coli SC and the peptidic ligands 
Studies found consensus sequences QL[S/D]LF and QLxLxF/L,18,38 in the sliding 
clamp's partner proteins. A number of crystal structures of the E. coli SC in complex 
with partner proteins or peptides derived from these partner proteins were solved. These 
peptide ligands uniformly bind to a common pocket on the surface of the SC (Figure 
1.3). This binding pocket consists of two subsites (Figure 1.4-1.7): subsite I (formed by 
residues S346, V360, V347, L177, P242, Y154, T172, L155, R152, G174 and M362) 
and subsite II (formed by residues M362, P363, N320, H175 and Y323).13,39 Burnouf 
and co-workers30 found that 7 of 13 residues that are located at the peptide-binding site 
are more than 80% conserved. This suggests that the SC binding sites are conserved 
across bacterial species (see also Figure 1.2). This hypothesis was supported by the 
later findings that the Mycobacterium tuberculosis SC binds two peptides derived from 
Pol III α subunit C-terminus of the same species37 and binding by the Streptococcus 
pyogenes SC of a Pol III δ-derived peptide.31 
The structure of the E. coli SC in complex with the 'little finger' domain of Y-family 
DNA polymerase IV, which binds to the SC with a C-terminal hexapeptide motif 
(QLVLGL) is shown in Figure 1.4.39 E. coli SC structures in complex with peptides 
derived from the Pol IV C-terminus (RQLVLGL),30 Pol III-α C-terminus 
(SEQVELEFD)40 and Pol II (GQLGLF)39 were solved and the consensus binding motifs 
observed (Figure 1.5-1.7).  
In all structures of SC/peptide complexes, a glutamine residue of the peptide is 
restrained by hydrogen bonds with a bridging water molecule and the backbone 
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carbonyl group of M362 of subsite II. A peptide leucine or valine residue is in 
hydrophobic contact with P363 of subsite II. Subsite II is connected to subsite I by a 
channel gated by residue M362 that separates the sub-sites.30 In this shallow channel is 
bound a glycine, valine, or glutamate residue. Subsite I hosts a leucine residue buried at 
the bottom of the pocket consisting of several hydrophobic residues: V360, V247 and 
L177. A phenylalanine or leucine residue occupies the rear of the subsite I, allowing one 
or two spacing residues between the leucine residue and the adjacent F or L residue. 
Where present, the spacing residue is not involved in the binding interaction. 
Recent work has shown different energetic contributions of the residues in the motif 
and highlighted the role of M362 as a gating residue between the two subsites.1 The LF 
portion of the motif occupies subsite I and contributes most of the energetic contribution 
to peptide binding as estimated by molecular dynamics simulation and molecular 
mechanics calculations.1 Previous biochemical studies suggested that the DLF tripeptide 
alone is capable of binding.18 
The in vivo effects of peptide-based inhibition of the SC are demonstrated by the 
polypeptides from bacteriophages Twort and G1, named as TwortORF168 and 
G1ORF240, the expression of which inhibited SC interactions and resulted in cell death 
in Staphylococcus aureus.41 Similarly, the expression of the plasmid-borne sliding 
clamp-binding peptides derived from the plasmid RK2 replication initiator protein 
(TrfA) is toxic to host E. coli cells.42 It was proposed that the TrfA-derived peptides 
physically interact with the SC via the N-terminal motif QLSLF.42 A deletion of the “LF” 
residues in this putative SC binding motif reversed the inhibitory effect of cell growth, 
DNA synthesis and filamentous phenotype.42 
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Mutational studies of the residues in or adjacent to the binding pocket of the E. coli 
SC have been carried out. A G157C mutation was introduced to the region close to the 
binding pocket. Cells containing the mutant displayed under-initiation of replication: SC 
concentration at the origin of replication was reduced.33 Mutating residues 148-152 
(located in domain II near the binding pocket) to alanine impairs clamp loading and 
retention on linear DNA in vitro, presumably by disrupting protein-DNA interactions.35 
 
 
 
 
Figure 1.3 Superimposed crystal structures of the E. coli SC (shown in pink)  in 
complex with DNA Pol IV (shown in blue) (PDB entry 1UNN). The grey rectangular 
square represent the binding area for the consensus motif. 
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Figure 1.4 Crystal structures of the E. coli SC bound to the little finger domain of DNA 
Pol IV (PDB entry 1UNN). The complexes are shown with the SC carbon atoms shaded 
white and with the DNA Pol IV carbon atoms colored grey (all other atoms in CPK 
colors). Dashed red lines represent H-bonds. A bridging water molecule is shown as a 
red sphere.  
 
Figure 1.5 Crystal structures of the E. coli SC bound to a C-terminal peptide from DNA 
Pol IV (PDB entry 1OK7). The complexes are shown with the SC carbon atoms shaded 
white and with the peptide carbon atoms colored grey (all other atoms in CPK colors). 
Dashed lines in red represent H-bonds. A bridging water molecule is shown as a red 
sphere. 
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Figure 1.6 Crystal structures of the E. coli SC bound with a Pol III alpha C-terminal 
peptide (PDB entry 3D1E), only the peptide residues in the SC binding pocket are 
shown for clarity. The complexes are shown with the SC carbon atoms shaded white 
and with the peptide carbon atoms colored grey (all other atoms in CPK colors). Dashed 
lines in red represent H-bonds. A bridging water molecule is shown as a red sphere. 
 
Figure 1.7 Crystal structures of the E. coli SC bound with a Pol II-derived peptide 
(PDB entry 3D1F), only the peptide residues in the SC binding pocket are shown for 
clarity. The complexes are shown with the SC carbon atoms shaded white and with the 
peptide carbon atoms colored grey (all other atoms in CPK colors). Dashed lines in red 
represent H-bonds. A bridging water molecule is shown as a red sphere. 
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Table 1.2 Crystal  structures of E. coli SC (DNA Pol III β subunit) with binding partners. 
PDB 
code 
Space 
Group 
Unit cell 
a, b, c (Å)/α, β, γ (°) Binding partner 
Ligand binding 
affinity References 
1OK7 P1 41.23, 65.22, 73.38/73.11, 85.58, 85.80 VTLLDPQMERQLVLGL 1.2 – 8 µM 30 
1UNN P21212 146.45, 70.12, 110.92/90, 90, 90 DNA Pol IV (243-351) N/A 39 
3D1F P32 65.78, 65.78, 209.47/90, 90, 120 Rh6G-SEQVELEFD 1.8  µM 40 
3D1E P1 40.14, 69.87, 73.12/112.89, 91.08, 99.28 Rh6G-TLMTGQLGLF 1.7  µM 40 
3BEP P1 40.20, 70.08, 73.87/113.28, 92.07, 99.36 dsDNA, ssDNA N/A 43 
3D1G P1 35.72, 79.39, 80.50/110.24, 100.58, 99.46 RU7 10  µM 40 
3QSB P21 79.18, 66.52, 83.12/90, 115.86, 90 Biphenyl small-molecule inhibitor 8.3 – 40  µM 44 
3Q4K P1 36.25, 80, 82.18/66.15, 74.94, 82.03 AcQChaDLpClF 0.16 – 13.9  µM 1 
3Q4L P1 34.84, 79.57, 81.64/65.28, 75.26, 82.22 AcQChaDLdiClF 0.08 – 17  µM 1 
3Q4J P1 38.09, 132.87, 137.27/62.73, 88.51, 89.77 AcQLDLF 1.1 – 1.2  µM 1 
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1.3.2 Chemically modified peptides with increased SC affinity  
Peptides derived from the Q1L2D3L4F5 motif (subscripts denoting position) were 
developed to enhance their interactions with the SC and resulted in increased potency.1 
An acetylated N-terminus (Ac0Q1L2D3L4F5) increased the IC50 (determined as the 
inhibition of a fluorescently-labelled peptide binding to the E. coli sliding clamp) of the 
non-acetylated form from 12 µM to 1.1 µM. Two residues were chosen by Wolff and 
the co-authors for making derivatives: the leucine residue at subsite II (L2) and the 
phenylalanine residue at subsite I (F5) (Figure 1.8-1.10). Since residue Q1 bound to 
subsite I is conserved, and residue D3 was not expected to contribute greatly to the 
affinity (as calculated by molecular mechanics) they were not modified. The authors 
replaced the L2 side chain with a cyclohexyl-L-alanyl group (Cha) that occupies the 
upper part of subsite II and F5 with para-chlorophenylalanine (pClF). This peptide, Ac-
Q Cha DL pClF (Figure 1.9) has increased the affinity to an IC50 of 0.16 µM. A 
similarly derivatized peptide, Ac-Q-Cha-DL-diClF (Figure 1.10), substituting the 
phenylalanine benzyl ring with a 3,4-dichlorophenylalanine, increased binding affinity 
to an IC50 of 0.08 µM.  
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Figure 1.8 Crystal structures of the E. coli SC bound with a derivatized peptide 
AcQLDLF (PDB entry 3Q4J). The complexes are shown with the SC carbon atoms 
shaded white and with the peptide carbon atoms colored grey (all other atoms in CPK 
colors). Dashed red lines represent H-bonds.  
 
Figure 1.9 Crystal structures of the E. coli SC bound with a derivatized peptide AcQ-
Cha-DL-pClF (PDB entry 3Q4K). The complexes are shown with the SC carbon atoms 
shaded white and with the peptide carbon atoms colored grey (all other atoms in CPK 
colors). Dashed red lines represent H-bonds. A bridging water molecule is shown as a 
red sphere. 
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Figure 1.10 Crystal structures of the E. coli SC bound with a derivatized peptide AcQ-
Cha-DL-diClF (PDB entry 3Q4L). The complexes are shown with the SC carbon atoms 
shaded white and with the peptide carbon atoms colored grey (all other atoms in CPK 
colors). Dashed red lines represent H-bonds. A bridging water molecule is shown as a 
red sphere. 
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1.3.3 ssDNA occupies part of subsite I 
The first dsDNA-bound SC structure was revealed by Georgescu and coworkers.43 
The DNA used in crystallization experiments contains a section of ssDNA that interacts 
with the previously described SC binding pocket in a symmetry-related SC molecule. 
The authors argued that the SC binding to the template ssDNA may serve to hold the 
clamp at a primed site after loading, or during switching of multiple factors on the 
sliding clamp.43 The ssDNA template makes extensive interactions with the residues 
close to the binding pocket (Figure 1.11). Many interactions are beyond the edge of the 
binding pocket, which are not observed in the peptide-bound structures (Figure 1.4-
1.10). Three dT nucleic acid residues (dT11-dT13) interact with subsite I primarily 
through hydrogen bonding: dT11 with T172 sidechain, dT12 with R245 and R240 side 
chains and D243 backbone NH group, and dT13 with R240 backbone carbonyl group 
(Figure 1.11). It is noteworthy that the two arginine residues also engage in cation-π 
interactions with the nucleobases.  
1.3.4 Small molecule inhibitors developed to date 
Small molecule inhibitors of the SC peptide-binding pocket reported to date are 
found to bind in subsite I40,44 (Figure 1.12). They overlap with the aforementioned 
peptide-L4F5 motif when the SC structures are superimposed, and share one common 
feature: a halogenated phenyl ring.40,44  
RU7, a small-molecule inhibitor discovered by Georgescu and co-workers40 from a 
high-throughput screen, occupies subsite I. A bromine atom forms a halogen bond with 
the T172 side chain (Figure 1.12). The other parts of the RU7 are mainly stabilized by 
hydrogen bonds that are similar to the ssDNA-binding pattern (Figure 1.11). The IC50 
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of RU7 was 10 µM as measured using a fluorescence polarization anisotropy-based 
assay.  A recently described biphenyl compound44 occupies the all of subsite I, 
presumably with favourable desolvation entropy due to its hydrophobicity (Figure 1.12). 
Its IC50 was determined to be around 40 µM in a plate-binding assay and 8.3 µM in an 
SPR-based assay. 
No small molecule inhibitors reported to date occupy both subsites. This is possibly 
due to the spatial separation of subsite I and II, the steric hindrance from the side chain 
of M362, and the rigidity of the compounds’ ring structures.  
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Figure 1.11 E. coli SC with a ssDNA motif at its recognition site (PDB code 3BEP). The atoms of binding pocket subsites (I and II) are 
presented in green with electrostatic surface display,  the ssDNA in grey. Non-carbon atoms are CPK colored. Protein structure is presented with 
ribbon diagram colored by secondary structure (Pink: β-sheet, Light blue: α-helix and White: others). 
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Figure 1.12. E. coli SC bound with RU7 (light blue) and a biphenyl compound (pink), respectively. The structures are colored accordingly. Non-
carbon atoms are CPK colored. Hydrogen bonds and a halogen bond are presented as red dashed lines.
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1.4 Small molecule intervention of protein-protein interactions (PPI) 
The largest class of currently marketed small-molecule drugs target G-protein-
coupled receptors, nuclear receptors, ion channels and enzymes. They are competitors 
of natural ligands, which are often small molecules themselves.45 However, there is 
increasing clinical need for a variety of drug interventions in many diseases for which 
conventional therapeutics fail to be effective.46 Protein–protein interactions (PPIs) are 
key to numerous biological processes such as cell cycle control, apoptosis, 
differentiation and signalling pathways. It has been shown that PPIs are disrupted in 
many diseases and can be potential targets for therapeutic intervention.47,48 It has been 
proposed that large-scale genomic and proteomic studies of protein-protein interaction 
networks within cells will identify a variety of therapeutic targets from various 
biological pathways.49 PPIs have been proposed to represent a novel class of targets for 
the development of new therapeutic drugs.50,51 
Targeting PPIs is considered to be more difficult than small molecule-binding sites 
since PPI interfaces are relatively large, less conserved, often flexible and flatter when 
compared with small-ligand binding pockets.52-56 Thereby comes the dilemma that 
drugs should be small enough to penetrate the cell and also be able to affect the 
relatively large surface area at PPI interaction sites. Small molecules were considered 
unlikely to be effective PPI inhibitors until evidence emerged showing that small 
molecules do not have to cover the entire PPI interface, but rather only bind to a 
“hotspot” that contributes the most to the binding free energy of the PPI.57-61 Hotspots 
comprise relatively small fraction of PPIs, and are usually found at the centre of the 
interface. In such cases, small molecules may act as effective PPI inhibitors.62-64 
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Targeting ‘promiscuous’ proteins that bind to several targets using the same hotspot 
region can be problematic, as the contact surfaces are adaptable, allowing one protein to 
bind to a range of structurally diverse partners.65 Furthermore, high-throughput 
screening (HTS) performs less well at identifying compounds that disrupt protein–
protein interfaces compared with enzymatic targets since the composition of the 
compound libraries are frequently biased toward enzymatic inhibitors.66,67 
Despite efforts made to date, there are relatively few reports of protein structures in 
complex with small molecule inhibitors that disrupt PPIs compared with other drug 
classes. PPI inhibitors are often relatively large (compared with other drug classes), 
rigid molecules, containing hydrophobic and aromatic rings.53,54 Beside empirical 
approaches, currently there are no generally applied structure-based approaches for the 
discovery of PPI inhibitors. Many approaches so far have focused on discovering 
druggable PPIs by in silico screening of small-molecule libraries and searching the 
chemical space of PPI inhibitors. Molecular dynamics simulations and protein-ligand 
docking studies may reveal the dynamic nature and physicochemical properties of 
protein–protein/protein-ligand complexes to identify a thermodynamically stable pocket, 
i.e. the “hotspot” that can be targeted in small-molecule library screenings.68 
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1.5 A fragment-based approach applied to PPI inhibitor design 
1.5.1 What is fragment-based design?  
Implicit in the lead discovery and optimization stages in drug design is the idea that 
molecules are modular: each molecular fragment contributes specific properties to the 
drug candidate as modules that can be combined while retaining their binding poses and 
specific binding interactions. Researchers have relied on the modular nature of 
molecules since the early days of drug discovery. Functional groups are swapped 
between candidates to improve overall affinity and alter some other property of the 
molecule to increase drug-like characteristics such as lipophilicity.  
Currently, many in silico methods for prediction of molecular properties have been 
based on the decomposition of molecules into their parts to develop predictive models.69 
Fragment-based techniques were pursued in the prediction of some physiochemical 
properties such as logP, and several biological characteristics including toxicity70,71. In 
recent years, fragment analysis has made contributions to the discovery and 
optimization of lead molecules and to the prediction of various chemical properties. 
This has generated great interest as an alternative paradigm for drug discovery72,73 for 
reasons outlined below. 
1.5.2 Why use a fragment-based approach? 
Traditional antibiotic discovery involved natural product screening. Early 
advancements include high-throughput screening and combinatorial chemistry. 
Advancements in biochemistry and molecular biology allowed molecular targets to be 
identified, cloned and produced by recombinant DNA methods. Analytical biochemical 
approaches with automation tools became widely available.74 However, these 
technologies did not live up to expectations with respect to the discovery of new 
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antibiotics, since major pharmaceutical libraries for high-throughput screening are 
designed principally for enzymatic targets within eukaryotic cells.75 The 
physicochemical properties of the would-be antibiotics that enable both penetration of 
prokaryotic membranes and binding to non-enzymatic targets may differ from those of 
the agents active against eukaryotic targets.76 Fragment-based design is not biased 
toward any particular target. The emphasis is on functional diversity with relatively 
small libraries, typically fewer than 1000 fragments.  
Although the specificity and potency of the fragments are poor compared to 
lead/drug-like compounds (since fragments lack structural complexity), the hit-rates and 
chemical distinctiveness with fragments are higher. Therefore they serve as good 
starting points for lead development.77 
1.5.3 How is fragment-based screening performed? 
The first examples of fragment-based screening utilised cocktail crystallography78, 
i.e., cocktails of fragments were soaked into crystals and their X-ray structures 
determined. However, the use of crystallography to screen for active fragments limits 
the size of the libraries that can be screened, albeit having the advantage of supplying 
immediate structural information for hits.79 This may result in many potential hits being 
missed due to the dual requirement to satisfy the conditions for weak binding and 
crystal formation. Other screening methods such as NMR80, surface plasmon resonance 
(SPR),81 and higher-throughput, high-sensitivity biochemical screening methods such as 
fluorescence correlation spectroscopy (FCS)82 and weak affinity chromatography 
(WAC)83 are also used to screen for bound fragments. The combination of biochemical 
screening and NMR-based screening provides a particularly effective approach for the 
discovery of fragment hits.84,85 There has also been interest in the use of mass 
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spectrometry or isothermal titration calorimetry (ITC) in FBDD screening.86,87 All of 
these techniques can be used to confirm the hits from one of the screening methods. X-
ray crystallography is usually a vital part of the fragment-to-lead and lead-optimization 
process following the discovery of a fragment hit.88 
1.6 Scope of this study  
The overall aim of the study  is the design of small-molecule inhibitors as potential 
drug leads against bacterial SC. Since medicinal design often require in-depth 
understanding of the drug target when interacting with its physiological binding partners, 
the work presented in this thesis begins with the delineation the nature of peptides 
binding to the E. coli SC as its natural ligands. Using biochemical, biophysical, and 
structural evidences as well as theoretical approach, a model was proposed to account 
for the binding events. 
This model of receptor-ligand interaction reveals a “hot-spot” on the E. coli SC 
favorable for ligand binding. Focusing on the “hop-spot” identified, fragment-based 
screening targeting the E. coli SC using X-ray crystallography was carried out. Initial 
hits were then identified binding to the “hot-spot”. 
The model also defines the binding areas beyond the “hot-spot” and subsequent 
development after the fragment-based screening were carried out, which led the 
development of high-affinity small-molecular inhibitors of the E. coli SC with expanded 
binding area beyond the “hot-spot”. 
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Chapter 2  
General Materials and Methods. 
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2.1 Protein over-expression 
Protein production and purification followed the published protocol.36 Briefly, E. coli 
strain AN1459 carrying plasmid pND261 carrying a bacteriophage λ-promoter was 
grown in 6 L of LB medium with 50 mg each of thymine and ampicillin at 300 K for 5 
hours and moved to a water bath pre-heated to 315 K. After a 3-hour incubation, the 
culture was centrifuged and the pellets were collected and stored at 253K.  
2.2 Protein purification 
The pellets were thawed and resuspended in 100 mL lysis buffer (50 mM Tris-HCl, 
pH 7.6, 1 mM EDTA, 1 mM DTT and 20 mM spermidine) and passed twice through a 
French press (82.7 MPa). PMSF (1 mM) was added to the homogenate, which was 
centrifuged at 15,000 rpm for 30 min; ammonium sulfate was added to the supernatant 
(0.32 g/mL), stirred on ice for 30 min and centrifuged at 15,000 rpm for 30 min. The 
pellets were then re-dissolved in 50 ml buffer A (50 mM Tris-HCl pH 7.6, 1 mM EDTA, 
1 mM DTT) and centrifuged to remove insoluble material. The solution was dialyzed 
against 2 L buffer A with 0.17 M NaCl and passed at 5 ml/min through a column (2.5 x 
20 cm) of Toyopearl TSK DEAE-650M anion exchange resin equilibrated with the 
same buffer. The flow-through was collected, dialyzed against 2 L of buffer A and 
loaded onto the same column pre-equilibrated with the same buffer. After washing the 
column with 100 ml buffer A, the column was washed with buffer A with 200 mM 
NaCl and the SC was eluted as a single sharp peak. The elution was collected and 
dialyzed against 2 L buffer B (20 mM sodium phosphate pH 6.5 and 1 mM DTT) and 
then passed at 2 mL/min through a column (2.5 x 15 cm) of hydroxyapatite (BioRad) 
pre-equilibrated with buffer B. The SC was eluted in a linear gradient of 20-200 mM 
sodium phosphate (pH 6.5). The purity of the β SC was then checked with SDS-PAGE 
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and precipitated with ammonium sulfate (0.5 g/mL) and dialyzed against storage buffer 
(20 mM Tris-HCl pH 7.2, 0.5 mM EDTA, 1 mM DTT and 15% (v/v) glycerol). 
2.3  Nanoelectrospray ionization (ESI) mass spectrometry (MS) 
The accurate molecular mass of purified SC protein was analysed after purification 
using ESI-MS, which can be accurate to <0.01% of the total molecular mass of the 
protein. A Waters ESI-Q-TOF Ultima mass spectrometer was used for nanoelectrospray 
ionization mass spectrometry. The SC was dialyzed against 100 mM ammonium acetate, 
pH 7.2 and was tested at concentrations of 1 to 10 µM. The SC was injected into a gold-
coated capillary needle. The capillary voltage was 1.5 kV, the cone voltage was 35 V 
and RF lens was 175 V. Data were collected over the mass range 2000-8000 m/z (100 
acquisitions, 2s each). The spectra were analysed using Masslynx™ and further 
processed with GraphPad Prism. 
2.4 Protein crystallization 
The SC stock solution contains the SC at 53 mg/mL in 20 mM Tris-HCl pH 7.2, 0.5 
mM EDTA, 1 mM DTT and 15% (v/v) glycerol.Crystals of the SC were grown at 285 K 
by the hanging-drop vapour diffusion method. The hanging drop was composed of 1 µl 
of SC stock solution mixed with the same volume of a reservoir solution composed of 
100 mM MES pH 6.5, 100-150 mM CaCl2 and 25-30% (v/v) PEG400. The reservoir 
volume was 1 mL. Ligands were pre-dissolved in DMSO at 10-100 mM and soaked into 
the crystal at the final concentration of 2-5 mM with < 10 % (v/v) DMSO.  
2.5 X-ray data collection 
Procedures for cryo-protection of the protein crystals were exempted as the reservoir 
contains ~30% PEG400, which is sufficient for cryo-protection upon freezing. 
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All crystals were mounted onto MiTeGen™ loops on pins with magnetic caps. For 
in-house data collection, crystals were flash-frozen to 100 K using an Oxford Cryo-
stream. Diffraction data were collected using a MAR345 desktop beamline using CuKα 
X-ray from a Rigaku 007HF rotating anode generator with Varimax™ optics. Frames 
were collected for each crystal with 1° increment. Exposure times ranging from 2 to 5 
min were used. 
For synchrotron data collection, the SSRL Automated Mounting system (SAM) was 
used. Mounted crystals were flash-frozen in liquid nitrogen and placed in the SAM 
cassettes. Diffraction data were collected at the Australian Synchrotron, Beamline MX1 
using X-rays of wavelength 0.95 Å. 
2.6 Data processing, structural solution and refinement 
 Crystal data sets were integrated, merged and scaled with either HKL200089 or 
MOSFLM and SCALA of the CCP4 software package.90 The structures were solved by 
molecular replacement with MOLREP91 using the Protein Data Bank entry 1MMI (an 
apo-crystal of E. coli SC of space group P21) as a starting model.36 All waters, ions and 
ligands were removed before molecular replacement. Iterative model building and 
refinement was done with COOT92 and REFMAC593. Electron density maps 
(2mFo−DFc and mFo−DFc) were calculated using structure factor amplitudes and phase 
angles derived from REFMAC5. Water molecules, ions and PEG fragments observed in 
the electron density map were added to the model using COOT92. In case residues 
and/or ligands demonstrated poor electron density, occupancies of corresponding atoms 
were adjusted accordingly. Geometric restraints for ligands without library description 
were prepared using Monomer Library Sketcher of CCP4 software package90 or an 
online server PRODRG (http://davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg ).  
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Chapter 3 
Structural and thermodynamic elucidation of 
linear motif recognition 
by the E. coli sliding clamp 
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3.1 Introduction  
Protein-protein interaction sites govern numerous biological processes and are a 
well-known class of drug target.94 Linear motifs (LMs) are short (4-10 residues) 
intrinsically disordered sequences that are often found at the termini of proteins and 
sometimes in loop regions.95-97 Recognition of LMs98,99 by rigid protein domains 
represents a distinct category of protein-protein interaction, with many examples 
involved in cell signaling, DNA replication and other cell-regulatory processes.100-102 
Recognition of LMs by their partner proteins often show both specific and promiscuous 
characteristics.103 Promiscuity arises because the protein acts as a binding “hub” capable 
of interacting with multiple partners bearing distinct (but related) LMs.103,104 Specificity 
arises from the interaction of conserved LM “anchor” residues105-107 with target receptor 
“hot spots”108,109 which when removed lead to loss of binding affinity. In general, LM 
recognition events are transient and show only weak affinity (1–100 µM)110 and it has 
been proposed that this may arise from the configurational entropy loss that occurs 
when LMs adopt the bound conformation.111 This is supported by the fact that most LM 
peptides do not induce conformational changes in their binding partners.109 
Hydrophobic residues commonly found in LMs are also thought to contribute 
entropically favorable desolvation free energy to the binding.96,112,113 A sequential 
model of LM-binding via partially bound states has been proposed and is consistent 
with the typically observed fast on-and-off binding kinetics.105,106,114 
While there is growing interest in the design of drugs targeting LM-recognition 
sites115,116 these efforts are being hampered by a lack of further mechanistic insights into 
the binding process. Additional structural evidence in support of the sequential binding 
model is required along with further evidence connecting LM characteristics with their 
dynamic behavior. 
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As described in Chapter 1, the E. coli SC is a protein-protein interaction hub for 
consensus LMs of various binding partners. The LMs of SC partner proteins are usually 
found at their N- or C-termini and these isolated peptides tend to bind to the SC with 
affinities similar to their parent proteins.38,44 Conversely, when LMs are removed the 
truncated proteins lose all binding affinity.18,42 Previous studies have shown that the 
consensus motif (QLx1Lx2F/L: S/D preferred at x1, x2 may be absent) binds to a specific 
pocket on the SC monomer comprised of two subsites, I and II.30,40 A pentapeptide 
derived from the consensus motif, Ac0Q1L2D3L4F5, binds to the SC with equivalent 
affinity to SC-binding proteins (Kd ~ 1 µM ). It is considered to be the minimal binding 
motif.1,40,117 
As described in this chapter, a combination of biochemical/biophysical assays and 
structural and theoretical approaches have been used to gain key mechanistic insights 
into E. coli SC-LM recognition. Single-residue substitutions of the Ac0Q1L2D3L4F5 
consensus peptide were used to characterize the binding determinants and to elucidate 
the structural basis for the specificity of LM-binding. The weak and transient nature 
typical of LM recognition was computationally probed with supporting evidence 
provided from calorimetric data. The study has led us to propose a sequential binding 
model wherein the anchor residues of the LM establishes initial contacts with subsite I 
which is then followed by binding of the flanking residues to subsite II. The model is 
supported by steered molecular dynamics (SMD) simulations and crystal structures 
which provided snapshots into the sequential binding pathway. The 
desolvation/resolvation profile of almost-buried polar atoms (ABPA)118 is shown to 
account for the priority of anchor-residue positioning over positioning of other residues 
in the LM. 
 30 
3.2 Materials and Methods 
3.2.1 Fluorescence polarization assay  
All FP experiments were conducted with a POLARstar Omega plate reader using 
non-treated black sterile 96-well plates (Greiner, USA). The buffer contains 10 mM 
HEPES (pH 7.4), 1 mM EDTA, 1 mM DTT, 0.07% (v/v) Nonidet P-40 and 5% (v/v) 
DMSO. Various fluorescently-labelled peptides were designed and tested. One 
fluorescent peptide, 5’-fluorescein (FAM)-QLDLF-OH (GL Biochem, China) with > 95% 
purity confirmed by the manufacturer using HPLC-MS, was used for the competition 
assay with 10 nM of tracer and 50 nM of the SC monomer.  Blank control (buffer), 
negative control (buffer and the peptide) and positive control (buffer, peptide and the 
sliding clamp) were used for data standardization to yield the extent of inhibition.  
Experiments were carried out in duplicate. Curves were fitted using GraphPad Prism 
v5.01 (GraphPad Software, USA). Binding-saturation curve fitting was applied to tracer 
binding. Dose-response curve fitting was applied to competition assays with variable 
slope, constraining Top at 100 and Bottom at 0. 
3.2.2 Isothermal Titration Calorimetry 
ITC was performed using a MicroCal Auto-iTC200 calorimeter (Microcal, GE 
Healthcare) at 298 K. The SC was dialyzed against a buffer (10 mM HEPES pH 7.2, 
0.15 M NaCl and 1 mM EDTA) and the same buffer was used to dissolve the peptides. 
The feedback mode was “high” with the reference power setting of 10 µcals-1. The cell 
was stirred at 1000 rpm and the thermostat was set to 25 °C. Experiments were 
conducted with 19 injections of 2 µL of the mixture over 4s with 200s spacing. The first 
injection of 0.4 µL was discarded in all cases. Peptides of 2-5 mM were titrated in 
sequential injections (2 µL each) into 54 or 90 µM SC monomer. Data were corrected 
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for control experiments with peptide titrated into buffer only. Data analysis was carried 
out with Origin 7.0 using one-site binding data fitting. 
3.2.3 Molecular dynamics simulation, molecular mechanics calculation 
Molecular dynamics simulations were performed with the Amber11 software 
package.119 The starting coordinates were extracted from the complex crystal structures 
SCAcALDLF, SCAcQADLF, SCAcQLALF, SCAcQLDAF and SCAcQLDLA and SCAcQLDLF(PDB entry 
3Q4J1). A simulation of native SC was performed using the apo crystal structure 
determined in space group P21 (PDB 1MMI36). Monomers with domain I (residues 1-
125) removed were used in all cases due to the software limitation on normal mode 
analysis when processing large systems. Thus, truncated SC monomers (residue range 
126 to 365, domain III truncated) with peptide ligands (except for the native sliding 
clamp) were simulated. 
To prepare coordinates for simulation, crystallographic waters > 3.5 Å away from 
any protein atoms were deleted. Hydrogen atoms were built and partial charges assigned 
using xLeap (ff99SB force field). To the resulting system, TIP3P molecules were added 
to form a rectangular box with edges a minimum of 10 Å from the solute. The system 
was subjected to energy minimization in two stages, first with 10 kcal/mol/Å2 harmonic 
restraints on the solute and crystallographic waters and then with the restraint removed. 
Each stage consisted of 2500 steps of steepest descent and 2500 steps of conjugate 
gradient energy minimization. The system was then heated from 0 to 300 K in 20 ps 
with the 10 kcal/mol/Å2 harmonic restraints on the solute and crystallographic waters (at 
constant volume), equilibrated at 300 K for 50 ps with 2 kcal/mol/Å2 restraint on the 
protein (at constant pressure) and then equilibrated at 300 K for 50 ps without harmonic 
restraint under constant pressure (1 atm, using isotropic positional scaling). For all MD 
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runs, the Langevin temperature control algorithm was used with a time constant and 
collision frequency of 2.0 ps. Production runs (10 ns) were performed with PMEMD. 
The non-bonded cut-off was set to 10 Å. The SHAKE algorithm was used to constrain 
all bonds to hydrogen atoms. An integration time-step of 2 fs was used and atomic 
coordinates were saved every 1 ps for analysis. The PTRAJ program was used for 
calculation of root mean square fluctuations and radial pair distributions. Simulations of 
peptides in explicit water were carried out using the same protocol but with production 
runs extended to 50 ns. Subsequent MM-PBSA calculations and normal mode analyses 
of trajectories were carried out on each complex using the MMPBSA module. MM-
PBSA calculations were done to coordinate snapshots 10 ps apart with ionic strength set 
at 0.1 M. Single trajectory calculations were performed to avoid errors introduced due 
to insufficient sampling of such a large system. Separate calculations were performed 
on peptides bound to the SC and in water. Normal mode calculations of configurational 
entropy used a triple trajectory approach with the calculations performed on the 
complex, and on the SC and ligands in isolation. Snapshots 200 ps apart were extracted 
and calculated. 
3.2.4 Steered molecular dynamics simulations  
SMD simulations were carried out with the AMBER 11 package119 using published 
methods.118 A total of three systems were simulated. For the first two, starting 
coordinates were taken from the SCAcQLALF and SCAcLF complex crystal structures. The 
coordinates of the third system (the SC in complex with AcQL) were modelled using 
the SCAcQLALF complex structure. 
All residues of the SC or crystallographic waters beyond 12 Å of the 
AcQLALF/AcQL/AcLF ligands were deleted. The three truncated systems were 
neutralized and TIP3P water molecules were added, extending 18 Å out from the 
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dimension along which the pulling forces were to be applied, and 10 Å extending from 
the other two dimensions. 
All three systems were subject to 2500 steps of steepest descent energy minimization, 
followed by 2500 steps of conjugate gradient energy minimization. Harmonic restraints 
(10 kcal/mol/Å2) were placed on the solute. Another 5000 energy minimization steps 
followed with the same restraints applied to the backbone atoms (Cα, C, O, N). The 
systems were then heated from 0 to 300 K in 20 ps with the same restraint and at 
constant volume, then equilibrated at 300 K for 50 ps with harmonic restraints (10 
kcal/mol/Å2) on the solute. Another 50 ps equilibration run followed with harmonic 
restraints (10 kcal/mol/Å2) on the backbone atoms (Cα, C, O, N). Equilibration runs 
were done under constant pressure. A 10 ns production NPT run was performed with 
PMEMD. The non-bonded cut-off was set to 10 Å. The SHAKE method was applied to 
constrain all bond lengths involving hydrogen atoms. The temperature control was 
based on the Langevin algorithm with a time constant and collision frequency of 2.0 ps. 
The pressure was kept at 1.0 atm using isotropic positional scaling. An integration step 
of 2 fs was used and coordinates were saved every 1.0 ps. 
A total of 20 snapshots spaced 500 ps apart were extracted from each production run 
trajectory and subjected to 1 ns SMD simulation each. In each SMD simulation, the 
ligands were pulled for 6 Å (in cases of AcQL/AcLF) or 15 Å (in the case of AcQLALF) 
from the binding pocket. The pulling forces were applied to the centre of mass of the 
receptor Cα atoms and the heavy atoms of the ligand. The pulling of AcQLALF was 
performed three times with the force applied on the AcQL- sub-motif, the -LF sub-motif 
or the entire peptide. The pulling distance was used as the reaction coordinate with 5000 
kcal/mol/A2 force constant. All backbone atoms of the receptor were restrained with 10 
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kcal/mol/Å2 harmonic restraints during the SMD simulation. Other parameters of SMD 
simulation followed the same protocol as was used in the production runs. The 
cumulative work measured along the reaction coordinates were Boltzmann-averaged 
using the Jarzynski relation.120 The Jacobian correction121 was then applied and the 
cumulative work was standardized by subtracting the initial value. The distances and the 
numbers of water contacts were calculated with PTRAJ for each SMD simulation 
trajectory and Boltzmann-averaged as described.118 
3.3 Results and discussion 
3.3.1 Fluorescence polarization assay development 
3.3.1.1 Design of fluorescently labelled tracers 
The fluorescently-labelled tracers were designed based on the sequence of the 
consensus motif (QLDLF). Two fluorescent peptides were designed by fusing a 5-
fluorescein to the consensus motif: AcQLK(5FAM)LF-OH with the 5-fluorescein fused 
to the lysine residue in the middle of the sequence and 5FAM-QLDLF-OH with the 5-
fluorescein fused at the N-termini of the sequence. The former was designed to avoid 
possible reduced affinity that might occur through the disruption of the positioning of 
the N-terminal residues, in this case the glutamine residue. 
Both tracers were obtained and tested at 10 nM, around which concentration the 
tracer is usually used in fluorescence polarization-based assays.122,123 Their binding-
saturation curves were plotted (Figure 3.1) against the receptor (the SC monomer) 
concentration. The 5FAM-QLDLF-OH showed superior binding properties as the 
AcQLK(5FAM)LF-OH did not reach complete saturation even with very high receptor 
concentration. Therefore the 5FAM-QLDLF-OH was chosen as the tracer to be used in 
inhibition assay. 
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3.3.1.2 Characterization of the fluorescent tracer 
As the primary assay used in peptide/inhibitor testing and IC50 determination, it was 
necessary that the assay was both sensitive and robust. Since DMSO is used to dissolve 
both peptides and compounds to make stock solutions, the assay system was tested for 
DMSO tolerance by titrating the SC of various concentrations into the buffer system 
containing 10 nM tracer and various DMSO concentrations (0%, 5% or 10%). DMSO at 
three concentrations was tested, and DMSO at up to 10% (v/v) did not significantly alter 
the binding-saturation curve (Figure 3.2). Therefore 10% (v/v) DMSO was chosen for 
the buffer condition which is tolerated by the SC-tracer binding. 
The affinity (dissociation constant, Kd) was calculated using a binding-saturation 
curve taking ligand depletion into account.124,125 The dissociation constant of the tracer 
was determined to be 70 nM (Figure 3.3), tighter that that estimated for AcQLDLF (Kd 
~ 1 µM). This could be due to the 5-fluorescein on the N-terminus of the tracer peptide 
having an interaction with the SC and contributing positively to the binding affinity. 
3.3.1.3 Inhibition assay design 
The fluorescent tracer (10 nM) with the SC as the receptor (50 nM) was used in the 
competition/inhibition assay to determine the IC50 of the inhibitors (either peptides or 
synthetic compounds). The receptor concentration was near the Kd of the tracer-receptor 
system allowing sensitive analysis of inhibitory interactions. 
To validate the inhibition assay, the AcQLDLF peptide was used as the reference, 
which was previously reported as a tight binder with Kd ~ 1 µM affinity.1 The extent of 
inhibition (% Inhibition, Figure 3.4) of the tracer binding to the receptor was calculated 
from the milli-polarization (mP) values using the generally applied equation for 
standardization.126 The extent of inhibition was plotted against the inhibitor 
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concentration and the IC50 value was calculated by fitting the curve to a dose-response 
curve with variable slope. The AcQLDLF peptide inhibited the tracer binding to the 
receptor with an IC50 value of 1.85 µM (Figure 3.4). This value can be further 
transformed into a Kd (or Ki) value using the Kenakin correction for ligand depletion.127 
Here, the ligand depletion refers to the depletion of the tracer when >10% of the tracer 
is bound to the receptor, and the effective tracer concentration is significantly reduced 
which causes an underestimation of the actual affinity. In the case of AcQLDLF peptide 
as the inhibitor, its Kd after Kenakin correction is 0.9 µM. This corrected value is 
similar to the reported affinity of ~1 µM. 
These procedures were applied to all FP inhibition assays described here. 
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Figure 3.1 Binding-saturation curves of the SC titrated into two fluorescently labelled 
peptides at 10 nM. Curves were fitted to one-site binding model taking into account of 
ligand depletion. Error bars represent ± 1 standard deviation (n=2). Where not visible, 
error bars are within the markers. 
 
Figure 3.2 Binding-saturation curves of the SC titrated into the fluorescent tracer with 
various amounts of DMSO in the buffer. Curves were fitted to one-site binding model 
taking into account of ligand depletion. Error bars represent ± 1 standard deviation 
(n=2). Where not visible, error bars are within the markers. 
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Figure 3.3 Binding-saturation curves of the SC titrated with the fluorescent tracer. 
Curves were fitted to one-site binding model taking into account of ligand depletion. 
The calculated dissociation constant (Kd) is shown. Error bars represent ± 1 standard 
deviation (n=2). Where not visible, error bars are within the markers. 
 
Figure 3.4 Dose-response curve (with variable slope) of the reference peptide titrated 
with 50 nM SC pre-mixed with 10 nM of the fluorescent tracer. The calculated IC50 
value for the inhibition relating to the tracer binding to the SC is shown. Error bars 
represent ± 1 standard deviation (n=2). Where not visible, error bars are within the 
markers. 
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3.3.2 Interactions of Q1 with subsite II and L4F5 with subsite I  
The published X-ray crystal structure of the consensus pentapeptide Ac0Q1L2D3L4F5 
in complex with the E. coli SC (PDB entry3Q4J)1 is shown in (Figure 3.5). In this 
structure the N-terminal Ac0Q1L2 dipeptide sub-motif occupies subsite II making three 
H-bonds to the backbone of M362, P363 and R365, and one H-bond to a bridging water 
molecule (W0). The side chain of L2 is involved in hydrophobic interactions with P363. 
The non-polar C-terminal L4F5 dipeptide sub-motif occupies subsite I and makes 
interactions with the hydrophobic side chains of L177, V247, V360 and M362. In the 
current work, X-ray crystal structures of the SC were obtained in complex with all five 
possible alanine mutants of the consensus peptide; AcA1L2D3L4F5, AcQ1A2D3L4F5, 
AcQ1L2A3L4F5, AcQ1L2D3A4F5 and AcQ1L2D3L4A5 (Complexes are denoted SCAcALDLF, 
SCAcQADLF, SCAcQLALF, SCAcQLDAF and SCAcQLDLA; Figure 3.5 B–F. Crystallographic 
data are provided in Table 3.1). The individual structures are discussed below in the 
context of their SC binding affinities.  
The binding contribution of each residue in Ac0Q1L2D3L4F5 was probed using a 
systematic series of mutant peptides (Table 3.2). Binding affinities for the mutants were 
measured using a fluorescence polarization (FP) assay employing a fluorescently-
labeled tracer peptide (Kd = 70 nM, determined with binding-saturation curve fitting). 
Inhibition of tracer binding to the SC was plotted against peptide concentrations and 
their IC50 values calculated and transformed into Kd using the Kenakin correction for 
ligand depletion (Table 3.2).127  
The acetylated N-terminus (Ac0) of AcQLDLF mimics the main-chain of LMs in 
providing a carbonyl oxygen to accept an H-bond (Figure 3.5A). Replacing Ac0 with a 
charged primary amine at the N-terminus significantly decreased affinity (Table 3.2). 
Replacing Q1with glutamate increased Kd significantly but changing to asparagine led 
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only to a modest increase. Reducing Q1 down to alanine or glycine greatly reduced 
affinity and this change also precluded correct positioning of the Ac0A1L2- sub-motif, as 
evidenced by the lack of electron density in the map of the SCAcALDLF complex (Figure 
3.5B). These findings establish the crucial importance of the two H-bonds formed from 
the Q1 side chain for binding in subsite II. 
Replacing the hydrophobic residue L2 with valine, alanine or glycine had a less 
dramatic effect on binding than changes at Q1, while substituting D3 for alanine or 
glycine had almost no effect. Additionally, replacing L2 or D3 with alanine did not alter 
the bound peptide conformations relative to the consensus sequence (Figure 3.5C, D 
relative to A). 
Substitution of L4 with valine had a strongly detrimental effect on binding, 
highlighting the strict steric requirements for binding in this region of subsite 1. 
Replacing L4 with alanine significantly reduced affinity as well as crystallographic 
ligand occupancy, as evidenced by the poor peptide electron density in the SCAcQLDAF 
complex (Figure 3.5E). A glycine residue at this position further reduced affinity. The 
significant difference in binding energy observed for the alanine- versus glycine-
substituted peptides at position 4 (ΔΔΔG = 1.08 kcal/mol; Table 3.2) may be due to the 
higher flexibility of glycine. This increased flexibility would impose a larger entropic 
cost upon binding and reduce the likelihood of G4F5 binding in subsite I and triggering 
subsequent subsite II binding events (see sequential binding model below). 
Replacement of F5 with leucine produced a modest increase in Kd, but when replaced 
with alanine or glycine there was a detrimental effect on binding that was similar to the 
same substitutions at the L4 position. Interestingly, the SCAcQLDLA complex structure 
(Figure 3.5F) showed that replacement of F5 with alanine causes this residue to be 
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flipped out of subsite I leaving half of the subsite unoccupied. This is consistent with a 
sub-motif (e.g. L4F5) needing to fully occupy subsite I before binding interactions are 
triggered in subsite II (see sequential binding model below). 
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Figure 3.5. Crystal structures of the E. coli SC bound toAc0Q1L2D3L4F5 consensus 
peptide (SCAcQLDLF, A)1 and its alanine mutants: SCAcALDLF (B), SCAcQADLF (C), 
SCAcQLALF (D), SCAcQLDAF (E) and SCAcQLDLA (F). The complexes are shown with the 
SC carbon atoms shaded white and with the peptide carbon atoms colored grey (all 
other atoms in CPK colors). Electrostatic potential surfaces of the binding site are 
shown with blue = positive and red = negative. Dashed lines in red represent H-bonds. 
A bridging water (W0) is shown as a red sphere. Electron density maps (mFo–DFc) 
contoured at 3σ are shown in green wire-basket form. 
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Table 3.1. Data collection and refinement statistics of E. coli SC in complex with 
AcALDLF, AcQADLF, AcQLALF, AcQLDAF, AcQLDLA, or AcLF. 
Name SCAcALDLF SCAcQADLF SCAcQLALF 
PDB Code 4K3M 4K3O 4K3P 
Data collection 
Space group P21 
Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
79.85, 67.29, 81.19 /      
90.00, 113.75, 90.00 
a, b, c (Å)/α, β, γ (°) 
79.98, 67.24, 81.43/ 
90.00, 113.78, 90.00 
a, b, c (Å)/α, β, γ (°) 
79.96, 66.68, 80.92 /      
90.00, 114.16, 90.00 
Resolution (Å) 50.00-1.85(1.92-1.85) 50.00- 2.00 (2.07-2.00) 73.83 - 2.15 (2.27-2.15) 
Rmerge (%) 3.8(31.6) 2.8 (21.8) 6.9(41.1) 
No. of Reflections 247402 131408 118432 
Unique Reflections 66828 (6455) 48290 (4496) 38882 (5440) 
Mean I/σ(I) 7.9 (3.1) 31.1 (3.7) 9.7 (2.2) 
Completeness 
 
99.3 (96.9) 89.5 (84.3) 91.7 (88.5) 
Multiplicity 3.7 (3.1) 2.6 (2.5) 3.0 (2.8) 
Refinement 
Resolution (Å) 30.65 -1.85 (1.90-
 
21.36 -2.00 (2.05-
 
49.49 - 2.15 (2.20-
 Rwork/Rfree 
 
20.2(27.8)/25.8(37.3) 19.9(22.4)/24.8(32.9) 22.3(30.7)/27.3(36.4) 
R.m.s 
 
   
Bond lengths 
Å  
0.007 0.005 0.006 
Bond angles (º) 1.145 1.114 1.133 
B-factors    
M. Chain 17.4 24.4 31.3 
S. Chain & 
 
21.6 28.0 33.7 
Ligands** 29.5 29.5 36.1 
Ramachandran 
Plot Outliers 
0.29% 0.28 % 0.43 % 
The value for the highest resolution shell is given in parenthesis. Diffraction data 
collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. Diffraction 
data for SCAcQLALF and SCAcQLDLA were processed with MOSFLM and SCALA while 
others were with HKL2000. 
* Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the 
wavelength of 0.95 Å; **Ligands refer to the short peptides/analogues. 
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Table 3.1 (continued). Data collection and refinement statistics of E. coli SC in 
complex with AcALDLF, AcQADLF, AcQLALF, AcQLDAF, AcQLDLA, or AcLF. 
Name SCAcQLDAF SCAcQLDLA SCAcLF* 
PDB Code 4K3Q 4K3R 4K3L 
Data collection 
Space group P21 
Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
79.87, 67.22, 81.19 /      
90.00, 113.95, 90.00 
a, b, c (Å)/α, β, γ (°) 
79.96, 67.09, 81.18/ 
90.00, 113.82, 90.00 
a, b, c (Å)/α, β, γ (°) 
79.84, 67.46, 81.36/      
90.00, 113.73, 90.00 
Resolution (Å) 50.00-1.85 (1.92-1.85) 74.27- 1.86 (1.96-1.86) 50.00 - 1.5 (1.55-1.50) 
Rmerge (%) 2.7(22.9) 6.0 (50.9) 5.8(91.9) 
No. of Reflections 238136 191427 900023 
Unique Reflections 66782 (6374) 61020 (7479) 125264 (12575) 
Mean I/σ(I) 43.8 (4.6) 9.7 (2.4) 34.1 (2.1) 
Completeness 
 
99.2 (95.6) 92.5 (78.4) 99.0 (100.0) 
Multiplicity 3.6 (3.1) 3.1 (2.9) 7.2 (6.8) 
Refinement 
Resolution (Å) 30.53 -1.85 (1.90-
 
43.98 -1.86 (1.91-
 
27.06 - 1.50 (1.54-
 Rwork/Rfree 
 
19.7(27.1)/24.2(34.3) 20.9(32.2)/26.4(35.8) 21.7(23.9)/25.5(29.1) 
R.m.s 
 
   
Bond lengths 
Å  
0.006 0.006 0.005 
Bond angles (º) 1.158 1.068 1.120 
B-factors    
M. Chain 16.9 28.2 16.7 
S. Chain & 
 
22.0 31.9 21.2 
Ligands** 38.7 31.5 17.4 
Ramachandran 
Plot Outliers 
0.44 % 0.29 % 0.29 % 
The value for the highest resolution shell is given in parenthesis. Diffraction data 
collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. Diffraction 
data for SCAcQLALF and SCAcQLDLA were processed with MOSFLM and SCALA while 
others were with HKL2000. 
* Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the 
wavelength of 0.95 Å; **Ligands refer to the short peptides/analogues. 
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Table 3.2. Effects of single-residue mutations on LM consensus peptide binding to the SC as determined by FP. 
Mutation Peptide IC50(µM) Kd (µM) ∆G (298K) (kcal/mol) a∆∆G b∆∆∆GA–G 
 AcQLDLF 1.9 0.9 –8.3 0.00  
Ac0 QLDLF 63.2 29.5 –6.2 2.10  
Q1 
AcELDLF 222.1 103.6 –5.5 2.85  
AcNLDLF 43.6 20.3 –6.4 1.88  
AcALDLF 602.6 281.2 –4.9 3.44  
AcGLDLF 976.5 455.7 –4.6 3.73 0.29 
L2 
AcQVDLF 60.4 28.2 –6.2 2.07  
AcQADLF 78.6 36.7 –6.1 2.23  
AcQGDLF 36.1 16.8 –6.5 1.76 -0.46 
D3 
AcQLALF 3.4 1.6 –7.9 0.37  
AcQLGLF 10.4 4.9 –7.3 1.03 0.66 
L4 
AcQLDVF 1215.0 567.0 –4.4 3.86  
AcQLDAF 246.7 115.1 –5.4 2.91  
AcQLDGF 1524.0 711.2 –4.3 3.99 1.08 
F5 
AcQLDLL 20.96 9.8 –6.9 1.44  
AcQLDLA 555.2 259.1 –4.9 3.39  
AcQLDLG 1067.0 497.9 –4.5 3.78 0.39 
a Binding energy difference compared to AcQLDLF. b Difference in binding energy upon replacing alanine with glycine. 
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3.3.3 Entropy loss upon binding diminishes linear motif affinity for the E. coli SC 
 The alanine and glycine scans above showed that these mutations significantly 
reduce binding affinity, with a higher penalty observed for glycine (except at position 
L2). This can be explained by the reduced hydrophobic interactions possible with 
glycine (vs alanine) and because of the higher flexibility of glycine residues. Since 
glycine can adopt a greater range of backbone phi/psi angles compared to alanine there 
is a greater entropic cost associated with its binding. 
Molecular dynamics (MD) simulations and molecular mechanics (MM) calculations 
with Poisson-Boltzmann surface area (PBSA) solvation were performed to decompose 
the energy of LM peptides binding to the SC and to quantify the contribution of ligand 
deformation entropy. The following equation shows how the changes in Gibbs free 
energy (∆G) were decomposed:119 
∆G = Gcomplex–Greceptor– Gligand 
 =EMM + Esolv +Edef – T∆S 
 =Evdw +Eelec + Epb + Ecavity +Edef– T∆S 
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Table 3.3 MD simulation and MM-PBSA calculation data for peptides binding to the E. 
coli SC (units in kcal/mol, details in Table 3.4). 
 EMM + Esolv Edef –T∆Sdef –T∆S ∆G 
AcQLDLF –49.6 1.4 6.5 20.8 –27.3 
AcALDLF –40.7 3.2 4.2 21.6 –15.8 
AcQADLF –45.9 –0.1 5.5 18.3 –27.7 
AcQLALF –47.3 –0.8 –1.1 22.5 –25.6 
AcQLDAF –44.4 0.4 4.8 20.2 –23.8 
AcQLDLA –45.7 2.0 4.2 23.6 –20.1 
Briefly, EMM represents the molecular mechanics (MM) interaction energy difference 
upon complex formation, which comprises the van der Waals (VDW) interaction energy 
(Evdw) and electrostatic interaction energy (Eelec). Esolv is the difference in solvation 
energy and is comprised of electrostatic contribution to the solvation free energy (Epb) 
and non-polar contribution to the solvation free energy (Ecavity). Both EMM and Esolv were 
calculated for the complex using a single-trajectory approach.119 The ligand energy 
difference upon binding (deformation energy, Edef) was calculated from a separate MD 
simulation and MM/PBSA calculation on the free peptide alone in explicit water (EFree), 
and the energy of the bound peptide (Ebound). Receptor deformation in the calculation of 
EMM and Esolv was ignored for two reasons: (1) the SC undergoes minor, uniform 
structural changes upon binding and (2) significant errors are possible due to 
insufficient sampling of large systems in MM-PBSA calculations. Such errors cannot be 
cancelled out as they can when using the single-trajectory approach. Conformational 
entropy was calculated using the triple-trajectory approach with normal mode 
analysis;119 the trajectories for the complex (10 ns), the receptor (10 ns) and the ligand 
(50 ns) were analyzed and their entropic contributions to the Gibbs free energy (–T∆S) 
are presented (Table 3.3). Ligand deformation entropy (–T∆Sdef) is also presented. 
Although these calculations (Table 3.3 and Table 3.4) did not reproduce the 
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experimentally determined binding free energies,1 they performed well in distinguishing 
the good (i.e. AcQLDLF, AcQADLF and AcQLALF) from the poor binders (i.e. 
AcALDLF, AcQLDAF and AcQLDLA) in a pattern consistent with the FP data (Table 
3.2). 
The VDW interactions (Evdw, Table 3.4) are proportional to ligand size, but increases 
in Evdw are offset by loss of conformational entropy upon binding. Greater VDW 
interactions are also offset by higher desolvation penalties. Similarly, enhanced 
electrostatic interactions (Table 3.4) are offset by unfavorable desolvation energy 
changes resulting in a net unfavorable contribution to ∆G. The penalized contributions 
(Eelec + Epb + Ecavity, Table 3.4) were similar (~10 kcal/mol) for AcQLDLF, AcALDLF 
and AcQLALF, where the latter two peptides had polar residues substituted with alanine. 
This is lowered by ~5 kcal/mol for AcQADLF, AcQLDAF and AcQLDLA, where non-
polar residues L/F had been replaced by alanine.  
Ligand deformation energy (Edef, Table 3.3) was similar among the peptides relative 
to AcQLDLF. The peptides with reduced numbers of atoms experienced conformational 
entropy costs (–T∆S, Table 3.3) similar or even higher to peptides with greater numbers 
of atoms. The normal mode analysis of entropy showed that, in almost all cases, the 
entropic cost of ligand deformation (–T∆Sdef, Table 3.3) accounts for a significant 
portion of the unfavorable conformational entropy loss (–T∆S).  
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Table 3.4 MD simulation and MM/PBSA calculation of SC/peptide complexes.* 
MM calculation SCAcQLDLF SCAcALDLF SCAcQADLF SCAcQLALF SCAcQLDAF SCAcQLDLA 
EVDW -58.1±0.1 -50.7±0.1 -48.7±0.12 -54.4±0.1 -47.1±0.1 -50.2±0.1 
Eelec -72.3±0.8 11.1±0.9 -10.0±0.9 -30.0±0.8 -7.7±1.01 -38.8±1.7 
EPB 86.0±0.7 3.9±0.7 17.6±0.8 42.2±0.7 15.2±0.9 48.2±1.6 
ECAVITY -5.2±0.01 -5.0±0.01 -4.7±0.01 -5.1±0.01 -4.8±0.01 -4.8±0.01 
EMM + Esolv -49.59±0.2 -40.7±0.3 -45.9±0.2 -47.3±0.2 -44.4±0.20 -45.7±0.3 
Ligand Deformation**       
EFREE -215.1±0.1 -150.9±0.1 -198.5±0.1 -145.8±0.1 -198.9±0.1 -219.8±0.1 
EBOUND -213.7±0.2 -147.7±0.2 -198.6±0.2 -146.6±0.2 -198.5±0.2 -217.8±0.2 
Edef 1.4 3.2 -0.06 -0.8 0.4 2.0 
Conformational Entropy       
TS complex 2839.9±0.1 2831.3±0.1 2835.8±0.1 2832.1±0.1 2834.1±0.1 2829.3±0.1 
TS receptor 2765.1±0.1 2765.1±0.1 2765.1±0.1 2765.1±0.1 2765.1±0.1 2765.1±0.1 
TS free ligand 95.7±0.03 87.8±0.03 88.9±0.04 89.6±0.04 89.2±0.04 87.8±0.03 
TS bound ligand 89.1±0.05 83.6±0.04 83.4±0.05 90.7±0.01 84.4±0.04 83.6±0.03 
-∆TSdef*** 6.5 4.2 5.5 -1.1 4.8 4.2 
-∆TS 20.8 21.6 18.3 22.5 20.2 23.6 
∆G -27.3 -15.8 -27.7 -25.6 -23.8 -20.1 
∆∆G 0.00 11.6 -0.3 1.7 3.5 7.3 
*Errors represent standard error of mean. 
**Ligand deformation is the difference between the internal energy of the ligand in the bound and free states.  
***Entropy of ligand deformation is the difference between the entropy by normal mode calculation in the bound and free states.  
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Table 3.5 Thermodynamic data for peptides binding to the E. coli SC as determined by 
ITC (at 298K, units in kcal/mol). 
 ∆H  –T∆S ∆G  
 AcQLDLF –13.66 5.36 –8.30 
Ac0 QLDLF –6.39 0.35 –6.03 
Q1 AcNLDLF –7.40 1.83 –5.57 
L2 AcQVDLF –11.93 5.60 –6.33 
 AcQADLF –13.60 7.21 –6.39 
 AcQGDLF –14.66 8.05 –6.61 
D3 AcQLALF –12.18 3.73 –8.46 
F5 AcQLDLL –11.00 3.99 –7.01 
Isothermal titration calorimetry (ITC) was used to further investigate the impact of 
ligand deformation on entropy. Only strong binders were examined in these experiments 
as ligand solubility and receptor concentration placed limitations on the measurable 
binding constants. The ∆G values from the ITC measurements (Table 3.5, Figure 3.6) 
were found to be consistent with the FP results (Table 3.2). Entropy values (–T∆S) 
derived from the ITC measurements included both the conformational entropy and 
desolvation entropy and hence are not identical to the corresponding term in the 
computational studies (Table 3.3). 
The greatly reduced entropic cost of binding observed when Q1 was mutated to 
asparagine suggests that the bound N1-containing peptide is poorly ordered. This 
correlates well with the poorly ordered peptide structure observed in the SCAcALDLF 
crystal structure (Figure 3.5B). The peptide lacking the Ac0 group is probably also 
disordered when bound given its low binding entropic penalty. The entropic costs of 
binding for peptides with mutations at positions L2, D3and F5 were all similar to the 
reference peptide, suggesting these would likely adopt similar peptide-binding poses to 
that observed in the reference SCAcQLDLF structure. In the cases of D3 and F5 
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replacement, it is likely that reductions in residue size and the resulting reductions in 
desolvation energy produced the net reductions in entropic cost of binding when 
compared to the reference AcQLDLF peptide. 
Replacement of L2 with valine, alanine or glycine showed similar binding enthalpy 
with increased entropic costs of binding compared with the reference peptide. This may 
be explained by the higher flexibility (and hence conformational entropy) of unbound 
peptides containing smaller side chains at position 2 resulting in increased entropy loss 
upon binding of these peptides to the SC. This supports our hypothesis that differences 
in ligand deformation accounts for a significant part of the entropy of binding. By 
comparison, F5 is a terminal residue and its contribution to overall vibrational freedom 
(and hence conformational entropy) would be smaller. 
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Figure 3.6 Isothermal titration calorimetry data of peptides (A-I, AcQLDLF, QLDLF, 
AcNLDLF, AcQVDLF, AcQADLF, AcQGDLF, AcQLALF, AcQLGLF and 
AcQLDLL, respectively) binding to the E. coli SC. Curves were fitted using the model 
for one-site binding. 
A B 
C D 
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Figure 3.6 (continued). Isothermal titration calorimetry data of peptides (A-I, 
AcQLDLF, QLDLF, AcNLDLF, AcQVDLF, AcQADLF, AcQGDLF, AcQLALF, 
AcQLGLF and AcQLDLL, respectively) binding to the E. coli SC. Curves were fitted 
using the model for one-site binding. 
E F 
G H 
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Figure 3.6 (continued). Isothermal titration calorimetry data of peptides (A-I, 
AcQLDLF, QLDLF, AcNLDLF, AcQVDLF, AcQADLF, AcQGDLF, AcQLALF, 
AcQLGLF and AcQLDLL, respectively) binding to the E. coli SC. Curves were fitted 
using the model for one-site binding. 
  
I 
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3.3.4 An anchor-based sequential binding model for LM recognition by the E. coli SC  
The impact of A or G mutations at L4 on binding affinity, as measured by FP (Table 
3.2), suggested a crucial role for this residue in the binding process: the alanine mutant 
had reduced affinity due to reduced interaction, while the glycine mutant impaired 
binding to a much greater extent. It is proposed that deformation entropy of the ligand 
cannot fully account for the disproportionate effect of alanine to glycine substitution at 
position L4 (and to a lesser extent D3) compared to other positions. This finding led us 
to propose a sequential binding model whereby the L4F5 sub-motif establishes primary 
contacts with the subsite I pocket, which is then followed by orientation and binding of 
the flanking residues of the peptide in subsite II. According to this model, the entropic 
penalty of ligand deformation for glycine mutations at the D3 or L4 positions would 
disfavor subsequent binding of the Ac0Q1L2 sub-motif. This model can explain the 
impact of mutations on the kinetic constants of LM association and dissociation, with 
surface plasmon resonance experiments having shown that such interactions are fast-on 
and fast-off,38 a feature which is commonly observed in LM binding.128 Given the rapid 
kinetics, the dissociation phenomenon was considered to be amenable to steered 
molecular dynamics (SMD) simulations. 
The early dissociation process of the Ac0Q1L2A3L4F5mutant peptide from the SC was 
chosen for the simulation. The D3 to alanine mutant was used because of its small size 
and because D3 was shown to make only a minor contribution to the binding energy. 
Three calculations were performed where steering forces were applied to the mass 
centers of (1) the whole peptide, (2) the Ac0Q1L2 and (3) L4F5 sub-motifs (Figure 3.7). 
The Boltzmann-averaged cumulative work calculated after Jacobian correction121 
suggested that the L4F5 sub-motif is more likely to dissociate from the complex first as it 
requires the least work (i.e. shallowest slope in the trajectory). Additionally, the 
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calculations showed that a lower energy barrier lies along the L4F5 binding/dissociating 
pathway in comparison with the pathway in which Ac0Q1L2 dissociates first (as 
indicated by reduced cumulative work).  
Binding of the dipeptides AcQL, AcLF (and their various C/N-terminal variants) to 
the SC was assessed next by FP assay and X-ray crystallography to test the hypothesis 
that the L4F5 sub-motif must bind/unbind first. AcQL and its analogues failed to show 
any binding to the clamp by either method. In contrast, AcLF and its analogue 4MF 
((S)-2-(4-methylpentanamido)-3-phenylpropanoic acid) showed weak affinity (IC50=1.1 
and 4.4 mM respectively, Table 3.6) and both were shown to occupy subsite I in their 
respective X-ray structures, SCAcLF and SC4MF (Figure 3.8A–C, crystallographic data in 
Table 3.1 and Table 3.7). AcQL and its C-terminal variants failed to demonstrate 
binding by X-ray crystallography even when AcLF was pre-bound into subsite I 
(crystallographic data not shown).  
The SC4MF complex structure, determined in space group (P1), showed that binding 
of 4MF causes a minor perturbation of the binding pocket at S346 and H175 (Figure 
3.8A) when compared with an apo-SC structure determined in the same space group 
(SCP1, crystallographic data in Table 3.7). A gating residue M362 retains a “closed” 
conformation (Chi2 angle –177°) in both of these structures, which blocks the 
passageway between subsites I and II (Figure 3.8A). 
The structure of the SCAcLF complex, determined in space group P21, showed that 
binding of dipeptide AcLF to chain B of the SC (Figure 3.8B) causes no apparent 
changes in the binding site, as compared with the apo-clamp structure determined in the 
same space group (PDB entry 1MMI, Figure 3.8B). In both of these structures, the 
M362 gating residue retains the “closed” conformation. However, when the same 
dipeptide bound to chain A (Figure 3.8C) the binding features observed were similar to 
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those seen with longer peptides (e.g. AcQLDLF and DNA Pol IV little finger domain, 
Figure 3.8D), including movements in the side chains of M362 and S364. The binding 
observed in chain B appears to be due to stabilization by a nearby symmetry-related 
molecule (Figure 3.9) and may represent a pre-equilibrium state, with equilibrium 
binding guided by desolvation and formation of an H-bond between the L4 amide and 
G174 carbonyl groups. The gating residue M362 is unmoved in chain B (Chi2 angle –
170°) but is in a "half-open" conformation (Chi2 angle –74° and -93° for alternate 
conformers) in chain A, which exposes the G174 carbonyl group as an H-bond acceptor. 
The SCAcLF and SC4MF crystal structures suggest that the L4F5 sub-motif acts as an 
anchor capable of binding on its own. The SC4MF, SCAcLF and SCAcQLALF complex 
structures are proposed to exemplify snapshots along the pathway to binding. The 
compound 4MF bound in subsite I highlights the initial contact, while AcLF makes an 
additional H-bond with G174 and subsequently triggers partial opening of the M362 
gate. AcQLALF occupies subsite I and subsite II with the M362 in the fully "open" 
conformation (Chi2 55°, Figure 3D). The SMD simulation of AcQLALF dissociation 
(Figure 3.7) demonstrated that “pulling” the anchor sub-motif (L4F5) reduces the 
energetic barrier for dissociation of the rest of the peptide.  
In summary, the model proposes that the binding (or unbinding) of the L4F5 anchor 
sub-motif triggers subsequent binding (or unbinding) of the Ac0Q1L2 sub-motif. Acting 
together, these two sub-motifs contribute most of the binding energy of the consensus 
motif, as evidenced by the FP data. Since the binding of the consensus motif determines 
the binding of the entire protein,42,44 the binding of the consensus motif should precede 
the binding of the rest of protein. For instance, in the case of the "little finger" domain 
of DNA Pol IV (PDB entry 1UUN, Figure 3.8D), the terminal residues equivalent to 
the consensus motif should initiate both binding and unbinding. 
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Figure 3.7 Plot of cumulative work vs distance during SMD simulated dissociation of AcQLALF from the SC. Steering forces were applied to 
the three different centers of mass indicated. 
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Table 3.6 Dipeptides and analogues used to probe the minimal binding motif. 
 
 
Original sequence Dipeptide/analogues IC50 (by FP assay) 
-L4F5 
(NH2)-LF-(COOH) N/A 
Ac-LF-(COOH) 1.1 mM 
4MF 
 
4.44 mM 
Ac0Q1L2- 
AcQL-(COOH) N/A 
AcQL-(CONH2) N/A 
AcQL-(CONHCH3) N/A 
 
N/A 
 
N/A 
N
H
OOH
O
N
H
O NH2
N
H
O
O
N
H
O NH2
N
H
O
O
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Table 3.7. Data collection and refinement statistics of E. coli SC in its native form 
(space group P1) and in complex with 4MF ((S)-2-(4-methylpentanamido)-3-
phenylpropanoic acid). 
 
Name SCP1* SC4MF** 
PDB Code 4K3S 4K3K 
Data collection 
Space group P1 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
40.98, 64.97, 71.93/      73.81, 
82.46, 84.04 
a, b, c (Å)/α, β, γ (°) 
41.02, 64.69, 71.78 /      74.66, 
83.22, 85.18 
Resolution (Å) 68.68-1.75 (1.84-1.75) 50.00-1.85 (1.92-1.85) 
Rmerge (%) 6.7(45.6) 2.9(12.9) 
No. of Reflections 246547 219297 
Unique Reflections 67726 (9775) 56309 (4695) 
Mean I/σ(I) 10.7 (2.4) 44.4 (9.4) 
Completeness (%) 95.3 (93.8) 93.2 (78.4) 
Multiplicity 3.6 (3.5) 3.9 (3.6) 
Refinement 
Resolution (Å) 28.24 -1.75 (1.80-1.75) 34.95 -1.85 (1.90-1.85) 
Rwork/Rfree (%) 19.5(29.0)/22.9(32.8) 19.4(22.7)/22.9(27.5) 
R.m.s deviations   
Bond lengths (Å) 0.007 0.005 
Bond angles (º) 1.247 1.063 
B-factors   
M. Chain 22.8 17.2 
S. Chain & Water 26.9 20.5 
Ligands*** N/A 20.0 
Ramachandran Plot 
Outliers 
0.29 % 0.28 % 
The value for the highest resolution shell is given in parentheses.  
Diffraction data for SCP1 were processed with MOSFLM and SCALA while SC4MF were with 
HKL2000. 
* Diffraction data collected at BeamlineMX1, Australian Synchrotron, at wavelength 0.95 Å; 
**Diffraction data collected at home-sourced X-ray generator at the wavelength of 1.5418 Å; 
***Ligands refer to the short peptides/analogues. 
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Figure 3.8. Crystal structures of SC4MF (A), and SCAcLF chain B (B) and SCAcLF chain A 
(C). SC residues are presented in white with non-carbon atoms CPK-colored. Structures 
of the equivalent native SC structures with equivalent crystal packing are superimposed 
and shown in yellow (SCP1 onto SC4MF, chain B and A of PDB entry 1MMI onto SCAcLF 
chain B and A, respectively). The peptide atoms are CPK-colored. Dashed lines in red 
represent H-bonds. Electron density maps (mFo–DFc) contoured at 3σ are shown in 
green wire-basket form. (D) The crystal structure of the SC/pol IV little finger domain 
(PDB entry 1UNN) is shown superimposed onto SCAcQLALF. The DNA Pol IV little 
finger domain is shown in pink. The enlarged view of the binding pocket in the 
SCAcQLALF structure shows the SC pocket (white), the AcQLALF peptide (grey). Non-
carbon atoms are CPK-colored. Dashed lines in red represent H-bonds. A bridging 
water molecule (W0) is shown as a red sphere. 
 
A B C 
 
D 
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Figure 3.9. The region around the AcLF dipeptide bound to SC chain B in the SCAcLF 
complex (P1 space group). A symmetry-related molecule (cyan) is in contact with the 
AcLF dipeptide. The SC is present in white/cyan with non-carbon atoms CPK-colored. 
The AcLF atoms are CPK-colored. The dashed line represents an H-bond. Electron 
density maps (mFo–DFc) contoured at 3 σ are shown in green wire-basket form. 
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3.3.5 Almost-buried polar atoms (ABPAs) present a kinetic barrier  
The mutational analysis of consensus peptide binding suggested equal importance for 
the L4F5 and Ac0Q1 motifs to affinity, with the L4F5 sub-motif functioning as an anchor 
to initiate binding. Initially the "closed" conformation of M362 was considered to act as 
a gate blocking binding at subsite II. However, MD simulations of the native SC 
monomer showed that the M362 Chi2 angles corresponding to the open/closed 
conformations are equally populated in the trajectory (Figure 3.10), suggesting that the 
conformation of M362 is probably not determining the order of binding. 
A kinetic barrier, caused by differences in the nature of desolvation and resolvation 
of subsites I and II, is proposed to be responsible for the L4F5 sub-motif to act as the 
anchor sub-motif.  Subsite I consists mostly of hydrophobic residues which contact the 
side chains of L4F5 (Figure 3.13A). In contrast, subsite II makes multiple H-bonds with 
the Ac0Q1L2 sub-motif (Figure 3.13B), including some mediated by the bridging water 
(W0). The trajectory of a 5 ns native SC simulation, which included all crystallographic 
water molecules, showed that W0 remained bound (Figure 3.11) and was tightly 
restrained by H-bonds toM362O and N320N (Figure 3.12). It was therefore concluded 
that W0 is a structural water molecule in the SC. 
A recent study showed that H-bond interactions between the protein and ligands that 
are shielded from bulk solvent contribute to slow binding/unbinding kinetics.118 This 
was explained by the desolvation and resolvation of "almost-buried polar atoms" 
(ABPAs) upon ligand binding/unbinding, which involves a transition state that is 
energetically unfavorable because it occurs asynchronously with 
dehydration/rehydration.118 ABPA refers to atoms with <10 Å2 solvent accessible 
surface area (SASA) located within a concave site where the ∆SASA is < 0 (change of 
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SASA with increased probe radius). For the E. coli SC, W0 and M362O are ABPA 
atoms according to this definition while all other polar atoms making H-bonds in both 
subsites I and II are non-ABPAs (Table 3.8). 
To determine the role of W0 and M362O as ABPAs along the proposed dissociation 
pathway, SMD simulations of a model AcQL dipeptide dissociating from subsite II 
were performed using initial coordinates from the SCAcQLALF complex structure. For 
comparison, a SMD simulation was carried out for dissociation of AcLF from subsite I, 
using coordinates from the SCAcLF complex as the starting structure. The AcLF 
dipeptide makes one H-bond with a G174O, a non-ABPA. Jacobian corrections were 
applied in the cumulative work calculations.121 
The cumulative work plot for AcLF dissociation is uniformly ascending showing 
only one energetic minimum (Figure 3.13C). As a non-ABAP, the G174O in subsite I 
is solvent accessible even when AcLF is bound (Figure 3.13G). The breaking of the H-
bond with the dissociating AcLF (Figure 3.13E) is offset by increasing contacts with 
bulk solvent (Figure 3.13G), thus no kinetic barrier is observed in the case of AcLF 
dissociation (Figure 3.13C). 
The cumulative work of steered dissociation of the model AcQL began with a steep 
ascending curve which quickly flattened (Figure 3.13D). This represents the peak of an 
energy barrier where the system could dissociate or re-associate. Dissociation was 
accompanied by the breakage of the H-bond between the W0 and the Q1 side chain 
(Figure 3.13F) and reformation of H-bonds with the solvent (i.e. first layer resolvation) 
(Figure 3.13H). Breakage of the H-bond between M362O and the Q1 side chain 
preceded breakage of the W0 to Q1 H-bond (Figure 3.13F), while resolvation of M362O 
was insignificant (Figure 3.13H). At a distance of 1.5 Å, abrupt dissociation of the W0 
to Q1 H-bond occurs, leading to greater movement of the Q1 side chain (Figure 3.13F) 
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and formation of the first solvent layer in subsite II. Prior to this event, W0 is completely 
shielded from bulk solvent. Thus, there was a transient state (distance <1.5 Å) where the 
system increases in energy as the H-bond with W0 is broken with no compensatory 
formation of H-bonds with the first solvation layer.  
It is proposed that the desolvation and resolvation of the structural water W1 as an 
ABPA represents the kinetic barrier on the pathway of dissociation. The same barrier 
must be present in association since the ligand is barred by the first solvent layer that 
forms H-bonds with the W0 shielded from bulk solvent. Such a kinetic barrier may have 
a larger impact on the association rate constant than on the dissociation rate constant of 
AcQL and its variants, and therefore reduced the affinity. However, in case of the 
AcQLALF binding (Figure 3.7), the first solvent layer should be disrupted by the 
presence of Ac0Q1L2 sub-motif near subsite II as a result of L4F5 binding to subsite I, 
and thus the kinetic barrier presents greater resistance to dissociation than association. 
This explains the energetic contribution of the Ac0Q1L2 sub-motif observed earlier 
(Table 3.2). 
Conversely, binding of AcLF to the SC is not opposed by this barrier as it is not 
present in subsite I. A similar kinetic barrier was observed in the work plot for the SMD 
simulation of the SCAcQLALF complex structure steered at the Ac0Q1L2 sub-motif 
(Figure 3.7). 
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Figure 3.10 M362Chi2 angle during a 10 ns simulation of the E. coli SC. Green arrows 
indicate the "closed" conformation with Chi2 angle distributed around -180°; Red arrow 
indicates the "open" conformation with Chi2 angle around 70°. 
 
Figure 3.11 RMSF (Root Mean Square Fluctuation) plot of crystallographic waters 
during a 5 ns MD simulation of the native SC. Red square represents the structural 
water W0. 
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Figure 3.12 Radial distribution function of the distances between W0 and 
M362O/N320N, respectively. Data extracted from a 5 ns MD simulation of a native SC. 
 
Table 3.8 Solvation profile of the hydrogen bonding polar atoms in subsite I and II. 
 SASA (Probe radius 1.4 Å) 
SASA 
 (Probe radius 1.5 Å) 
∆SASA 
 (probe radius +0.1 Å) ∆SASA, % 
W0 2.7 2.3 -0.4 -15.6 
M362O 2.1 1.7 -0.4 -20.3 
P363O 19.2 19.1 -0.1 -0.6 
R365N 9.7 9.5 -0.2 -2.1 
G174O 28.1 28.3 0.2 0.6 
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Figure 3.13 (A, B) Model structures for SMD simulation of AcLF and AcQL 
dissociation from subsites I and II, respectively. The dipeptides are colored grey and the 
binding pockets white. Non-carbon atoms are CPK-colored.  Dashed lines represent H-
bonds. A bridging water (W0) is shown as a red sphere. (C, D) Boltzmann-averaged 
cumulative work of the dipeptides pulled for 5 Å from the mass center of the pockets. 
(E, F) Distances of H-bond pair atoms presented as a Boltzmann-average of 20 
simulation trajectories. (G, H) Number of water contacts (<3.4 Å) Boltzmann-averaged 
with 20 simulation trajectories. 
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3.4 Conclusion 
The E. coli SC has several binding partners,25 all interacting via a surface binding 
pocket through LMs with conserved residues. Such modularity is made possible with 
specific LM-SC interaction pairs in subsites I and II. This study has identified two 
critical subsite-specific interactions: (1) the non-polar contacts of the L4F5 sub-motif 
with subsite I, and (2) the H-bond network of the Q1 residue with subsite II mediated by 
a structurally conserved water molecule. In the proposed binding model, the L4F5 sub-
motif establishes primary contact with subsite I, and that this interaction should be 
entropically favourable due to desolvation of the hydrophobic L4F5 sub-motif and 
binding site. Anchoring of the L4F5 sub-motif assists the Q1 side chain in overcoming 
the kinetic barrier caused by slow formation of H-bonds with the conserved water as an 
ABPA of subsite II. The H-bond network formed upon positioning of Q1 in subsite II 
stabilizes the complex as the kinetic barrier similarly opposes association and 
dissociation. Dissociation occurs in the same order, with the L4F5 sub-motif dissociating 
first. 
This sequential binding model with the L4F5 sub-motif acting as an anchor driving 
both association and dissociation explains several biophysical observations, such as the 
impaired binding observed for alanine and glycine mutants at positions L4 and D3 
(glycine mutants pay a higher entropic penalty in ligand deformation, thus making the 
Ac0Q1L2 sub-motif less likely to bind). Another example is the electron density of the 
peptide in the SCAcALDLF complex, where the Ac0A1L2- sub-motif was absent while the 
L4F5 anchor still showed clear electron density. A third example comes from the fact 
that all peptides are fast binders because the kinetic barriers are absent or reduced 
following initial association of the L4F5 anchor.  
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Understanding the structural and thermodynamic basis for ligand recognition by the 
E. coli SC could inform design strategies for small-molecule inhibitors as probes or 
drugs. The sequential binding mechanism may be an important consideration for small-
molecule inhibition design if the critical interactions are to be reproduced.  
Our observations of LM binding to the SC may be broadly applicable to the many 
other examples of protein-LM recognition. As a general principle, the entropic penalty 
associated with reduction of LM flexibility on receptor binding could be an important 
factor that limits affinity. This principle may explain the commonly observed 
micromolar affinity associated with LM recognition. The flexibility of LMs is universal 
and since flexibility is a structural prerequisite for sequential binding, LMs can use this 
strategy for finding their optimal binding poses. The generality of sequential binding 
with LMs is supported by the prevalence of hydrophobic residues (leucine and/or 
phenylalanine)96,106,112,129 which could serve as the anchor points with their lower 
desolvation penalties driving binding in hydrophobic pockets. 
To date, inhibition of LM recognition for therapeutic purposes has yielded few 
successes. Despite the similarities, LM recognition may differ in the composition of the 
anchor motif (e.g. phosphoserine/threonine-containing anchor motif recognized by 
SH2/WW domains,130 PxxP binding to SH3 domain131) and potential structural 
transformation (folding-coupled binding in the case of P53 binding to MDM2).132 These 
factors complicate any effort to completely elucidate the binding process. The LM 
recognition by the E. coli SC is a relatively simple case where the binding has no 
allosteric consequences, allowing the effect of the sub-motifs to be partitioned. The 
sequential binding model with differential solvation as a key driver revealed here may 
also apply to evolutionarily related and/or biochemically similar systems, such as the 
PCNA-mediated interactions in eukaryotic DNA replication via recognition of a -
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Qxx[I/L]xxFF motif.133 Taking into account those structural and kinetic factors will 
assist drug design efforts targeting these systems. 
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Chapter 4  
Fragment screening  
with X-ray crystallography 
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4.1 Introduction 
X-ray crystallography was used as the primary technique in obtaining fragment hits 
against the SC. The E. coli SC gives crystals that are particularly robust and amenable 
to compound soaking as demonstrated in previous work regarding various peptidic 
ligands binding to the SC (see Chapter 3). The SC crystals have around 50% solvent 
content and therefore can be regarded as a highly concentrated protein at near molar 
level. Such high concentrations are favourable in identifying weak binders. Similarly, 
the fragment compounds can be used at high concentration (5 mM), which is the level 
of the expected binding affinity (Kd) of those fragments. High concentrations of both the 
receptor (the SC) and the ligands (fragment compounds) ensure the detection of weak 
binding affinity at the millimolar level. These interactions are barely detectable using 
solution-based assays owing to limited receptor concentration (usually at the 
micromolar level).  
4.2 Materials and Methods 
4.2.1 Fragment cocktails 
The First-Pass Screen library from Zenobia Therapeutics was chosen as a fragment 
library containing 352 fragment compounds in powder form. Their plate locations and 
IDs are shown in Appendix Table 1–4. These fragments were dissolved and diluted to 
the final concentration of 5 mM before screening. DMSO (50 µL) was added to each 
well of a 96-well plate to yield a 200 mM stock solution. Cocktails were prepared by 
mixing equal amounts of the 4 fragments: e.g. the first 4 fragments in a column (rows A, 
B, C and D) as one cocktail and the last 4 fragments (rows E, F, G and H) as another 
cocktail. A total of 88 cocktails were prepared and aliquoted into a separate plate (the 
cocktail plate). The concentration of each fragment in the cocktail was 50 mM. 
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4.2.2 Fragment compound soaking 
Crystals were grown as described in Chapter 2. Cocktails were added to the 
reservoir buffer of crystallization to yield a 10% (v/v) DMSO concentration equivalent 
to 5 mM concentration of each fragment compound. Soaking was carried out by moving 
crystals to reservoir buffer containing cocktail fragments. The SC crystals did not 
deteriorate significantly during the overnight soaks. One crystal experienced cracking or 
re-dissolved in the reservoir buffer.  
Additional cryo-protection agents were not needed since > 20% (v/v) PEG 400 was 
present in the reservoir buffer and that alone was sufficient. 
4.2.3 Crystal mounting, X-ray data collection, data processing and structure solution 
The general methods used in data collection at the Australian Synchrotron were 
described in Chapter 2. Diffraction images were collected at 100 K on beamline MX1. 
Crystals were rotated through 1° per frame, with 360 or 720 sequential frames collected 
per crystal. Exposure time was 0.4 to 0.8 second per frame. In most cases the crystal 
diffracted to resolutions of 3.0 Å or higher. Diffraction data sets were collected for 
crystals soaked with cocktails. Due to limited beam time at the Australian Synchrotron, 
3 X-ray data sets were collected using the in-house X-ray source (see Chapter 2). 
Diffractions images were reduced and crystal structures were determined as 
described in Chapter 2. Fragments bound with the SC were interpreted based on the 
electron density map and composition of the cocktail soaked into the crystal. The 
cocktails generally contain fragments of different geometry which aided the 
interpretation of the electron density and to decide which fragment to be modelled into 
the map. Individual validation of the fragment hits using an additional round of X-ray 
crystallography was not carried out due limited resources. 
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4.3 Results and Discussion 
4.3.1 Model building of the SC crystal structure and the fragment ligand 
Crystal structures were obtained for 87 out of 88 fragment soaks. One soak failed due 
to crystal disintegration. Crystals belonged to either the triclinic P1 or monoclinic P21 
space groups, which however could not be distinguished from examination under 
microscope). In both cases, there is one SC dimer per asymmetric unit comprised of two 
monomers. The SC structure was solved with molecular replacement using PDB 
deposition 1MMI36 (an apo-SC structure of space group P21) removed of all non-protein 
residues as the starting model. The binding pockets of both monomers are located 
adjacent to crystal contacts (Table 4.1). The electron densities of all structures were 
examined with particular emphasis on subsite I and II regions of each monomer. In 
several structures, electron density peaks not found in subsites I or II were interpreted as 
PEG chains of various length, calcium ions, chloride ions, or water molecules. 
Fragment compounds totalling 18 in number (Table 4.1 and Table 4.2) were 
identified corresponding to (> 3σ) positive density peaks in the mFo − DFc maps in 
subsite I of Chain A and/or Chain B in crystals of both P1 and P21 space groups. Those 
fragment hits were distinguished from the cocktails of fragments used based on the 
electron density map and its geometry. The chance of two fragments bound to the same 
site was considered unlikely due to the low hit rate. The fragment compounds were built 
into the electron density map using geometric restraints prepared using Monomer 
Library sketcher or PRODRG as described in Chapter 2. In case of ligands with poor 
electron density, occupancies were adjusted accordingly. These complex crystal 
structures are denoted as SCZTXXXX (SC for SC and ZTXXXX for the ID of the fragment 
compound, i.e. ZT0008) and their crystallographic data are shown in Table 4.3.  
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The corresponding fragments (Table 4.2) were built into the density and refined. 
Only subsite I was observed to bind fragments. In no cases was subsite II observed to 
bind any fragment compounds, although it appeared to be solvent accessible in most 
cases (Table 4.1). 
Compared with each other, subsite I in Chain A and Chain B have different local 
chemical environments due to different crystal packing (Table 4.1). This results in 
interference in the fragment binding at the subsite I of Chain B of P1-crystals. Detailed 
descriptions are given in Table 4.1.  
4.3.2 Pseudo-hits identified in the subsite I of Chain B of crystals of P1 space group 
Seven fragment compounds (ZT0784, ZT0273, ZT0694, ZT0789, ZT0773, ZT0860 
and ZT0817) were observed to bind to subsite I of chain B in P1-crystals only (Table 
4.2). One fragment compound (ZT0007, Table 4.2) was found to bind to subsite I in 
both chain A and chain B of crystals belonging to space group P1. Its electron density at 
chain A was very poor (detailed in section 4.3.3.4) in comparison to the binding at 
Chain B. Of these seven fragment compounds bound in subsite I of Chain B (but not 
Chain A), interaction with the residues of a symmetry-related molecule was observed. 
No binding in subsite I of Chain A was observed, and no symmetry-related molecule 
equivalent to that observed near subsite I of Chain B was present. These compounds 
were considered to be pseudo-hits since the interaction appears only to occur where 
crystallographic interactions are present. Their crystal structures will not be discussed 
further. Compound ZT0007, which also binds to the subsite I of Chain A, was 
considered a hit (Table 4.2). 
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4.3.2 Fragment hits 
4.3.2.1 ZT0602 
The fragment hit ZT0602 (3,4-difluorobenzamide), was found to bind to subsite I of 
Chain A of a crystal belonging to the P1 space group (Figure 4.1) but not Chain B, 
likely due to the presence of the crystal contact in Chain B. No apparent changes in the 
protein were found compared with the native structure. An alternative side chain 
conformation of S346 was observed, possibly as a result of the partial occupancy of the 
ZT0602. This ligand has relatively poor electron density to one side of the fragment ring, 
likely due to thermal fluctuations. The fluorine atom of the ligand is buried in a 
spherical pocket comprising amide backbones and side chains of hydrophobic residues 
V360 and M362. This pocket seems to favour the binding of halogen atoms bonded to 
phenyl rings due to its complementary shape. This region accommodates the leucine 
side chain of peptide ligands previously discussed (see Chapter 3.3.2). 
4.3.2.2 ZT0250 
The fragment hit ZT0250 (5-chloroindoline-2,3-dione), was found to bind to subsite I 
of Chain A of a crystal belonging to the P1 space group (Figure 4.2). No apparent 
differences in the protein were found compared with the native structure. An alternative 
side chain conformation of S346 was observed, probably as a result of the partial 
occupancy of ZT0250. This fragment has prominent electron density corresponding to 
the chlorine atom on the phenyl ring in comparison with other groups. The chlorine 
group is found buried in the spherical pocket in a manner similar to the halide group of 
ZT0602 (Figure 4.1). It could be a result of the larger atomic radius of a chlorine atom 
compared to carbon atom, and thus the stronger electron density. It could also partly due 
to that the binding at the spherical pocket is thermodynamically more stable than the 
binding to the rest of the subsite I. 
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4.3.2.3 ZT0082 
The fragment hit ZT0082 (5-chloro-1H-benzo[d]imidazole), was found to bind to 
subsite I of Chain A of a crystal belonging to the P1 space group (Figure 4.3). No 
disruption of the protein was found compared to the native structure. ZT0082 has 
weaker electron density compared with other fragments, making it a less reliable hit. 
This suggests lower ligand occupancy and thus poorer binding affinity.  
4.3.2.4 ZT0007 
The fragment hit ZT0007 (4-bromobenzamide), was found to bind to subsite I in 
both Chain A and Chain B of a triclinic crystal. Its binding at Chain B appears to be due 
to a symmetry-related molecule. Its binding to Chain A (Figure 4.4) appears more 
likely to reflect the binding in solution as there are no nearby crystal contacts. No 
apparent disruption of the protein was found compared with the native structure. An 
alternative side chain conformation of S346 was found, possibly as a result of the partial 
occupancy of ZT0007. This fragment has prominent electron density corresponding to 
the bromine atom on the phenyl ring, while the rest of the compound had poorer density 
apparently due to low occupancy. Therefore the binding pose of ZT0007 is not 
convincing since the poor electron density does not support a clear orientation of the 
ring. 
4.3.2.5 ZT0642 
The fragment hit ZT0642 (3-iodobenzoic acid), was found to bind to the subsite I of 
Chain B of a crystal belonging to the P21 space group (Figure 4.5). No apparent 
disruption of the protein was found compared to the native P21 structure, except for the 
side chain of M362. The shift in the M362 side chain is likely due to the large size of 
the iodine atom. ZT0642 has prominent electron density for the iodine atom on the 
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phenyl ring but not for the rest of the compound. Thus the ambiguous placement of the 
phenyl ring casts doubt on the overall binding pose of the ligand. 
4.3.2.6 ZT0447 
The fragment hit ZT0447 (6-nitro-1H-indazole), was found to bind to subsite I of 
Chain A of a triclinic crystal (Figure 4.6). No apparent changes in protein structure 
were found comparing to the native P1 crystal structure. ZT0447 has excellent electron 
density that allowed unambiguous interpretation of the binding pose. ZT0447 does not 
have any halogen-containing moiety occupying the hydrophobic and spherical pocket 
but instead has a nitro-group forming H-bonds with both the side chain of S346 and a 
crystallographic water molecule.  
4.3.2.7 ZT0445 
The fragment hit ZT0445 (5-nitro-1H-indole), was found to bind to the subsite I of 
Chain A of a crystal belonging to the P1 space group (Figure 4.7). No apparent 
disruption of the SC was found compared to the native structure. ZT0445 has very good 
electron density allowing unambiguous assignment of the binding pose, which is the 
same as in the case of ZT0447.  Similar to ZT0447, ZT0445 does not have any halogen-
containing moiety occupying the spherical pocket but instead has a nitro group in H- 
bonding distance of both the side chain of S346 and a crystallographic water molecule.  
4.3.2.8 ZT0834 
The fragment hit ZT0834 (1-(4-nitrophenyl)piperazine), was found to bind to the 
subsite I of Chain A of a SC crystal belonging to the P1 space group (Figure 4.8). No 
apparent changes in the binding site due to fragment binding were observed. ZT0834 
has poor electron density, and neither the phenyl ring nor the piperazine ring could be 
modelled into the electron density map with confidence. However, the overall electron 
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density does suggest its binding, particularly the nitro group which is involved in an H-
bond with the side chain of S346. The geometry of ZT0834 adopts an “S” shape 
complementary to the shape of subsite I. This was not observed in the previous 
fragment-bound structures: the other fragment compounds are smaller and only occupy 
about a half of the subsite and have no interactions with P242 or R152. However, 
although the ZT0834 indicate the possibility of fragment growth to occupy all of subsite 
I, it is not a good example owing to the poor electron density and thus apparent low 
occupancy compared with other hits. 
4.3.2.9 ZT0428 
The fragment hit ZT0428 (4-methyl-5-nitropyridin-2-amine), was found to bind to 
the subsite I of Chain A of a triclinic crystal (Figure 4.9). No apparent disruption of the 
protein structure was observed in comparison to the native structure. ZT0445 has good 
electron density for the nitro group but not for the rest of the compound. The nitro group 
is involved in an H-bond with the side chain of S346, similar to the binding of both 
ZT0447 and ZT0445. 
4.3.2.10 ZT0835 
The fragment hit ZT0835 (1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone), was 
found to bind to the subsite I of Chain A of a crystal belonging to the P1 space group 
(Figure 4.10). No changes in protein structure were observed due to fragment binding. 
ZT0445 has poor electron density overall. However, the ligand was placed in density in 
a similar fashion to the piperazine scaffold as ZT0834. It also shares a binding pose 
similar to ZT0834 with an H-bond observed between the phenol group and the S346 
side chain. 
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4.3.3 Summary of the fragment hits. 
All fragment hits were found to bind in subsite I. Several of them had halogen atoms 
buried in a pocket consisting of the side chains of V360, Val361, Met 362 and S346. 
Those fragments without this interaction had nitro- or phenol-groups forming hydrogen 
bonds with the side chain of S346. The binding of the fragments had no observable 
effect on the overall shape of the protein structure. With the exception of residues S346 
and M362, no side chain conformations were observed to change. The binding of 
halogen-containing fragments appeared to induce a shift in the S346 side chain, but the 
effect was ambiguous due to the limited occupancy of the ligands. One fragment, 
ZT0642 (Table 4.2, Figure 4.5) contains an iodine atom that bound close to M362 and 
appears to be responsible for the observed shift in the side chain conformation. 
Movements in S364 and M362 were previously observed in crystal structures of SC-
peptide complexes (see Chapter 3). 
4.3.4 Affinity estimation based on crystallographic occupancy determined with relative 
temperature factors 
4.3.4.1 Binding affinity estimation based on crystallographic occupancy 
The fragment compounds screened using X-ray crystallography have an average 
molecular weight around 150 Dalton, approximately 4 times smaller than pentameric 
peptides (see Chapter 3). The small size and the limited number of possible 
interactions impose a limit on the affinity of the fragment compounds. The consensus 
motif of a pentameric peptide generally has micromolar Kd affinity, equivalent to a 
Gibbs free energy of binding of around -8 kcal/mol. A fragment compound that are 
about one quarter of the size should have proportionally smaller Gibbs energy of 
binding (in the order of -2 kcal/mol), placing their Kd values in the millimolar range. 
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Binding affinities in the millimolar range cannot be accurately measured with 
fluorescence polarization assays (or indeed most solution-based assays) due to the low 
receptor (SC) concentrations and limited ligand solubility at the concentration range 
required for binding assays. The poor electron density observed for most fragment 
compounds in the crystal structures support their low affinity and therefore the low 
ligand occupancy (this could be attributed to incomplete soaking but unlikely). Ligand 
occupancy can be estimated using the relative B-factors of ligand and receptor atoms 
and can be used to estimate the dissociation constant (Kd) in the crystal.134 The 
temperature factor of T172Oγ atom was used as a reference to represent the 
thermodynamic movement of molecules in the region closest to the bound ligand. The 
temperature factor of the ligand atom closest to the T172Oγ was compared to that of 
T172Oγ, and the ratio can be deemed as the crystallographic occupancy. The Kd can be 
approximated taking into account the fragment compound concentration used in soaking 
([L]), which was 5 mM in all cases:134  
Occupancy = (Ligand B-factor)/( T172Oγ B-factor) 
Kd = ((1/Occupancy)-1) x [L] 
The resulting Kd values were used to calculate the Gibbs free energy of binding and 
ligand efficiency (See Table 4.4). 
4.3.4.2 Lipoligand efficiency (LLEAT) 
Ligand efficiency (LE) is generally used to show the efficiency of ligand-binding in 
terms of binding affinity and ligand size. A limitation of LE is the failure to account for 
the solvation/desolvation profiles of the ligand. For example, a potent hydrophobic 
ligand may not be soluble enough to have a favourable pharmacological profile. The 
solvation and desolvation profiles of a compound (i.e., the LogD value under 
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physiological conditions) is critical to a compound’s pharmacological potential. 
Lipoligand efficiency (LLEAT) was used as an indicator of the suitability of the ligands 
(or compounds) which takes the LogD values (at pH 7.2) of the compounds into account. 
LLEAT was introduced by Mortenson et al. as an advanced indicator of compound 
potency and potential to be developed into drug-like molecules.135 Its calculation 
includes the compound’s solubility as a variable.  
The equations used to determine the LLEAT and related terms in Table 4.4 are 
detailed below: 
LE = –∆G/HAC 
      = –RTln(Kd)/HAC 
∆G* = ∆G – ∆Glipo 
        =RTln(Kd) + RTLogD 
LLEAT = 0.11 - ∆G*/HAC 
Where LE is the Ligand efficiency, HAC is the heavy atom counts, LogD is the 
Partition coefficient at pH 7.2 and LLEAT is the Lipoligand efficiency. Ligands with 
values around 0.3 suggest balanced binding affinity, molecular weight and solubility. 
4.3.4.3 Estimated affinity and LLEAT for the fragment hits 
The temperature factors for ligands (Ligand B-factor, Table 4.4) are generally higher 
than the temperature factors for the receptor residue (T172Oγ B-factor, Table 4.4). This 
gave ligand occupancies mostly less than 50% (Occupancy, Table 4.4). Since the 
concentration of the fragment compounds used for soaking was 5 mM, the affinity in 
crystallo (Kd, Table 4.4) and Gibbs free energy (ΔG, Table 4.4) can be calculated. The 
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numbers of the non-hydrogen heavy atom were presented (HAC, Table 4.4) and then 
the ligand efficiency values followed (LE, Table 4.4). 
The fragment hits generally have estimated affinities in the range 5 to 20 mM. These 
estimates are only approximate: the tightest binding fragments cannot be distinguished 
among the ensemble. Since the differences of the affinity values of the fragment hits 
were not in the order of magnitudes, it does not contribute significantly to the 
calculation of LLEAT values, which are more reliant on the solvation and desolvation 
profiles of a compound. The LLEAT values were used to aid the decision of which 
fragments to select for further development. However, the results (LLEAT, Table 4.4) 
found that most of the fragment lay within the range of 0.2 to 0.4. The LLEAT metric 
puts significant weight on the desolvation energy. LLEAT values for fragments can be 
misleading since modification of functional groups or the scaffold can significantly alter 
the LogD values (LogD, Table 4.4) in comparison to the effects of modification on 
larger compounds. Therefore, those fragments with LLEAT values between 0.2-0.4 are 
considered worthy of further consideration. 
4.3.5 Directions for fragment growth 
4.3.5.1 The preference of halogenated aromatic rings 
Many fragment hits had halogenated aromatic rings. The halogen atoms of the 
fragments were consistently found to occupy an approximately spherical pocket 
comprised of the side chains of hydrophobic residues. In these complex crystal 
structures, the halogen atoms are the most prominent, as demonstrated by the clear 
electron density, suggesting thermodynamically stabilized interactions of the halogen 
atoms with the adjacent residues and/or the higher number of electrons possessed by 
chlorine, bromine and iodine atoms. Halogenated aromatic rings were therefore 
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postulated to be desirable moieties to be preserved in further development of the 
fragment hits. As to which halogen might be used in further design, iodine- and 
bromine-containing fragment hits (ZT0007 and ZT0642, Figure 4.4-4.5) that had 
relatively poor electron density were precluded. The LLEAT values for the two fragment 
compounds are not within the acceptable range (0.2 - 0.4). Further design efforts 
focused mainly on fluoro and chloro substitutions on aromatic rings. 
4.3.5.2 H-bonds with S346 are critical to the affinity 
Several fragment hits featured nitro-groups on aromatic rings. Despite having no 
halogen atoms to occupy the spherical pocket, good electron was density for ZT0047 
and ZT0045 was observed in their respective complex crystal structures with the SC 
(Figures 4.6-4.7). These fragment compounds have hetero rings of similar geometry to 
ZT0082 (Figure 4.3) but much better electron density and possibly higher binding 
affinity (Table 4.4). The major difference is the presence of H-bonds with the side chain 
of S346: ZT0047 and ZT0045 have multiple H-bonds including one with S346 while 
ZT0082 forms no H-bonds. The H-bond with S346 is a favourable interaction that could 
be reproduced in candidate inhibitors. Halogenated rings could be combined with 
functional groups capable of making H-bonds with S346 (e.g., carboxylic acid, phenol, 
or carbonyl groups). A cursory examination of the binding poses of fragment hits 
containing halogen atoms or nitro groups indicate that these two substitutions should be 
able to form favourable interactions with the substituents in the ortho position. 
4.3.5.3 Fragment growth to occupy the entire subsite I 
All fragment hits occupied subsite I, having contacts with residues S346, V360, L177, 
V247, M362 and T172. Two other fragment hits (ZT0834 and ZT0835) extended 
toward a shallower region in the vicinity of P242 and R152. These two residues are 
responsible for the slight bend in the subsite I cavity, mostly because the side chain of 
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P242 protrudes into the binding site. In the cases of the binding of both ZT0834 and 
ZT0835 (Figure 4.8-4.9), their piperazine rings have the flexibility to prevent clashes 
with P242. The guanidine group of the R152 side chain may be another driving force of 
the positioning of ZT0834 and ZT0835 due to the formation of H-bonds with the aceto 
group of ZT0835, and the presence of a bridging water molecule in between the R152 
and the piperazine amine of ZT0834. Although these two fragment hits had poor 
electron density, they are informative in guiding the design of an aromatic scaffold with 
an extended flexible component. 
4.3.5.4 M362 as a gating residue may allow extension of developed fragments to subsite 
II 
Residue M362 was previously identified as a gate controlling the channel from 
subsite I to subsite II. M362 had no significant change in conformation in most crystal 
structures of the fragment hits bound with the SC. The only exception was ZT0642 
(Figure 4.5), which triggered the opening of the gating residue M362 in a similar 
fashion to what was observed with the binding of AcLF dipeptide (see Chapter 3). The 
AcLF dipeptide has an acetyl group occupying the channel between subsite I and 
subsite II, but ZT0642 does not have such substructure. A plausible explanation for the 
perturbation of M362 is that the large radius of the iodine atom, which may impose 
steric hindrance upon the M362 side chain.  
4.4 Conclusion 
A total of 352 fragment compounds were screened with X-ray crystallography and, 
despite 6 questionable hits that appeared to be a result of crystal packing, 11 hits were 
identified. Among them 4 (ZT0602, ZT0250, ZT0447 and ZT0445) have electron 
density in the 2mFo-DFc map that unambiguously support the binding pose of the 
fragments compounds while the other 7 had weaker electron density.  
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Analysis of protein-fragment interactions revealed binding of halogen groups at a 
pocket comprised of hydrophobic residues V360, L177, V247 and M362. A halogen-
bond with the side chain of S346 was found to be important to the binding affinity.  
Most fragment hits occupy only the deep region of subsite I while binding at the 
shallow region of the subsite I was observed two larger fragment hits (ZT0834 and 
ZT0835). 
The finding that most fragment hits bind to the deep region of subsite I and no hits in 
subsite II is consistent with the study of LM recognition by the E. coli SC (Chapter 3). 
The sequential binding model proposed for LM recognition suggests the subsite I as the 
“anchor site” which shall be preferentially occupied compared with subsite II. All 
fragment hits have aromatic ring(s) with or without halogen substituents bound at the 
deep region, where the leucine residue of the LF sub-motif of peptidic ligands is 
positioned when bound. This is corroborative evidence that the deep region of subsite I 
is the hotspot of molecular recognition by the SC. Additionally, ZT0834 and ZT0835 
also occupy the shallow region where the phenylalanine residue of the LF sub-motif is 
positioned, which may have positive contributions to the binding affinity. 
Ligand occupancies of the fragments were estimated based on the temperature 
factors of a ligand atom relative to the closest SC atom. In turn, the occupancy was used 
to estimate the affinity in crystallo. The calculated Kd values suggested millimolar 
affinity for all fragment hits and further analysis of their lipo-ligand efficiency (LLEAT, 
Table 4.4) provided aid in the decision as to which fragment were entered into the next 
round of development. The fragment hits with LLEAT values between 0.2-0.4 were 
deemed most promising with favourable desolvation profiles and will be highlighted in 
future hit-to-lead development. 
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Table 4.1 Summary of fragment hits found in the binding pocket of the SC monomers (Chain A and Chain B) in crystals of P1 or P21 space 
groups. 
 Chain A Chain B 
Space 
group Subsite I Subsite II Subsite I Subsite II 
P1 
Accessible 
 11 fragment hits were found 
Occupied, 
by a loop from the symmetry 
related molecule. 
No fragment hit was found. 
Partially occupied, 
by a Glu residue of a 
symmetry related molecule. 
6 fragment hits were found. 
Accessible. 
No fragment hit was found. 
P21 
Accessible, 
but slightly compressed by a 
symmetry related molecule. 
No fragment hit was found. 
Accessible. 
No fragment hit was found. 
Accessible 
1 fragment hit was found. 
Occupied, 
by a loop from the symmetry 
related molecule. 
No fragment hit was found. 
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Table 4.2 Fragment compounds identified to bind to the subsite I of the SC. 
 
Plat
e 
No. 
Well ID Chemical structures 
Space 
group 
Binds to 
Chain A 
Binds to 
Chain B 
1 1 1C ZT0007 
 
P1 Y Y 
2 1 4G ZT0250 
 
P1 Y N 
3 1 10H ZT0602 
 
P1 Y N 
4 1 11H ZT0428 
 
P1 Y N 
5 2 1G ZT0447 
 
P1 Y N 
6 2 6E ZT0445 
 
P1 Y N 
7 2 7B ZT0082 
 
P1 Y N 
8 3 2H ZT0784 
 
P1 N Y 
9 3 7A ZT0273 
 
P1 N Y 
10 3 8E ZT0642 
 
P21 N Y 
11 3 9H ZT0817 
 
P1 Y Y 
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Table 4.2 (continued) Fragment hits identified to bind to the subsite I of the SC. 
 
Plat
e 
No. 
Well ID Chemical structures 
Space 
group 
Binds to 
Chain A 
Binds to 
Chain B 
12 4 3B ZT0694 
 
P1 N Y 
13 4 3F ZT0789 
 
P1 N Y 
14 4 6G ZT0860 
 
P1 N Y 
15 4 8D ZT0773 
 
P1 N Y 
16 4 7G ZT0834 
 
P1 Y N 
17 4 8G ZT0835 
 
P1 Y N 
Y: yes; N: no. 
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Table 4.3 Data collection and refinement statistics of E. coli SC in complex with fragment hits. 
Name SCZT0007 SCZT0835* SCZT0250 SCZT0602 SCZT0428 SCZT0447 
Data collection 
Space group P1 P1 P1 P1 P1 P1 
Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
41.16, 64.60, 71.99/      
74.61, 83.32, 84.90 
a, b, c (Å)/α, β, γ (°) 
40.92, 65.01, 72.02/ 
74.15, 83.37, 85.12 
a, b, c (Å)/α, β, γ (°) 
40.72, 64.04, 71.70/      
73.88, 82.29, 84.03 
a, b, c (Å)/α, β, γ (°) 
40.74, 64.51, 71.72/      
74.01, 83.21, 84.54 
a, b, c (Å)/α, β, γ (°) 
40.87, 64.38, 71.67/ 
73.97, 82.57, 84.60 
a, b, c (Å)/α, β, γ (°) 
40.88, 64.67, 72.02/      
73.97, 83.55, 84.36 
Resolution (Å) 28.75-1.67(1.76-1.67) 53.97- 2.03 (2.14-2.03) 28.86 - 1.80 (1.90-1.80) 30.38-1.73 (1.82-1.73) 30.33- 2.00 (2.11-2.00) 30.51 - 1.70 (1.79-1.70) 
Rmerge (%) 5.6(40.3) 5.3 (31) 6.4(39.9) 6.7(55.1) 6.2(23.4) 4.8(32.8) 
No. of Reflections 234038 167496 235693 242483 144280 242187 
Unique Reflections 79710 (11444) 42901 (6002) 61187 (8833) 66608 (8933) 39267 (4918) 64167 (9074) 
Mean I/σ(I) 13.3 (2.6) 18.7 (4.3) 14.3 (3.2) 9.9 (2.1) 14.4 (6.2) 15.2 (3.4) 
Completeness 
 
96.9 (95.4) 94.1 (90.3) 91.7 (91.9) 91.7 (84.2) 83.6 (71.8) 83.0 (80.4) 
Multiplicity 2.9 (3.0) 3.9 (3.6) 2.0 (1.9) 3.6 (3.6) 3.7 (3.5) 3.8 (3.7) 
Refinement 
Resolution (Å) 27.72 -1.67 (1.71-1.67) 53.97 -2.03 (2.08-2.03) 28.32 - 1.80 (1.85-1.80) 29.91 -1.73 (1.78-1.73) 28.08 -2.00 (2.05-2.00) 28.72 - 1.70 (1.74-1.70) 
Rwork/Rfree (%) 17.7(25.6)/22.3(31.6) 23.3(26.8)/30.1(36.3) 18.6(26.4)/22.4(30.3) 24.8(35.5)/29.2(44) 20.2(28.0)/26.4(29.6) 22.9(33.3)/27.4(41.9) 
R.m.s 
 
      
Bond lengths 
 
0.0206 0.0115 0.0068 0.0098 0.0084 0.0084 
Bond angles (º) 2.1209 1.4105 1.2819 1.4687 1.2873 1.3279 
B-factors       
M. Chain 16.7 21.4 18.5 20.6 19.3 19.4 
S. Chain & Water 23.4 24.8 23.3 24.1 23.2 22.8 
Ligands** 64.4 50 49.7 41.5 43.3 35.6 
Ramachandran 
Plot Outliers 0.43% 0.84 % 0.43 % 0.57 % 0.28 % 0.43 % 
Values for data in the highest resolution shell are given in parentheses.  
Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the wavelength of 0.95 Å Diffraction data were processed with MOSFLM and SCALA. 
*Diffraction data collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. **Ligands refer to the fragment compounds bound with Chain A. 
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Table 4.3 (continued) Data collection and refinement statistics of E. coli SC in complex with fragment hits. 
Name SCZT0445 SCZT0082 SCZT0784 SCZT0273 SCZT0642 SCZT0817 
Data collection 
Space group P1 P1 P1 P1 P21 P1 
Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
40.88, 64.78, 72.59/      
73.91, 84.51, 84.89 
a, b, c (Å)/α, β, γ (°) 
40.75, 64.33, 72.17/ 
74.05, 82.47, 84.15 
a, b, c (Å)/α, β, γ (°) 
41.21, 64.67, 71.92/      
74.46, 83.50, 84.94 
a, b, c (Å)/α, β, γ (°) 
41.09, 64.55, 72.01/      
74.25, 83.51, 84.60 
a, b, c (Å)/α, β, γ (°) 
79.73, 68.07, 82.72/ 
90.00, 115.81, 90.00 
a, b, c (Å)/α, β, γ (°) 
40.89, 64.65, 71.96/      
74.01, 82.86, 84.10 
Resolution 
Å  
28.90-1.97(2.08-1.97) 30.19- 2.05 (2.16-2.05) 29.23 - 2.00 (2.11-2.00) 29.07-1.83 (1.93-1.83) 30.5- 2.30 (2.42-2.30) 30.34 - 1.8 (1.90-1.80) 
Rmerge (%) 5.6(19.1) 12.8 (59) 4.2(15.3) 4.4(20.4) 11.2 (61.3) 7.2(41.4) 
No. of Reflections 153662 158461 80216 202200 204523 226644 
Unique Reflections 42650 (6264) 40969 (5896) 41193 (5348) 52413 (6975) 34671 (4631) 59986 (8586) 
Mean I/σ(I) 12.7 (6.4) 9.2 (2.2) 11.8 (6.8) 17.8 (6.5) 11.4 (2.3) 9.2 (2.5) 
Completeness 
 
84.8 (85.2) 93.7 (92.7) 85.9 (76.4) 84.2 (77.0) 97.2 (89.2) 92.3 (90.3) 
Multiplicity 3.6 (3.3) 3.9 (3.7) 1.9 (1.9) 3.9 (3.8) 5.9 (5.2) 3.8 (3.5) 
Refinement 
Resolution (Å) 28.90 -1.97 (2.02-1.97) 30.19 -2.05 (2.10-2.05) 28.01 - 2.00 (2.05-2.00) 29.07 -1.83 (1.877-1.83) 28.38 -2.5 (2.35-2.3) 27.6 - 1.80 (1.85-1.80) 
Rwork/Rfree 
 
23.5(30.8)/30.5(42) 20.1(26.2)/24.8(31.2
 
21.1(25.2)/25.5(28.4) 22.1(30.3)/28.5(37.1
 
28.4(34.5)/34.4(34.8) 26.4(34.1)/30.4(41.5
 R.m.s 
 
      
Bond lengths 
Å  
0.0078 0.01 0.0063 0.0092 0.0049 0.0114 
Bond angles 
 
1.3037 1.4456 1.1794 1.3732 0.9546 1.5433 
B-factors       
M. Chain 20.2 21.2 16.8 20.1 34.8 20.6 
S. Chain & Water 22.9 25.0 19.28 24.2 35.5 24.1 
Ligands** 36.3 62.5 27.4 29.1 86.7 65.7 
Ramachandran 
Plot Outliers 0.56% 0.70 % 0.28 % 0.42 % 0.87 % 0.84 % 
Values for data in the highest resolution shell are given in parentheses.  
Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the wavelength of 0.95 Å Diffraction data were processed with MOSFLM and SCALA. 
*Diffraction data collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. **Ligands refer to the fragment compounds bound with Chain A 
(Chain B in the case of SCZT0642). 
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Table 4.3 (continued) Data collection and refinement statistics of E. coli SC in complex with fragment hits. 
Name SCZT0694 SCZT0789 SCZT0860 SCZT0773 SCZT0834*  
Accession code unavailable unavailable unavailable unavailable unavailable  
Data collection 
Space group P1 P1 P1 P1 P1  
Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
41.11, 64.62, 71.97/      
74.77, 83.50, 84.96 
a, b, c (Å)/α, β, γ (°) 
40.85, 64.36, 71.82/ 
74.31, 83.10, 84.24 
a, b, c (Å)/α, β, γ (°) 
41.05, 64.77, 72.07/      
74.33, 83.37, 85.08 
a, b, c (Å)/α, β, γ (°) 
40.97, 64.68, 72.22/      
74.50, 83.55, 84.99 
a, b, c (Å)/α, β, γ (°) 
41.01, 64.76, 72.07/ 
74.30, 83.08, 84.90 
 
Resolution (Å) 29.25-1.80(1.90-1.80) 30.32- 2.10 (2.21-2.10) 29.24 - 1.89 (1.99-1.89) 29.18-1.90 (2.00-1.90) 53.78- 2.10 (2.21-2.10)  
Rmerge (%) 4.3(16) 7.0 (25.7) 6.9(36.9) 4.4(12.3) 11.8 (60.5)  
No. of Reflections 191150 144776 196211 178727 151631  
Unique Reflections 55546 (8292) 37517 (5427) 52282 (7174) 46580 (5411) 38819 (5539)  
Mean I/σ(I) 17.3 (6.5) 15.1 (4.7) 13.2 (3.2) 21.3 (10.8) 10.0 (2.7)  
Completeness 
 
84.6 (86.7) 92.1 (90.8) 92.1 (86.8) 83.4 (66.2) 94.0 (91.6)  
Multiplicity 3.4 (3.4) 3.9 (3.7) 3.8 (3.4) 3.8 (3.7) 3.9 (3.8)  
Refinement 
Resolution (Å) 29.25 -1.80 (1.85-
 
28.94 -2.10 (2.15-
 
28.67 - 1.89 (1.94-
 
27.99 -1.90 (1.95-
 
41.16 -2.10 (2.15-
 
 
Rwork/Rfree 
 
20.9(24.1)/26.3(32.3) 19.8(20.7)/23.5(26.3) 19.8(24.7)/24.5(30.1) 20.9(33.0)/25.0(36.6) 23.1(29.0)/29.0(36.5)  
R.m.s 
 
      
Bond lengths 
Å  
0.0079 0.0064 0.0083 0.0085 0.0065  
Bond angles (º) 1.2917 1.1450 1.3213 1.2818 1.2044  
B-factors       
M. Chain 15.7 20.1 20.6 16.5 21.1  
S. Chain & Water 20.1 23.1 24.6 20.1 24.0  
Ligands** 19.9 16 47.8 29.4 64.1  
Ramachandran 
Plot Outliers 0.28% 0.28 % 0.28 % 0.56 % 0.42 %  
Values for data in the highest resolution shell are given in parentheses.  
Diffraction data collected at BeamlineMX1, Australian Synchrotron, at the wavelength of 0.95 Å Diffraction data were processed with MOSFLM and SCALA. 
*Diffraction data collected at home-sourced X-ray generator at the wavelength of 1.5418 Å. **Ligands refer to the fragment compounds bound with Chain A. 
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Figure 4.1 Fragment hit 3,4-difluorobenzamide found in subsite I of Chain A 
(Fragment ID: ZT0602). The SC is shown with carbon atoms coloured white and the 
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK 
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red 
spheres represent water molecules. 
 
Figure 4.2 Fragment hit 5-chloroindoline-2,3-dione found in subsite I of Chain A 
(Fragment ID: ZT0250). The SC is shown with carbon atoms coloured white and the 
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK 
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red 
spheres represent water molecules. 
 95 
 
Figure 4.3 Fragment hit 5-chloro-1H-benzo[d]imidazole found in subsite I of Chain A 
(Fragment ID: ZT0082). The SC is shown with carbon atoms coloured white and the 
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK 
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red 
spheres represent water molecules. 
 
Figure 4.4 Fragment hit 4-bromobenzamide found in the subsite I of Chain A 
(Fragment ID: ZT0007). SC is shown with carbon atoms coloured white and the carbon 
atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK colours. 
Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red spheres 
represent water molecules. 
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Figure 4.5 Fragment hit 3-iodobenzoic acid found in subsite I of Chain B (crystal space 
group P21, Fragment ID: ZT0642). SC is shown with carbon atoms coloured white and 
the carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in 
CPK colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. 
Red spheres represent water molecules. 
 
Figure 4.6 Fragment hit 6-nitro-1H-indazole found in subsite I of Chain A (Fragment 
ID: ZT0447). The SC is shown with carbon atoms coloured white and the carbon atoms 
of the fragment hit coloured light green. Non-carbon atoms are in CPK colours. Wire 
basket represents 2mFo-DFc electron density map contoured at 1 σ. Red spheres 
represent water molecules. Red dashed lines represent H-bonds. 
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Figure 4.7 Fragment hit 5-nitro-1H-indole found in subsite I of Chain A (Fragment ID: 
ZT0445). The SC is shown with carbon atoms coloured white and the carbon atoms of 
the fragment hit coloured light green. Non-carbon atoms are in CPK colours. Wire 
basket represents 2mFo-DFc electron density map contoured at 1 σ. Red spheres 
represent water molecules. Red dashed lines represent H-bonds. 
 
Figure 4.8 Fragment hit 1-(4-nitrophenyl)piperazine found in subsite I of Chain A 
(Fragment ID: ZT0834). The SC is shown with carbon atoms coloured white and the 
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK 
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red 
spheres represent water molecules. Red dashed lines represent H-bonds. 
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Figure 4.9 Fragment hit 4-methyl-5-nitropyridin-2-amine found in subsite I of Chain A 
(Fragment ID: ZT0428). The SC is shown with carbon atoms coloured white and the 
carbon atoms of the fragment hit coloured light green. Non-carbon atoms are in CPK 
colours. Wire basket represents 2mFo-DFc electron density map contoured at 1 σ. Red 
spheres represent water molecules. Red dashed lines represent H-bonds. 
 
Figure 4.10 Fragment hit 1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone found in 
subsite I of Chain A (Fragment ID: ZT0835). The SC is shown with carbon atoms 
coloured white and the carbon atoms of the fragment hit coloured light green. Non-
carbon atoms are in CPK colours. Wire basket represents 2mFo-DFc electron density 
map contoured at 1 σ. Red spheres represent water molecules. Red dashed lines 
represent H-bonds. 
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Table 4.4 Binding affinities of fragment hits based on crystallographic occupancy and lipoligand efficiency (LLEAT) analysis. 
Fragmen
t hits 
Plate 
No. Well 
Ligand B-
factor 
T172 Oγ 
B-factor 
Occupan
cy Kd, mM 
ΔG at 
300K, 
kcal/mo
l 
HA
C 
LE, 
kcal/mol 
LogD 
(pH 
7.2) 
ΔGlipo, 
kcal/mol 
ΔG*, 
kcal/mo
l 
LLEAT 
1  
1 1C 35.45 12.13 0.34 9.61 -2.78 10.00 0.28 1.47 -2.02 -0.76 0.19 
2  1 4G 39.35 5.49 0.14 30.84 -2.08 
12.0
0 0.17 1.12 -1.54 -0.54 0.15 
3  
1 10H 38.28 14.07 0.37 8.60 -2.85 11.00 0.26 1.08 -1.49 -1.36 0.23 
4  1 11H 42.86 9.40 0.22 17.80 -2.41 
11.0
0 0.22 0.94 -1.30 -1.12 0.21 
5  2 1G 24.64 16.43 0.67 2.50 -3.59 
12.0
0 0.30 1.35 -1.86 -1.73 0.25 
6  2 6E 33.66 14.38 0.43 6.70 -3.00 
12.0
0 0.25 -0.48 0.66 -3.66 0.41 
7  
2 7B 66.21 12.14 0.18 22.27 -2.28 12.00 0.19 2.00 -2.76 0.48 0.07 
8  
3 2H n/a n/a n/a n/a n/a 15.00 n/a 3.59 n/a n/a n/a 
9  3 7A n/a n/a n/a n/a n/a 
16.0
0 n/a 2.29 n/a n/a n/a 
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Table 4.4 (continued) Binding affinities of fragment hits based on crystallographic occupancy and lipoligand efficiency (LLEAT) analysis. 
Fragment 
hits 
Pla
te 
No
. 
Well Ligand B-factor 
T172 Oγ 
B-factor 
Occupan
cy 
Kd, 
mM 
ΔG at 
300K, 
kcal/mo
l 
HA
C 
LE, 
kcal/mo
l 
LogD 
(pH 
7.2) 
ΔGlipo, 
kcal/mol 
ΔG*, 
kcal/mol LLEAT 
10  3 8E 24.65 28.61 1.16 -0.69 n/a 
10.0
0 n/a -0.50 0.68 n/a n/a 
11  
3 9H 71.31 13.16 0.18 22.09 -2.28 14.00 0.16 2.93 -4.04 1.76 -0.02 
12  
4 3B n/a n/a n/a n/a n/a 12.00 n/a -2.05 n/a n/a n/a 
13  4 3F n/a n/a n/a n/a n/a 
13.0
0 n/a 1.04 n/a n/a n/a 
14  
4 6G n/a n/a n/a n/a n/a 11.00 n/a 2.77 n/a n/a n/a 
15  
4 8D n/a n/a n/a n/a n/a 11.00 n/a -2.05 n/a n/a n/a 
16  
4 7G 43.62 13.85 0.32 5.37 -3.13 15.00 0.21 -0.31 0.43 -3.55 0.35 
17  
4 8G 50.09 15.95 0.32 5.35 -3.13 16.00 0.20 0.52 -0.72 -2.41 0.26 
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Chapter 5  
Fragment development  
and binding characterization 
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5.1 Introduction 
5.1.1 Design strategy for fragment development 
Three classical strategies for fragment development: expansion, merging and 
tethering, have been explored. Expansion refers to finding chemical structures that 
contain the scaffold of a fragment hit. Merging refers to chemical structures that are 
composites of moieties of two or more fragment hits. Tethering, however, requires two 
fragment hits bound respectively to individual sites adjacent to each other.  
The three strategies were used in the search for candidate compounds from the UCSF 
ZINC library. The ZINC Database contains commercially available compounds for 
structure-based virtual screening.136 It currently contains about 21 million compounds 
that are commercially available, provided in ready-to-dock 3D-structure formats with 
molecules represented in biologically relevant forms.136 Substructure searches and 
similarity searches based on the fragment chemical structures were carried out to 
identify candidate binders. 
5.1.2 Prediction of ligand binding pose using molecular docking 
Molecular docking was applied in pose prediction. Most scoring functions for 
docking programs are empirical and are derived from the affinity of known inhibitors to 
their targets. Since most known targets are enzymes, membrane transporters and/or G-
protein coupled receptors, there is bias toward these targets. The SC, on the other hand, 
is a hub mediating protein-protein interaction, and therefore the aforementioned 
empirical functions may be biased against such a distinct class of targets. Therefore, 
UCSF DOCK6, which applies force-field based functions in scoring, was selected.137 
Grid score is a fast, force field-based scoring function that was used as the primary 
metric used to rank initial hits. Grid score is a fast force field-based scoring function 
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accounting for van der Waals (VDW) interaction and electrostatic interactions. The 
Hawkins GB/SA score is used as a secondary ranking metric. Amber score138 was used 
as an additional ranking metric. The Amber score is obtained through a molecular 
dynamics simulation of the ligand-receptor complex and molecular mechanics 
calculation of the binding energy with GB/SA solvation. 
Chimera was used for molecular visualization. It affords the visualization of docked 
ligands in various poses139 and can cluster predicted binding poses based on interactions 
with adjacent amino acid residues.  
Fragment hits described in Chapter 4 were docked to the SC and analysed based on 
the scores (with emphasis on the Amber score). Their binding poses were visually 
inspected. Substructure and similarity searches were carried out and the candidate 
compounds were computationally docked and analysed. Several compounds were 
purchased and tested using the fluorescence polarization assay to determine the IC50 
values and the crystallographic binding pose. 
5.1.3 Repetitive search for optimal binder of similar scaffold 
Hits confirmed by the fluorescence polarization assay were put through the 
substructure search process to find similar candidates for further testing. Since 
molecular docking is a prediction tool of limited precision, both in terms of the binding 
poses and the ranking of ligand affinities, initial hits were expected to be weak binders 
and further searches based on their scaffolds were carried out in the search for similar 
compounds with potentially higher affinity. This approach may balance the bias in the 
docking program and its scoring functions and allow the testing of a structurally diverse 
range of candidates. 
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5.2 Materials and methods 
5.2.1 Chemo-informatics 
Fragment hits were paired and merged to yield larger scaffolds. These scaffolds were 
used in the search for similar compounds that might fully occupy subsite I. Candidates 
with molecular weight < 300 Dalton or with scaffolds > 200 Da and overall molecular 
weight < 350 Dalton were docked with Grid score as a primary score to generate 50 top 
poses which are clustered and the cluster heads were in turn scored with Hawkins 
GB/SA score as a secondary score. The top scored compounds were Amber scored and 
the manually selected ones were bought for testing.138 
Derivatives based on the fragment scaffold as substructures were narrowed to those 
with molecular weights in the range 200 Dalton to 300 Dalton. They were then docked 
and scored in a way similar to the merging strategy. The manually selected derivatives 
were purchased for testing. 
Molecular docking was performed using UCSF DOCK 6 software.137 The receptor 
was prepared by removing all crystallographic water molecules in the sidling clamp, 
except for a structurally conserved water molecule near residue M362. The receptor 
structure was truncated of residues within 15 Å of the binding pocket. Hydrogen atoms 
were added and partial charges were assigned using Chimera139. Ligands were prepared 
using UCSF Chimera or obtained from the UCSF ZINC library. Spheres for ligand 
orientation were generated using the identified fragment binders. A grid map for scoring 
was generated encompassing residues within 15 Å of the spheres. Docking was carried 
out using Grid score as the primary score and GB/SA Hawkins score as a secondary 
scoring method. The top 50 poses were clustered and the top 10 cluster heads assessed 
using the secondary scoring method. Additionally, Amber scoring138 was performed 
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with 100 steps of minimization, 3000 steps and another 100 minimization steps, and 
each step corresponds to 2 fs. In all cases, ligand flexibility was allowed with the 
receptor kept rigid. Selected molecules were checked for their commercial availability 
and some of these were acquired for testing. 
5.2.2 Organic chemistry 
Compounds (>95% purity) were sourced from commercial suppliers. Several 
derivatives based on the tetrahydrocarbazole scaffold were synthesized by Dr. Louise 
Whittell under the supervision of Dr. Michael Kelso from the School of Chemistry, 
University of Wollongong. The synthesized compounds were of > 95% purity as 
confirmed by mass spectrometry. 
5.2.3 Fluorescence polarization assay 
See Chapter 3. 
5.2.4 Crystallization, co-crystallization and soaking of compounds 
See Chapter 2 for method used in crystallization of the E. coli SC and the soaking of 
compounds. Co-crystallization was performed to obtain a co-crystal of the compound 
P1A7 with the sliding clamp. 0.5 µL of 100 mM of P1A7 pre-dissolved in DMSO were 
added to 10 µL solution of the SC protein (53 mg/ml) and incubated for 10 min. 
5.2.5 Data collection, processing, structural solution and refinement. 
See Chapter 2.  
5.3 Results and Discussion 
5.3.1 Chemo-informatics and molecular docking 
About 25,000 candidate compounds were drawn from the ZINC library based on the 
fragment hits. These were docked into the subsite I of the SC. Initially, 45 candidates 
 106 
within the top 500 candidates ranked by Amber score were selected based on their 
chemical diversity and availability and purchased. A carbazole derivative (see 5.3.2.3) 
was found that had weak affinity. Subsequently, a tetrahydrocaobazole scaffold was 
designed based on the carbazole scaffold and derivatives from substructure searches 
were bought and tested (see 5.3.2.4). Another scaffold was designed and substructure 
searches were performed in order to select candidates based on chemical diversity and 
found other hits with these two different scaffolds (see 5.3.2.1 and 5.3.2.2).  
5.3.2 Fragment development and characterization. 
In total, about 300 candidate compounds (including the 45 initial candidates 
identified by docking and the additional candidates selected by structural similarity 
searches) were purchased and their IC50 values determined by the FP assays, which 
were then corrected of ligand depletion to yield Ki values.127 Some hits with affinities < 
1 mM were selected and their structures in complex with the SC were determined. 
Many positive hits based on four different scaffolds were obtained from this repetitive 
search for optimal binders. They are discussed below. 
5.3.2.1 P1B8 (4'-fluorobiphenyl-4-carboxylic acid) 
One candidate, designated P1B8 (4'-fluorobiphenyl-4-carboxylic acid) as an 
expanded fragment, was found to bind to the SC with an IC50 of about ~500 µM and Ki 
value of ~283 µM (Figure 5.1). High uncertainty was attributed to these values due to 
the inhibition of tracer binding rising to only ~50% at the maximum concentration. 
(Curve fitting was performed using 100% as the top inhibition rate.) 
The crystal structure of P1B8 with the SC was solved (crystallographic data in Table 
5.1). As expected for merged fragments, P1B8 occupies all of subsite I, forming a salt 
bridge with R152 and an H-bond with the side chain of Y154 (Figure 5.2). No 
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significant changes in the conformations of residues in the binding pocket were 
observed except for the Chi2 angle of M362. Two conformations of the M362 side chain 
were found within the crystal structure. Chi2 of 177° corresponds to a "closed" 
conformation of M362 as observed in a native crystal structure as aforementioned. Chi2 
of -56° corresponds to an "open" or "half-open" conformation of M362 where the 
passage from subsite I to subsite II is accessible. 
Since the salt-bridge and H-bond between the compound and the R152 and Y154 
side chains were the major difference to the binding of the fragment compounds, it's 
likely that these interactions caused the slanted pose of the biphenyl ring and triggered 
open the gating residue M362. 
Although P1B8 may be a good candidate for lead development, further development 
was hampered by limited commercial availability of derivatives in which potential 
substitutions on the biphenyl moiety that will not interfere with the favourable 
interactions P1B8 makes with the SC. Therefore investigation of P1B8 was 
discontinued. 
  
 108 
F
HO
O
F
F
O
NH2
1 10 100 1000-20
0
20
40
60
80
100 P1B8
Compound concentration, µM
In
hi
bi
tio
n 
%
 
 
   
 
 
 
 
 
 
 
 
Figure 5.1 Dose-response curve (fitted using variable slope) for binding of P1B8 (4'-
fluorobiphenyl-4-carboxylic acid), as an expansion product of fragment hit ZT0602, 
inhibiting the fluorescent tracer binding to the SC. Error bars represent ± 1 standard 
deviation (n=2). Where not visible, error bars are within the markers. 
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Figure 5.2 P1B8 (4'-fluorobiphenyl-4-carboxylic acid) bound to chain A of the SC 
(space group P21). The SC is shown with carbon atoms coloured white and the carbon 
atoms of the ligand coloured light green. Non-carbon atoms are in CPK colours. Wire 
basket represents (2mFo-DFc) electron density map contoured at 1 σ. Red spheres 
represent water molecules. Red dashed lines represent H-bonds. 
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Table 5.1 Data collection and refinement statistics of E. coli SC in complex with and 
P1B8(4'-fluorobiphenyl-4-carboxylic acid). 
 
Name SCP1B8 
Data collection 
Space group P21 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
79.90, 67.16, 81.06/90.00, 114.11, 90.00 
Resolution (Å) 30.50-1.70 (1.79-1.70) 
Rmerge (%) 9.7(68.3) 
No. of Reflections 603665 
Unique Reflections 86092 (12490) 
Mean I/σ(I) 9.2 (2.4) 
Completeness (%) 99.9 (99.8) 
Multiplicity 7.0 (6.9) 
Refinement 
Resolution (Å) 30.17 -1.70 (1.74-1.70) 
Rwork/Rfree (%) 25.7(30.1)/29.7(35.5) 
R.m.s deviations  
Bond lengths (Å) 0.0079 
Bond angles (º) 1.2868 
B-factors  
M. Chain 22.2 
S. Chain & Water 26.4 
Ligands* 39.8 
Ramachandran Plot Outliers 0.57 % 
The value for the highest resolution shell is given in parentheses.  
Diffraction data collected at BeamlineMX1, Australian Synchrotron, at 
wavelength 0.95 Å; Diffraction data were processed with MOSFLM and 
SCALA. 
*Ligands refer to the P1B8 with Chain A.  
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5.3.2.2 The phenylpiperazine scaffold 
Two fragment hits (ZT0834 and ZT0835) had a phenylpiperazine scaffold. This 
scaffold was used in a substructure search for commercially available candidates for 
testing. Derivatives with halogen atoms on the phenyl ring were visually inspected since 
the such sub-structures were found in many fragment hits. 
Selected candidates were purchased and their IC50 values and the Ki values 
determined after correction for ligand depletion. The affinity values were calculated 
with a degree of uncertainty since the inhibition rate of the tracer binding only achieved 
~50% at the maximum concentration. The curve fitting was performed using 100% as 
the top inhibition rate. 
Two compounds were found with ~500 µM affinity (P5aD8 and P5aB3, Figure 5.3-
5.4, Table 5.3). The binding poses of the two phenylpiperazine–containing compounds 
were determined by X-ray crystallography (Figure 5.5-5.6, crystallographic data in 
Table 5.2). The structures showed that, unexpectedly, the piperazine rings were not 
positioned within the binding pocket but rather above it (Figure 5.5-5.6). Subsite I was 
partially occupied by the halogenated phenyl ring and either an aldehyde- or nitro-
substituent on the phenyl ring. The halogen atom was situated in the previously 
identified “halogen-binding pocket”. The aldehyde group of P5aB3 (but not the nitro 
group of P5aD8) formed an H-bond with the T172 side chain. There are no other 
identifiable interactions that may have limited their binding affinity. 
In comparison with the fragment hits with the phenylpiperazine scaffold (ZT0834 
and ZT0835, Figure 4.8 and Figure 4.10), neither P5aD8 nor P5aB3 were bound with 
their respective nitro or aldehyde groups within hydrogen bonding distance of the S346 
side chain. Additionally, the binding pocket adopts a slightly curved geometry caused 
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by the presence of P352 and may therefore favour ligands with flexibility higher than 
that of rigid rings. Binding of P5aD8 or P5aB3 to the SC suggests that halogen 
substitutions on aromatic rings may be optimal at the meta position as opposed to the 
para position. 
Other candidates with similar scaffolds showed Ki values over 500 µM (Table 5.3). 
Owing to the low affinity and the unexpected binding pose of P5aD8 and P5aB3, 
investigation of the phenylpiperazine scaffold was discontinued. 
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Figure 5.3 Dose-response curve (fitted using variable slope) of P5aD8 (1-(4-(4-chloro-
2-nitrophenyl)piperazin-1-yl)ethanone) inhibiting the fluorescent tracer binding to the 
SC. Error bars represent ± 1 standard deviation (n=2).  
 
 
 
 
 
 
 
Figure 5.4 Dose-response curve (fitted using variable slope) of P5aB3 (methyl 4-(4-
chloro-2-formylphenyl)piperazine-1-carboxylate) inhibiting the fluorescent tracer 
binding to the SC. Error bars represent ± 1 standard deviation (n=2). 
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Figure 5.5 P5aD8 (1-(4-(4-chloro-2-nitrophenyl)piperazin-1-yl)ethanone) bound in the 
subsite I of Chain A of a crystal of P1 space group. The SC is shown with carbon atoms 
coloured white and the carbon atoms of the ligand coloured light green. Non-carbon 
atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron density map 
contoured at 1 σ.  
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Figure 5.6 P5aB3 (methyl 4-(4-chloro-2-formylphenyl)piperazine-1-carboxylate)  
bound in the subsite I of Chain A of a crystal of P1 space group. The SC is shown with 
carbon atoms coloured white and the carbon atoms of the ligand coloured light green. 
Non-carbon atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron 
density map contoured at 1 σ. Red dashed lines represent H-bonds. 
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Table 5.2 Data collection and refinement statistics of E. coli SC in complex with and 
P5aD8 and P5aB3, respectively. 
Name SCP5aD8 SCP5aB3 
Data collection 
Space group P1 
 
 
 
Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
41.07, 64.48, 71.92/74.16, 82.77, 
84.84 
a, b, c (Å)/α, β, γ (°) 
41.08, 64.49, 72.14/73.87, 82.57, 
84.69 
Resolution (Å) 50.00-2.55 (2.64-2.55) 50.00-2.30 (2.38-2.30) 
Rmerge (%) 7.1(35.7) 6.2(34.8) 
No. of Reflections 56937 112660 
Unique Reflections 23073 (2078) 31244 (2509) 
Mean I/σ(I) 14.9 (2.4) 20.6 (2.8) 
Completeness (%) 94.6 (91.4) 94.4 (80.5) 
Multiplicity 2.5 (2.0) 3.6 (3.2) 
Refinement 
Resolution (Å) 40.96 -2.55 (2.61-2.55) 40.87 -2.29 (2.34-2.29) 
Rwork/Rfree (%) 21.5(26.3)/29.8(38.9) 22.7(26.7)/28.0(44.2) 
R.m.s deviations   
Bond lengths (Å) 0.0057 0.0055 
Bond angles (º) 0.9295 0.9095 
B-factors   
M. Chain 21.0 19.1 
S. Chain & Water 22.0 20.0 
Ligand* 33.3 41.7 
Ramachandran Plot 
Outliers 0.70 % 0.55 % 
The value for the highest resolution shell is given in parentheses.  
*Diffraction data were collected at home-sourced X-ray generator at the wavelength of 
1.5418 Å and  processed with HKL2000. 
*Ligand refers to P5aD8 and P5aB3 bound with Chain A, respectively. 
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Table 5.3 Summary data of developed fragments with the phenylpiperazine scaffold. 
Plate 
No. Well CHEMISTRY IC50, µm 
Ki, 
µM 
ΔG at 
300K, 
kcal/mol 
HAC 
LE, 
kcal/mo
l 
LogD 
(pH 
7.2) 
ΔGlipo, 
kcal/mo
l 
ΔG*, 
kcal/mol LLEAT 
5a A11 
 
 
 
1554 863 -4.22 27 0.16 2.32 -3.19 -1.03 0.15 
5a B3 
 
  
 
855 475 -4.58 19 0.24 1.81 -2.50 -2.08 0.22 
5a B10 
 
 
 
1934 1074 -4.09 20 0.20 1.78 -2.44 -1.65 0.19 
5a D8 
 
 
 
909 505 -4.54 20 0.23 2.29 -3.15 -1.39 0.18 
5a E4 
 
 
 
2385 1325 -3.97 21 0.19 -0.37 0.51 -4.48 0.32 
N2O
NN Cl
NH
O
O
O
NO2
Cl N N
O
NO2
F N N
O
Cl
O
N N
O
O
COOH
Cl
Cl
N N
O
 118 
 
 
 
5a E8 
 
918 510 -4.54 22 0.21 2.10 -2.89 -1.65 0.18 
5b C6 
 
1187 659 -4.38 32 0.14 2.17 -2.99 -1.39 0.15 
5b D6 
 
2190 1217 -4.02 26 0.15 2.01 -2.77 -1.25 0.16 
5b F6 
 
1876 1042 -4.11 19 0.22 1.47 -2.03 -2.08 0.22 
CN
Cl N N
O
O
Cl
N
N
O
N
H N
H
S O
O
ClNN
O
NH
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5.3.2.3. The carbazole scaffold 
A number of fragment hits had indole, indazole or imidazole rings that share 
common geometric properties. A search of commercially available compounds with 
these substructures identified a carbazole scaffold. Carbazole derivatives with halogen 
(mostly chlorine) substitutions on the carbazole ring were obtained. 
Selected candidates were obtained and their IC50 values and the Ki values determined 
as described previously. as noted previously, affinity values were calculated with some 
uncertainty due to the inhibition rate of the tracer binding peaking at ~50% at the 
maximum concentration. The curve fitting was performed using 100% as the top 
inhibition rate. These compounds showed weak affinity (Ki~500 µM). The positive hits 
are listed in the Table 5.5. The hits featured two additional substitutions, one at the 
indole nitrogen and the other on the opposite ring, as indicated in Figure 5.7. 
The dose-response curve of the tightest-binding carbazole compound tested, P1A7, is 
shown in Figure 5.8. To relate the affinity data to structure, the SC crystal structure in 
complex withP1A7 ((R)-3-chloro-9-(oxiran-2-ylmethyl)-9H-carbazole) was determined 
(Figure 5.9).The crystallographic data are shown in Table 5.4. The binding of P1A7 is 
similar to the fragment hit ZT0082 containing an imidazole ring. P1A7 has an aromatic 
ring additional to that observed in ZT0082 and an epoxy group. The gating residue, 
M362, displays two conformations in the crystal structure. The Chi2 angles correspond 
to those previously identified as "closed" and "open" conformations (see Chapter 3). 
However, the epoxy group, the natural position for chemical modification of P1A7, was 
not observed to extend toward M362 (and hence not toward the passage to subsite II). 
The carbazole scaffold was therefore discontinued in further lead development. 
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Figure 5.7 The design of the carbazole scaffold based on the fragment hits. Various 
substituents at the R1 and R2 positions were tested. 
 
 
 
 
 
 
 
 
Figure 5.8 Dose-response curve (fitted using variable slope) of P1A7 ((R)-3-chloro-9-
(oxiran-2-ylmethyl)-9H-carbazole) inhibiting the fluorescent tracer binding to the SC. 
Error bars represent ± 1 standard deviation (n=2). 
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Figure 5.9 P1A7 ((R)-3-chloro-9-(oxiran-2-ylmethyl)-9H-carbazole) bound in the 
subsite I of Chain A of a beta-clamp crystal (P1 space group). The SC is shown with 
carbon atoms coloured white and the carbon atoms of the ligand coloured light green. 
Non-carbon atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron 
density map contoured at 1 σ.  
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Table 5.4. Data collection and refinement statistics of E. coli SC in complex with P1A7. 
Name SCP1A7 
Data collection 
Space group P1 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
41.01, 64.92, 71.94/74.44, 83.31, 85.28 
Resolution (Å) 50.00-1.93 (2.00-1.93) 
Rmerge (%) 4.5(18.9) 
No. of Reflections 181848 
Unique Reflections 53392 (4852) 
Mean I/σ(I) 23.1 (6.4) 
Completeness (%) 93.8 (90.7) 
Multiplicity 3.4 (3.3) 
Refinement 
Resolution (Å) 41.19 -1.93 (1.98-1.93) 
Rwork/Rfree (%) 24.7(36.0)/30.9(38.5) 
R.m.s deviations  
Bond lengths (Å) 0.0070 
Bond angles (º) 1.2673 
B-factors  
M. Chain 23.5 
S. Chain & Water 26.3 
Ligand* 66.0 
Ramachandran Plot Outliers 0.57 % 
The value for the highest resolution shell is given in parentheses.  
*Diffraction data were collected at home-sourced X-ray generator at the wavelength of 
1.5418 Å and  processed with HKL2000. 
*Ligand refers to theP1A7bound with Chain A. 
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Table 5.5 Summary data of developed fragments with the carbazole scaffold. 
Plate 
No. Well CHEMISTRY IC50, µm 
Ki, 
µM 
ΔG at 
300K, 
kcal/mol 
HAC 
LE, 
kcal/mo
l 
LogD 
(pH 
7.2) 
ΔGlipo, 
kcal/mo
l 
ΔG*, 
kcal/mol LLEAT 
1 7A 
 
  
 
842 467 -4.59 18.00 0.25 3.58 -4.92 0.33 0.09 
2 1F 
 
  
 
1097 609 -4.43 29.00 0.15 4.77 -6.56 2.13 0.04 
2 1H 
 
  
 
885 491 -4.56 28.00 0.16 4.41 -6.07 1.51 0.06 
2 4H 
 
  
 
1529 849 -4.23 26.00 0.16 4.81 -6.62 2.39 0.02 
4 H2 
 
  
 
2239 1243 -4.00 18.00 0.22 3.81 -5.24 1.24 0.04 
4 H4 
 
 
 1322 734 -4.32 21.00 0.21 3.21 -4.43 0.11 0.10 
N
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5.3.2.4 The tetrahydrocarbazole scaffold 
Those fragment hits containing isatin, phenylpiperazine, imidazole or indazole rings, 
which led us to the carbazole scaffold, also led to the identification of the 
tetrahydrocarbazole scaffold (Figure 5.10) that differs only in the saturation of one of 
the rings. Commercially available compounds with the tetrahydrocarbazole scaffold, 
particularly those with halogen substitutions on the rings were obtained and tested. 
Many hits were identified, the weaker binders with estimated Ki > 500 µM were not 
further explored. The summary data of the hits are in Table 5.8. 
5.3.2.4.1 P3E2 
P3E2 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid) was identified 
with good affinity (Ki of 216 µM, Figure 5.11, Table 5.8), better than any of the 
aforementioned carbazole hits. Its complex crystal structure with the SC (Figure 5.13, 
crystallographic data in Table 5.6) was solved, revealing H-bonding between its 
carboxylic acid group and the S346 side chain, and a backbone carbonyl oxygen of 
V247, which may be critical for its affinity. Moreover, the tetrahydro-ring has a flexible 
geometry in comparison with a phenyl ring, thus allowing the tetrahydrocarbazole to 
bend and better fit the geometry of the binding site. The S-shaped geometry is caused 
by residue P242 which would be an obstruction of a linear and rigid moiety like the 
carbazole scaffold. This may also be the reason for the superior binding of P3E2. 
It is noteworthy that the gating residue M362 remained closed with P3E2 bound in 
subsite I. Given that the carboxylic group of P3E2 is in contact with the side chain of 
S346, the carboxylic group could hinder the movement of the M362 Chi2 angle. 
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5.3.2.4.2 P5bH1 
Compound P5bH1 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid), as 
a racemic mixture, was found to inhibit the fluorescent tracer binding to the SC with 64 
µM Ki (Figure 5.l2, Table 5.8). Two similar compounds, P4A6 (methyl 6-chloro-
2,3,4,9-tetrahydro-1H-carbazole-1-carboxylate) and P4H1 (ethyl 6-chloro-2,3,4,9-
tetrahydro-1H-carbazole-1-carboxylate), as the racemic methyl- and ethyl-esters of 
P5bH1, were obtained and tested. They showed much weaker affinity (Figure 5.12, 
Table 5.8).  
The complex crystal structure of P5bH1 and the SC was solved (Figure 5.14, 
crystallographic data in Table 5.7). P5bH1 has a chiral centre and was tested as a 
racemic mixture but only the (R)-enantiomer was present in the electron density map 
(Figure 5.14). (R)-P5bH1 occupies subsite I but lacks the H-bond found between P3E2 
and the S346 side chain (Figure 5.13). Both P3E2 and P5bH1 have a partly saturated 
rings with sufficient flexibility to avoid steric clashes with P242. The binding of (R)-
P5bH1 caused conformation changes in M362 and S346. Its chloro substituent is well-
situated at the hydrophobic deep region. P5bH1 lacks the carboxylate group of P3E2 
and hence does not sterically hinder movement of M362 and S346. This may explain 
the superior affinity of (R)-P5bH1. The carboxylate group on the cyclohexyl ring can 
form a salt-bridge with R152, which may explain the preference for the (R)-enantiomer 
in crystallo.  
5.4 Conclusion 
Two strategies, expansion and merging, were used to grow fragments and led to the 
discovery of four scaffolds, the biphenyl scaffold, the phenylpiperazine scaffold, the 
carbazole scaffold and the tetrahydrocarbazole scaffold. However, only the biphenyl 
scaffold and the tetrahydrocarbazole scaffold fully occupied subsite I. They also have 
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superior binding affinity as demonstrated by the inhibition of the fluorescent tracer 
binding to the SC compared with the other two scaffolds. 
The biphenyl scaffold had few desirable commercially available derivatives and 
derivatization was not explored further. Nevertheless, the crystallographic binding pose 
of the only hit with the biphenyl scaffold, P1B8, presented a rationale for extending 
other hits to the shallow region of the subsite I. The extensive salt-bridge/H-bonds P1B8 
has with residues Y154 and R152 appeared to be key for both binding to the shallow 
region of subsite I and the relatively high affinity. 
The carbazole scaffold had a number of hits with > 500 µM Ki. One of these, P1A7, 
led to the design of the tetrahydrocarbazole scaffold with its complex structure with the 
SC. The rigid carbazole ring of P1A7 could clash with the adjacent residue P242, as 
suggested by its poor electron density. This finding was critical to the design of the 
tetrahydrocarbazole scaffold to introduce flexibility to the ligand. 
The tetrahydrocarbazole scaffold, as exemplified by P3E2 and P5bH1, is a promising 
scaffold whose shape complements the slightly "S" shape of subsite I due the flexibility 
of the cyclohexane ring. The cyclohexane ring partially occupies the shallow region, 
and substitutions on this ring could potentially result in additionally interaction with 
residues Y154 and R152, as demonstrated by P5bH1. Another desirable structural 
feature is the formation of H-bonds with S346 that greatly contributing to the binding 
affinity of P5bH1. Likely as the result of such features, the Ki values of P3E2 and 
P5bH1 are significantly lower than the other tested carbazole and tetrahydrocarbazole 
derivatives. 
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Figure 5.10 The design of the tetrahydrocarbazole scaffold based on the fragment hits. 
The R1, R2 and R3 groups indicate derivatizations on the scaffold observed in purchased 
compounds for testing. 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Dose-response curve (fitted using variable slope) of P3E2 (6-chloro-
2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid) inhibiting the fluorescent tracer 
binding to the SC. Error bars represent ± 1 standard deviation (n=2). 
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Figure 5.12 Dose-response curve (fitted using variable slope) of P5bH1 (6-chloro-
2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid) as a racemic mixture inhibiting the 
fluorescent tracer binding to the SC. Error bars represent ± 1 standard deviation (n=2). 
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Figure 5.13 P3E2 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid) bound 
in the subsite I of Chain A of a crystal of P1 space group. The SC is shown with carbon 
atoms coloured white and the carbon atoms of the ligand coloured light green. Non-
carbon atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron density 
map contoured at 1 σ. Red dashed lines represent H-bonds. 
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Table 5.6 Data collection and refinement statistics of E. coli SC in complex with and 
P3E2. 
 
Name SCP3E2 
Data collection 
Space group P1 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
41.01, 65.13, 73.24/72.95, 85.06, 85.24 
Resolution (Å) 40.95-2.30 (2.42-2.30) 
Rmerge (%) 14.7(64.3) 
No. of Reflections 112766 
Unique Reflections 29744 (4227) 
Mean I/σ(I) 8.5 (2.2) 
Completeness (%) 92.9 (89.9) 
Multiplicity 3.8 (3.7) 
Refinement 
Resolution (Å) 40.95 -2.30 (2.36-2.30) 
Rwork/Rfree (%) 26.1(32.1)/33.8(43.3) 
R.m.s deviations  
Bond lengths (Å) 0.0042 
Bond angles (º) 0.8787 
B-factors  
M. Chain 20.9 
S. Chain & Water 23.0 
Ligands* 51.7 
Ramachandran Plot Outliers 0.56 % 
The value for the highest resolution shell is given in parentheses.  
*Diffraction data were collected at home-sourced X-ray generator at the wavelength of 
1.5418 Å and  processed with HKL2000. 
*Ligand refers to theP3E2bound with Chain A. 
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Figure 5.14 P5bH1 ((R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid) 
bound in the subsite I of Chain A of a crystal of P21 space group. The SC is shown with 
carbon atoms coloured white and the carbon atoms of the ligand coloured light green. 
Non-carbon atoms are in CPK colours. Wire basket represents (2mFo-DFc) electron 
density map contoured at 1 σ. Red dashed lines represent H-bonds. 
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Table 5.7 Data collection and refinement statistics of E. coli SC in complex with and 
P5bH1. 
 
Name SCP5bH1 
Data collection 
Space group P21 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
79.78, 67.37, 81.12 /    
    Resolution (Å) 43.86-1.90 (2.00-1.90) Rmerge (%) 5.2(39.7) 
No. of Reflections 137425 
Unique Reflections 57937 (7647) 
Mean I/σ(I) 9.8 (2.4) 
Completeness (%) 93.7 (85.6) 
Multiplicity 2.4 (2.3) 
Refinement 
Resolution (Å) 36.46 - 1.90 (1.95-1.90) 
Rwork/Rfree (%) 21.4(38.8)/26.1(40.7) 
R.m.s deviations  
Bond lengths (Å) 0.0090 
Bond angles (º) 1.3791 
B-factors  
M. Chain 28.1 
S. Chain & Water 33.2 
Ligands* 42.1 
Ramachandran Plot Outliers 0.72 % 
The value for the highest resolution shell is given in parentheses.  
*Diffraction data were collected at home-sourced X-ray generator at the wavelength of 
1.5418 Å and  processed with HKL2000. 
*Ligand refers to the P5bH1 bound with Chain A. 
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Table 5.8 Summary data of developed fragments with the tetrahydrocarbazole scaffold. 
Plate 
No. Well CHEMISTRY IC50, µm Ki, µM 
ΔG at 
300K, 
kcal/mol 
HAC LE, kcal/mol 
LogD 
(pH 
7.2) 
ΔGlipo, 
kcal/mol 
ΔG*, 
kcal/mol LLEAT 
3 E2 
 
  
 
389 216 -5.05 17 0.30 -0.48 0.66 -5.71 0.44 
4 A6 
 
  
 
> 1000 n/a n/a n/a n/a n/a n/a n/a n/a 
4 A7 
 
1062 590 -4.45 18 0.25 2.93 -4.03 -0.41 0.13 
4 A10 
 
742 412 -4.66 22 0.21 2.31 -3.18 -1.47 0.17 
4 F5 
 
 
 
475 263 -4.93 20 0.25 3.77 -5.19 0.25 0.09 
4 H1 
 
 
 
899 499 -4.55 19 0.24 4.44 -6.11 1.56 0.02 
N
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5b D2 
 
2196 1220 -4.01 25 0.16 1.54 -2.12 -1.89 0.18 
5b G2 
 
2347 1303 -3.97 18 0.22 4.23 -5.83 1.85 0.006 
5b H1 
 
115 64 -5.78 17 0.34 0.36 -0.49 -5.29 0.42 
5b H5 
 
1903 1057 -4.10 15 0.27 5.20 -7.16 3.06 -0.09 
5b H6 
 
877.1 487 -4.56 18 0.25 -0.15 0.21 -4.77 0.37 
4 A3 
 
1599 888 -4.20 17 0.25 3.54 -4.88 0.67 0.07 
5a B11 
 
1301 722 -4.32 17 0.25 -0.66 0.91 -5.24 0.41 
4 C9 
 
1185 658 -4.38 23 0.19 3.15 -4.34 -0.04 0.11 
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6 1G 
 
566 314 -4.82 17 0.28 3.48 -4.79 -0.02 0.11 
6 2C 
 
1306 725 -4.32 17 0.25 2.151 -2.96 -1.36 0.19 
6 7C 
 
815 452 -4.60 25 0.18 4.04 -5.56 0.95 0.07 
N
H
OO
N
H
N
H
NH2
O
N
H
NH
O
O
 136 
 
 
 
Chapter 6  
Lead development   
 137 
6.1 Introduction 
The fragment development efforts described above offer perspectives where multiple 
ligand-SC interactions contain conserved features that might be incorporated into newer 
generations of molecules. The tetrahydrocarbazole scaffold was chosen for lead 
development and a derivative was designed by moving the carboxyl group of P3E2 
from the phenyl ring to the cyclohexane ring to resemble a similar substitution in P1B8. 
This was in order to mimic the two electrostatic interactions of P1B8 with the side 
chains of residues Y154 and R152 (Figure 5.2). Another reason for removing the 
carboxyl group from the phenyl ring of P3E2 was that the H-bond formed with S346 
could prevent the gating residue M362 from switching to an “open” conformation, 
blocking entry of substituted P3E2 derivatives into subsite II. 
6.2 Materials and methods 
6.2.1 Organic chemistry 
Compounds were synthesized by Dr. Louise R. Whittell and undergraduate student 
Thomas O'Meley, under the supervision of Dr. Michael J. Kelso from the School of 
Chemistry, University of Wollongong. The synthesized compounds were of >95% 
purity and confirmed with mass spectrometry (To be published in J. Med. Chem.) 
6.2.2 Fluorescence polarization assay 
FP assays were conducted as described in Chapter 3. 
6.2.3 Crystallization and soaking of compounds 
Crystals of the SC were prepared as described in Chapter 2. 
6.2.4 Data collection, processing, structural solution and refinement 
X-ray diffraction experiments, data processing, structure solution and refinement 
were conducted as described in Chapter 2. 
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6.3 Results and Discussion 
6.3.1 The lead compound (R)-P6B10 
The addition of a carboxylic acid group to the tetrahydrocarbazole scaffold (similar 
to that found in P1B8) yielded a tighter binding compound, P6B10 (6-chloro-2,3,4,9-
tetrahydro-1H-carbazole-2-carboxylic acid) with Ki of 166 µM (Figure 6.1, Table 6.2). 
The similar binding affinity of P6B10 to the SC compared with P3E2 (which has a Ki of 
216 µM) suggests that the relocation of the carboxylic acid moiety was successful, as 
the loss of two H-bonds with S346 and V360 was compensated by the formation of new 
H-bonds with Y154 and R152. The carboxyl group of P6B10 is located on the 
cyclohexane ring of the tetrahydrocarbazole scaffold and thus produced a chiral centre. 
The sample of P6B10 prepared and tested as described above was a racemic mixture. 
The two enantiomers of P6B10 were therefore separated (by Dr Louise Whittell) in 
order to determine the difference in binding affinity. The (S)-enantiomer (LWFB2_63B, 
Ki = 246 µM, Figure 6.2 and Table 6.5) showed inferior affinity to the (R)-enantiomer 
(LWFB2_62B, Ki = 74 µM, Figure 6.3 and Table 6.5).  
The crystal structure of P6B10 in complex with the SC was determined and the 
electron density map suggested the presence of the (R)-enantiomer (Figure 6.7, 
crystallographic data in Table 6.1). Compound (R)-P6B10 bound to subsite I of the SC 
as predicted: the carboxyl group formed an H-bond with the Y154 phenol group and a 
salt bridge with the R152 guanidine group. The tetrahydrocarbazole scaffold adopted a 
binding pose similar to that of P1B8 (Figure 5.2), resulting in the opening of the gating 
residue M362 (Chi2 = -69°, Figure 6.4). The M362 side chain is in the vicinity of both 
the phenyl ring of the ligand and the S346 side chain. The S346 side chain appeared to 
lie in two conformations, apparently due to both ligand binding and the side chain 
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movement of M362. This finding supports the hypothesis that the “open” conformation 
of M362 prevents H-bond formation between the ligand and the S346 side chain. 
The binding of (R)-P6B10 to the SC mimics the binding of the L4F5 sub-motif of SC-
binding LM peptides (See Chapter 3). The chlorine-substituent on the phenyl ring 
occupies the same space as the leucine side chain and the cyclohexane ring occupies the 
same region as the phenylalanine side chain (Figure 6.5). The carboxylic acid group 
forms multiple H-bond interactions with adjacent residues so as to stabilize binding, 
which may explain why P6B10 binds more tightly than the AcLF dipeptide which lacks 
these interactions at its C-terminal carboxylic acid group (See Chapter 3). The 
tetrahydrocarbazole scaffold leans toward gating residue M362 and derivatizations 
based on the indole nitrogen may provide opportunities to synthesize derivatives 
containing substituents oriented toward subsite II (Figure 6.5). 
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Figure 6.1 Dose-response curve (fitted using variable slope) of P6B10 (6-chloro-
2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid) as racemic mixture inhibiting the 
fluorescent tracer binding to the SC. Error bars represent ± 1 standard deviation (n=2). 
 
 
 
 
 
 
 
Figure 6.2 Dose-response curve (fitted using variable slope) of (S)-P6B10 ((S)-6-
chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid) inhibiting the fluorescent 
tracer binding to the SC. Error bars represent ± 1 standard deviation (n=2).   
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Figure 6.3 Dose-response curve (fitted using variable slope) of (R)-P6B10 (P6B10 
((R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid)) inhibiting the 
fluorescent tracer binding to the SC. Error bars represent ± 1 standard deviation (n=2).  
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Figure 6.4 (R)-P6B10 ((R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic 
acid)) bound in subsite I of Chain A of a crystal of P21 space group. The SC is shown 
with carbon atoms coloured white and the carbon atoms of the ligand coloured light 
green. Non-carbon atoms are in CPK colours. Wire basket represents the 2mFo-DFc 
electron density map contoured at 1 σ. Red dashed lines represent H-bonds. Red spheres 
represent crystallographic water molecules. 
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Table 6.1 Data collection and refinement statistics of E. coli SC in complex with the R-
enantiomer of P6B10. 
Name SCP6B10 
Data collection 
Space group P21 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
79.87, 67.26, 81.19/90.00, 114.27, 90.00 
Resolution (Å) 50.00-2.05 (2.17-2.08) 
Rmerge (%) 4.3(26.1) 
No. of Reflections 169346 
Unique Reflections 49386 (4716) 
Mean I/σ(I) 27.4 (3.5) 
Completeness (%) 96.4 (95.9) 
Multiplicity 3.43 (3.5) 
Refinement 
Resolution (Å) 34.61 -2.05 (2.10-2.05) 
Rwork/Rfree (%) 21.2(20.5)/27.5(30.7) 
R.m.s deviations  
Bond lengths (Å) 0.0057 
Bond angles (º) 1.1137 
B-factors  
M. Chain 22.6 
S. Chain & Water 26.4 
Ligands* 34.1 
Ramachandran Plot Outliers 0.43 % 
The value for the highest resolution shell is given in parentheses.  
Diffraction data were collected at home-sourced X-ray generator at the 
wavelength of 1.5418 Å and were processed with HKL2000. 
*Ligands refer to the compound bound with Chain A. 
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Figure 6.5 Superimposition of SCAcQLALF to SCP6B10. The peptide ligand of SCAcQLALF 
(carbon atoms coloured pink) is shown. The SC structure of SCP6B10 is shown with 
carbon atoms coloured white and the carbon atoms of the P6B10 coloured light green. 
Non-carbon atoms are in CPK colours. Red dashed lines represent H-bonds. Red 
spheres represent crystallographic water molecules. 
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6.3.2 Derivatives based on the structure of P6B10 
 Derivatives of P6B10 were prepared by Dr Louise Whittell to find variants with 
tighter binding (Table 6.5). Modifications were made to the carboxyl group and its 
position on the cyclohexane ring, resulting in decreased affinity (LWFB1_89B, 
LWFB1_93C, LWFB1_91B and LWFB1_94B, Table 6.5). This result emphasized the 
importance of the H-bonds and salt bridges of the carboxyl group with the side chains of 
Y154 and R152. 
The importance of the chloro substituent on the phenyl ring was explored by 
replacing it to with fluorine, bromine or iodine (TOMFB1-24, TOMFB1-25 and 
TOMFB1-30, Table 6.5). The bromo and iodo substitutions showed slightly increased 
affinity while the fluoro substitution had decreased affinity. These effects are likely due 
to the different shape complementarities of these halogen substituents with the deep 
region of the subsite I (Figure 6.7). bromo substituents on the tetrahydrocarbazole (R)-
enantiomers were investigated (LWFB2_83B and LWFB2_86B, Table 6.5). These 
showed superior affinity to the  chloro substituted variants. Thus, compounds containing 
both chloro and bromo substitutions were carried forward to the next stage of 
development. 
6.3.3 Derivatization of the indole NH group of the tetrahydrocarbazole scaffold 
The presence of the NH group of the tetrahydrocarbazole scaffold naturally serves as 
a synthetic handle. Derivatives at this position were made to find chemical moieties that 
mimic the binding orientation of the peptide sub-motifs occupying subsite II (See 
Chapter 3). An amide derivative on the indole nitrogen (LWFB2_45E, Table 6.5) was 
designed to probe the possibility of using a linker moiety to extend the lead compound 
so as to bind in subsite II. The affinity of LWFB2_45E (Ki = 201 µM, Figure 6.6 and 
Table 6.5) is similar to that of P6B10 (Ki = 166 µM). The pure enantiomers of 
 146 
LWFB2_45E were also made and tested (LWFB2_70C as the R-enantiomer and 
LWFB2_79C as the S-enantiomer, Table 6.5). The (R)-enantiomer showed higher 
affinity than the (S)-enantiomer, consistent with previous findings. 
The crystallographic binding pose of LWFB2_45E was determined (Figure 6.7, 
crystallographic data in Table 6.2) and the electron density map suggests the presence 
of the (R)-enantiomer. The overall binding pose of (R)-LWFB2_45E is similar to (R)-
P6B10 and forms H-bonds and a salt bridge with the side chains of Y154 and R152 
respectively (Figure 6.7). 
As expected, the (R)-P6B10 amide group forms an additional H-bond (2.7 Å, Figure 
6.7) with the G174 carbonyl group. This interaction is analogous to the H-bond formed 
between the L4 peptide amide of the LM described earlier (see Chapter 3) that was 
suggested to be important for peptide orientation. A comparison of the binding pose of 
(R)-LWFB2_45E and the AcLF dipeptide (see Chapter 3) is shown in Figure 6.8. 
These two compounds are approximately equal in size and occupy the same region of 
the SC binding pocket. 
The ability of the amide group of (R)-LWFB2_45E to form an H-bond with G174 
led to the formulation of a strategy for lead optimization targeting subsite II. A number 
of derivatives with substituents on the amide group were synthesized and tested. 
LWFB2_100E, containing a glycine substituent, had a Ki of 12 µM (Figure 6.9, and 
Table 6.5), which is similar in potency to most peptidic ligands (see Chapter 3). 
LWFB2_100E is an (R)-enantiomer with a bromo substituent (Figure 6.9). The 
crystallographic binding pose of LWFB2_100E was obtained (Figure 6.10, 
crystallographic data in Table 6.3). LWFB2_100E preserved the H-bond interaction 
with the G174 carbonyl group as well as the interactions with the side chains of Y154 
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and R152, similar to the binding pose of (R)-LWFB2_45E. It has an additional 
carboxylate group with a salt bridge with R152, which likely contributed to its superior 
affinity. A similar derivative, LWFB2_81D (Ki = 47 µM, Table 6.5), with a chlorine 
substituent was found to be less active than LWFB2_100E. Therefore, only compounds 
containing bromo substitutions were produced in further developments. 
A comparison of the binding of LWFB2_100E and the binding of AcALDLF is 
shown in Figure 6.11. The AcAL sub-motif was missing from the electron density map 
due to the inability of the peptide to bind in subsite II (see Chapter 3). The remaining 
DLF residues occupy subsite I and the connecting channel to subsite II. The aspartate 
residue of this motif forms a salt bridge with the R152 guanidinium group, an 
interaction that is mimicked by the carboxylate group of LWFB2_100E. The aspartate 
side chain does not appear to contribute much to the peptide binding affinity (see 
Chapter 3) whereas the carboxylate group of LWFB2_100E significantly increased the 
binding affinity.  
In addition to the glycine-containing compound LWFB2_100E, similar compounds 
were synthesized containing alternative amino acids. Three compounds (LWFB2_113D, 
LWFB3_05C and TOMFB1-51, Table 6.5) were made and tested by Dr Louise Whittell. 
LWFB2_113D contained a (D)-phenylalanine residue and showed tight binding with a 
Ki of 17 µM (Figure 6.12 and Table 6.5), similar to that of LWFB2_100E. The 
crystallographic binding pose of LWFB2_113D was observed (Figure 6.13, 
crystallographic data in Table 6.4). In addition to the interactions its predecessors made 
with the SC, the side chain of the (D)-phenylalanine moiety of LWFB2_113D is largely 
exposed to bulk solvent without significant interactions. LWFB3_05C is a similar 
compound made with (L)-phenylalanine with a Ki of 18 µM. The crystal structure of 
this complex is yet to be obtained due to poor electron density for the ligand. A 
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comparison of the binding of LWFB2_113D and the AcQADLF peptide to the SC is 
shown in Figure 6.14. The side chain of the (D)-phenylalanine moiety of 
LWFB2_113D is positioned close to the region that is occupied by the alanine residue 
of the AcQADLF peptide.  
Peptide binding at subsite II features an H-bond network between the glutamine 
residue and the adjacent subsite residues and a structurally conserved water molecule 
(Figure 6.14). The ultimate goal of inhibitor design is to block these interactions. 
LWFB2_113D represents a step toward this goal beyond LWFB2_100E, which extends 
a moiety from the tetrahydrocarbazole scaffold and is bound to the channel connecting 
the two subsites. The side chain of the (D)-phenylalanine of LWFB2_113D may be too 
large to fit the channel area, suggesting that other (D)-amino acids (e.g. (D)-Lys, (D)-
Gln, etc) in synthesis may produce derivatives capable of forming H-bonds in subsite II. 
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Figure 6.6 Dose-response curve (fitted using variable slope) of LWFB2_45E (((R)-9-
(2-amino-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid) 
inhibiting the fluorescent tracer binding to the SC. Error bars represent ±1 standard 
deviation (n=2). 
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Figure 6.7 (R)-LWFB2_45E ((R)-9-(2-amino-2-oxoethyl)-6-chloro-2,3,4,9-tetrahydro-
1H-carbazole-2-carboxylic acid) bound in the subsite I of Chain A in a SC crystal of P21 
space group. SC is shown with carbon atoms coloured white and the carbon atoms of 
the ligand coloured light green. Non-carbon atoms are in CPK colours. Wire basket 
represents (2mFo-DFc) electron density map contoured at 1 σ. Red dashed lines 
represent H-bonds. The red sphere represents a crystallographic water molecule. 
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Table 6.2 Data collection and refinement statistics of E. coli SC in complex with the R-
enantiomer of LWFB2_45E. 
Name SC45E 
Data collection 
Space group P21 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
80.08, 66.20, 80.62/90.00, 114.89, 90.00 
Resolution (Å) 40.00-1.90 (1.97-1.90) 
Rmerge (%) 2.8(17.1) 
No. of Reflections 219352 
Unique Reflections 60330 (6013) 
Mean I/σ(I) 41.5 (7) 
Completeness (%) 99.9 (100.0) 
Multiplicity 3.6 (3.5) 
Refinement 
Resolution (Å) 21.62 -1.90 (1.95-1.90) 
Rwork/Rfree (%) 20.5(23)/25.9(29.1) 
R.m.s deviations  
Bond lengths (Å) 0.0195 
Bond angles (º) 1.8756 
B-factors  
M. Chain 17.1 
S. Chain & Water 22.7 
Ligands* 33.4 
Ramachandran Plot Outliers 0.69 % 
The value for the highest resolution shell is given in parentheses.  
Diffraction data were collected at home-sourced X-ray generator at the 
wavelength of 1.5418 Å and were processed with HKL2000. 
*Ligands refer to the compound bound with Chain A. 
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Figure 6.8 Superimposition of SCAcLF to SC45E. SCAcLF is shown with carbon atoms 
coloured pink. SCP6B10 is shown with SC carbon atoms coloured white and the carbon 
atoms of the P6B10 coloured light green. Non-carbon atoms are in CPK colours. Red 
dashed lines represent H-bonds. The red spheres represents a crystallographic water 
molecule. 
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Figure 6.9 Dose-response curve (fitted using variable slope) of LWFB2_100E ((R)-6-
bromo-9-(2-(carboxymethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-
carboxylic acid) inhibiting the fluorescent tracer binding to the SC. Error bars represent 
± 1 standard deviation (n=2).  
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Figure 6.10 SC100E ((R)-6-bromo-9-(2-(carboxymethylamino)-2-oxoethyl)-2,3,4,9-
tetrahydro-1H-carbazole-2-carboxylic acid) bound in the subsite I of Chain A of a 
crystal of P21 space group. SC is shown with carbon atoms coloured white and the 
carbon atoms of the ligand coloured light green. Non-carbon atoms are in CPK colours. 
Wire basket represents (2mFo-DFc) electron density map contoured at 1 σ. Red dashed 
lines represent H-bonds. Red spheres represent crystallographic water molecules. 
  
 155 
Table 6.3 Data collection and refinement statistics of E. coli SC in complex with the R-
enantiomer of LWFB2_100E. 
Name SC100E 
Data collection 
Space group P21 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
80.03, 66.42, 80.79/90.00, 114.76, 90.00 
Resolution (Å) 30.00-2.25 (2.33-2.25) 
Rmerge (%) 7.1(45.6) 
No. of Reflections 116359 
Unique Reflections 37099 (3029) 
Mean I/σ(I) 16.6 (2.2) 
Completeness (%) 96.4 (82.4) 
Multiplicity 3.2 (2.6) 
Refinement 
Resolution (Å) 29.82 -2.24 (2.29-2.24) 
Rwork/Rfree (%) 18.9(21.0)/24.9(35.0) 
R.m.s deviations  
Bond lengths (Å) 0.0071 
Bond angles (º) 1.2525 
B-factors  
M. Chain 24.9 
S. Chain & Water 26.9 
Ligands* 33.8 
Ramachandran Plot Outliers 0.96 % 
The value for the highest resolution shell is given in parentheses.  
Diffraction data were collected at home-sourced X-ray generator at the 
wavelength of 1.5418 Å and were processed with HKL2000. 
*Ligands refer to the compound bound with Chain A. 
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Figure 6.11 Superimposition of SCAcALDLF to SC100E. SCAcALDLF is shown with carbon 
atoms coloured pink. SC100E is shown with SC carbon atoms coloured white and the 
carbon atoms of the LWFB2_100E coloured light green. Non-carbon atoms are in CPK 
colours. Red dashed lines represent H-bonds. Red spheres represent crystallographic 
water molecules. 
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Figure 6.12 Dose-response curve (fitted using variable slope) of LWFB2_113D ((R)-6-
bromo-9-(2-((R)-1-carboxy-2-phenylethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1H-
carbazole-2-carboxylic acid) inhibiting the fluorescent tracer binding to the SC. Error 
bars represent ± 1 standard deviation (n=2). 
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Figure 6.13 SC113D ((R)-6-bromo-9-(2-((R)-1-carboxy-2-phenylethylamino)-2-
oxoethyl)-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid) bound in subsite I of 
Chain A of a crystal of P21 space group. SC is shown with carbon atoms coloured white 
and the carbon atoms of the ligand coloured light green. Non-carbon atoms are in CPK 
colours. Wire basket represents (2mFo-DFc) electron density map contoured at 1 σ. Red 
dashed lines represent H-bonds. The red sphere represents a crystallographic water 
molecule. 
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Table 6.4 Data collection and refinement statistics of E. coli SC in complex with the R-
enantiomer of LWFB2_113D. 
Name SC113D 
Data collection 
Space group P21 
 Cell dimensions 
a, b, c (Å)/α, β, γ (°) 
79.86, 67.22, 81.07/90.00, 114.23, 90.00 
Resolution (Å) 30.00-2.05 (2.12-2.05) 
Rmerge (%) 4.2(38.2) 
No. of Reflections 175983 
Unique Reflections 50262 (4497) 
Mean I/σ(I) 27.9 (2.6) 
Completeness (%) 95.0 (90.1) 
Multiplicity 3.6 (3.2) 
Refinement 
Resolution (Å) 26.64 -2.03 (2.08-2.03) 
Rwork/Rfree (%) 23.1(27.9)/27.6(41.3) 
R.m.s deviations  
Bond lengths (Å) 0.011 
Bond angles (º) 1.5432 
B-factors  
M. Chain 22.9 
S. Chain & Water 26.5 
Ligands* 41.5 
Ramachandran Plot Outliers 0.96 % 
The value for the highest resolution shell is given in parentheses.  
Diffraction data were collected at home-sourced X-ray generator at the 
wavelength of 1.5418 Å and were processed with HKL2000. 
*Ligands refer to the compound bound with Chain A. 
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Figure 6.14 Superimposition of SCAcALDLF to SC100E. SCAcALDLF  is shown with carbon 
atoms coloured pink. SC100E is shown with SC carbon atoms coloured white and the 
carbon atoms of the LWFB2_100E coloured light green. Non-carbon atoms are in CPK 
colours. Red dashed lines represent H-bonds. Red spheres represent crystallographic 
water molecules. 
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6.4 Conclusion 
Based on the developed fragments described in Chapter 5, a lead molecule, P6B10 
that possesses an indole NH group as a synthetic handle was designed, enabling the 
design of inhibitors targeting subsite II. Our previous studies regarding linear motif 
recognition suggest that this strategy may improve ligand affinity. 
Compound P6B10 mimics the binding of the L4F5 sub-motif. The chlorine atom on 
the phenyl ring occupies the same volume as the peptide leucine side chain, and the 
cyclohexane ring occupies the space occupied by the phenylalanine side chain. The 
carboxylic group engaged in multiple H-bonds and stabilized the binding. The 
tetrahydrocarbazole scaffold leans toward the gating residue M362 and the indole 
nitrogen provides a vector pointing toward the passage to the subsite II. 
The crystal structure of P6B10 in complex with the SC suggested the preference for 
the (R)-enantiomer and thus the differences in the binding affinity of the (R)- and (S)-
enantiomers were explored. Additionally, the effects of different halogen substituents 
on the tetrahydrocarbazole scaffold were explored. The results indicate that the (R)-
enantiomer with a bromo substituent is optimal and this scaffolds containing this 
halogen were used to make derivatives at the indole NH group. 
In the complex crystal structure of (R)-P6B10 with the SC, the gating residue M362 
is in its “open” conformation. Tetrahydrocarbazole derivative LWFB2_45E was 
designed, synthesized and tested with a goal of blocking the passage between subsites. 
This compound was able to form an H-bond with the G174 carbonyl group, similar to 
the H-bond formed by SC-binding peptides. LWFB2_45E is approximately equal in 
size to the SC-binding dipeptide AcLF, reproducing the overall binding pose of AcLF in 
subsite I as well as the H-bond with G174, and demonstrated tighter binding. 
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LWFB2_100E was developed from LWFB2_45E by addition of a glycine residue. 
The carboxylate of this glycine moiety makes a salt bridge with the R152 side chain and 
may explain its high affinity (Ki = 12 µM). This carboxylate group binds in the channel 
connecting the two subsites that could be occupied by the aspartate residue of the SC-
binding pentapeptides. Thus the design mimicked the peptide binding strategy by 
reproducing the binding orientation and key interactions. 
LWFB2_113D was designed based on LWFB2_100E to further explore amino acid 
substitutions of the tetrahydrocarbazole. LWFB2_113D contains a (D)-phenylalanine 
residue that replaces the glycine residue in LWFB2_100E. The side chain of the (D)-
phenylalanine residue reached the edge of subsite II, indicating further strategies for 
optimizing the lead molecule based on the structure of LWFB2_100E. 
Both LWFB2_100E and LWFB2_113D have ~10 µM affinity, similar to the peptidic 
binders but are smaller in size, and thus possess higher ligand efficiency. They also 
possess ideal lipophilic ligand efficiency (Table 6.5) and thus suitable for further 
modifications that may increase the affinity while maintaining the drug-like profile. 
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Table 6.5 Summary data of developed fragments with the tetrahydrocarbazole scaffold. 
Plate 
No. Well CHEMISTRY IC50, µm 
Ki, 
µM 
ΔG at 
300K, 
kcal/mol 
HAC LE, kcal/mol 
LogD 
(pH 
7.2) 
ΔGlipo, 
kcal/mol 
ΔG*, 
kcal/mol LLEAT 
P6 B10 
 
299 166 -5.21 17 0.31 0.51 -0.70 -4.51 0.38 
n/a LWFB1_89B 
 
6084 3380 -3.41 17 0.20 2.64 -3.64 0.23 0.10 
n/a LWFB1_93C 
 
2656 1476 -3.90 17 0.23 0.63 -0.87 -3.03 0.29 
n/a LWFB1_91B 
 
1417 787 -4.28 18 0.24 3.91 -5.39 1.11 0.05 
n/a LWFB1_94B 
 
2492 1384 -3.94 18 0.22 3.91 -5.39 1.45 0.03 
N
H
Cl
O
OH
N
H
Cl
O
N2H
N
H
Cl
O
OH
N
H
Cl
O
O
N
H
Cl
O
O
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n/a LWFB2_45E 
 
361 201 -5.10 21 0.24 -0.75 1.03 -6.12 0.40 
n/a LWFB2_63B 
 
442 246 -4.98 17 0.29 0.51 -0.70 -4.28 0.36 
n/a LWFB2_62B 
 
134 74 -5.69 17 0.33 0.51 -0.70 -4.99 0.40 
n/a TOMFB1-24 
 
557 309 -4.84 17 0.28 -0.11 0.16 -4.99 0.40 
n/a TOMFB1-25 
 
145 81 -5.64 17 0.33 0.83 -1.14 -4.50 0.37 
n/a TOMFB1-30 
 
196 109 -5.46 17 0.32 1.45 -1.99 -3.47 0.31 
n/a LWFB2_70C 
 
  
 
368 204 -5.09 21 0.24 -0.75 1.03 -6.11 0.40 
N
Cl
O
OH
O
N2H
N
H
Cl
O
OH
N
H
Cl
O
OH
N
H
F
O
OH
N
H
Br
O
OH
N
H
IO
OH
N
Cl
O
NH2
O
OH
 165 
n/a LWFB2_79C 
 
  
 
888 493 -4.56 21 0.22 -0.75 1.03 -5.58 0.38 
n/a LWFB2_83B 
 
328 182 -5.15 17 0.30 0.83 -1.14 -4.02 0.35 
n/a LWFB2_86B 
 
204 113 -5.44 17 0.32 0.83 -1.14 -4.30 0.36 
n/a LWFB2_88C 
 
347 193 -5.12 23 0.22 0.01 -0.01 -5.11 0.33 
n/a LWFB2_81D 
 
85 47 -5.96 25 0.24 -4.76 6.55 -12.51 0.61 
n/a LWFB2_100E 
 
21 12 -6.80 25 0.27 -4.63 6.37 -13.17 0.64 
n/a LWFB2_98C 
 
362 201 -5.10 31 0.16 0.20 -0.28 -4.81 0.27 
N
Cl
O
NH2
O
OH
N
H
Br
O
OH
N
H
Br
O
OH
N
Cl
O
OH
O
N
H
COOH
N
Cl
O
OH
O
N
H
COOH
N
O
OH
O
N
H
Br
N
O
OH
O
N
H
Cl
O
NH2
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n/a LWFB2_104C 
 
150 83 -5.62 35 0.16 1.23 -1.69 -3.93 0.22 
n/a LWFB2_114C 
 
171 95 -5.54 25 0.22 -1.79 2.47 -8.01 0.43 
n/a LWFB2_108B 
 
208 116 -5.43 28 0.19 -1.00 1.38 -6.80 0.35 
n/a LWFB2_113D 
 
30 17 -6.59 32 0.21 -3.19 4.39 -10.97 0.45 
n/a LWFB3_05C 
 
32 18 -6.55 32 0.20 -3.19 4.39 -10.93 0.45 
n/a 
TOMFB1-51 
 
 
48 27 -6.30 29 0.22 -3.57 4.92 -11.23 0.50 
N
Br
O
OH
O
N
H
NO
O
N
Br
O
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O
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O
N
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Chapter 7  
Discussion 
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There is an indisputable need for new classes of antibiotics acting through new 
targets. Therefore, the identification of new compounds acting against novel bacterial 
targets is of great interest. The aim of the work described in this thesis was to develop 
small-molecule inhibitors of the E. coli SC as a critical component of the bacterial DNA 
replication and repair machinery. Such inhibitors may serve as a novel class of 
antibiotics with a novel mechanism of action. Since bacterial SCs appear to have 
conserved structures,30,31,37 potent SC inhibitors could demonstrate broad-spectrum 
activity. The SC functions by recognizing various LMs in binding partner proteins and 
thus the binding mechanism was studied. Understanding of the LM binding mechanism, 
together with structural data from fragment screening guided the design of inhibitors. 
Several inhibitors mimicked the binding mode of the LMs with superior affinity.  
7.1 The mechanism of LM recognition by the E. coli SC shed lights on ligand 
design 
LMs are frequently observed to mediate critical protein-protein interactions during 
signalling, cell proliferation and other regulatory processes. An on-line database called 
ELM (http://elm.eu.org/) contains biochemical and sequence data for a large number of 
eukaryotic linear motifs (of 4-20 residues) and their interacting partners. Despite being 
widely observed in nature, the binding processes of LMs by their receptors are poorly 
understood due in part due to LMs being disordered prior to binding.111  
LM recognition by the E. coli SC of the bacterial DNA replication machinery was 
examined. The E. coli SC mediates replisome formation and other interactions via 
recognition of LMs in various binding partners. Using the techniques of 
biochemistry/biophysics, molecular dynamics simulations and X-ray crystallography, a 
structural and thermodynamic dissection of the optimally-binding peptide  
Ac0Q1L2D3L4F5 binding to the E. coli SC was performed. Interactions made by -Q1- and 
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-L4F5 were found to be important structural determinants of LM recognition by the SC. 
Molecular dynamics simulations supported the hypothesis that the binding free-energy 
is diminished by the loss of conformation entropy as a result of peptide binding and 
deformation. Similar conformational entropy loss upon ligand binding was observed in 
the computational study of an HIV-derived PTAP-containing nonapeptide binding to 
the Tsg101 ubiquitin E2 variant domain.111  Fong and co-workers performed a large-
scale computational study of intrinsically disordered regions in proteins-protein 
complexes using hundreds of different protein complexes, suggesting that disordered 
peptides becoming structured upon binding is a fairly common phenomenon.95 The 
energetic profile of pentapeptides binding to the E. coli SC therefore appears to be 
typical of LM-binding and the observations reported here may assist in the 
understanding of interactions involving LMs generally.  
An anchor-based model of sequential binding of peptides to the SC was proposed: 
the -L4F5 sub-motif acts as the anchor, establishing the initial contact with SC subsite I, 
followed by the formation of a hydrogen-bonding network between the flanking 
residues and subsite II to stabilize the interaction. This model is supported by steered 
molecular dynamics simulations and crystal structures of the SC in complex with the 
dipeptide AcLF. A gating residue, M362, separates subsite I from subsite II and 
displayed alternate open and closed conformations depending on ligand binding. In the 
structure of the SC/AcLF complex, the open conformation of the M362 gating residue 
was observed. This dipeptide was proposed to represent the minimal binding element. 
Biochemical measurements established that the -Q1L2- sub-motif could not bind in the 
absence of -L4F5. SMD calculations suggested that the -Q1L2- sub-motif only binds after 
binding of the -L4F5 sub-motif. To account for this apparent sequential binding, the 
almost-buried polar atoms (ABPAs) of subsite II were proposed to create a kinetic 
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barrier to the binding of the peptide -Q1- residue. Steered molecular dynamics 
simulations were used to create a profile of the kinetic barrier. 
The anchor-based model of sequential binding offers an insight into the LM 
recognition by the E. coli SC and potentially LM-binding in general. A similar model 
was proposed to account for a very similar case: Lacy and co-workers found that a 
conserved RxLFG motif of p27 establishes the first contact with cyclin A followed by 
folding of the disordered region containing this hydrophobic motif, likely due to the 
lower barrier of dehydration as compared to the rest of the sequence.106 These 
observations suggest that sequential binding is guided by hydrophobic motifs, and that 
this may be a common feature in LM recognition. 
7.2 Fragment-based screening of binding inhibitors of the E. coli SC by X-ray 
crystallography 
A fragment-based screen of the SC by X-ray crystallography was undertaken to find 
fragment-like compounds binding to the LM-binding pocket. A total of 352 fragment 
compounds were screened by X-ray crystallography and in addition to several pseudo-
hits and partial hits, four fragment compounds (ZT0602, ZT0250, ZT0447 and ZT0445) 
were identified as valid hits with distinguishable electron density in 2mFo-DFc maps 
that unambiguously revealed their binding poses.  
All fragment hits were found to occupy subsite I of the binding pocket. This is 
consistent with the sequential binding model of LM recognition by the SC, where the 
subsite I serves as the “anchor site”, and must be occupied prior to subsite II. All hits 
had aromatic ring(s) bound at the deep region of subsite I that accommodates the 
leucine side chain of the LF sub-motif frequently found in the SC-binding LMs.  
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The fragment hits were estimated to bind to the SC with dissociation constants in the 
millimolar range. The binding affinity cannot be accurately measured since the 
compound solubility capped the measurable range of inhibitor concentrations.  Ligand 
occupancy of the fragments were used to estimate the approximate Kd based on the 
temperature factors of a ligand atom relative to the closest receptor atom (the SC) (See 
Chapter 3). In turn, the occupancy was used to estimate the approximate Kd as the 
affinity in crystallo. The calculated Kd values also suggested millimolar Kd affinity for 
all fragment hits and further analysis of their lipo-ligand efficiency provided aid in 
decision of which fragment to be entered into the next round of development. 
7.3 Fragment growth and lead development aided with X-ray crystallography 
Three strategies, expansion, merging and tethering, were used to grow fragments. 
Molecular docking was used as a tool to explore the plausible binding poses of inhibitor 
candidates retrieved from the online compound library UCSF ZINC136 by similarity and 
substructure searches based on the fragment hits. Although docking failed to identify a 
binder with superior affinities, it nevertheless led to the discovery of four scaffolds: the 
biphenyl scaffold, the phenylpiperazine scaffold, the carbazole scaffold and the 
tetrahydrocarbazole scaffold. Binding of compounds from these four classes to the SC 
was observed by X-ray crystallography. Only the biphenyl scaffold and the 
tetrahydrocarbazole scaffold occupied all of subsite I. The biphenyl and 
tetrahydrocarbazole derivatives had superior binding affinity for subsite I, as 
demonstrated by the inhibition of the fluorescent tracer binding to the SC compared 
with the other two scaffolds. The phenylpiperazine derivatives are half-buried in subsite 
I and half-exposed in bulk solvent. Only the carbazole derivatives occupied the deep 
region of subsite I. 
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The biphenyl scaffold had few desirable commercially available derivatives and 
these were not explored further. Nevertheless, the crystallographic binding pose of the 
only hit with the biphenyl scaffold, P1B8, presented a rationale for extending other hits 
to the shallow region of the subsite I (Figure 5.1 and 5.2). The extensive salt-bridge/H-
bonds P1B8 forms with adjacent residues are the key for both binding in the shallow 
region and the affinity. 
The tetrahydrocarbazole scaffold, exemplified by compounds P3E2 and P5bH1, was 
considered to be a more promising structure whose shape complements the slight “S” 
shaped curve of subsite I due the flexibility of the cyclohexane ring. The cyclohexane 
ring was observed to partially occupy the shallow region, and substitutions on this ring 
were postulated to result in additional H-bond interactions with residues Y154 and 
R152. These interactions were demonstrated by the binding of P5bH1, containing a 
carboxylic acid on the cyclohexane ring, to the SC. (The addition of this functional 
group resulted in the creation of a new chiral centre.) A structural feature contributing to 
affinity of P3E2 is the formation of H-bonds between the carboxylic acid group and the 
side chain of S346, greatly contributing to its binding affinity. Likely as the result of 
these features, the Ki values for P3E2 and P5bH1 are significantly lower than the other 
carbazole and tetrahydrocarbazole derivatives tested. 
Tetrahydrocarbazole derivative P6B10 was designed based on the structures and 
binding poses of P1B8, P3E2 and P5bH1. The crystal structure of P6B10 in complex 
with the SC suggested the (R)-enantiomer was preferred and thus the differences in the 
binding affinity of the (R)- and (S)-enantiomers were explored. The effects of different 
halogen substituents on the tetrahydrocarbazole scaffold were also explored. The results 
suggested superior affinity of the (R)-enantiomer with a bromine substituent. The 
resulting molecule, P6B10, was then used as a lead scaffold for derivatization of the 
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indole NH group. It was postulated that derivatives of the indole-functionalized branch 
could occupy the channel connecting the two subsites. 
A tetrahydrocarbazole derivative, LWFB2_45E, was designed containing an amide 
derivative at the indole nitrogen. It was observed to form an H-bond with the G174 
carbonyl group, similar to the H-bond formed between the backbone amide group of 
residue -D3- of the consensus peptide and residue G174. LWFB2_45E is approximately 
equal in size to SC-binding dipeptide AcLF, reproducing the overall binding pose of 
AcLF in subsite I as well as the H-bond with G174, but with tighter binding. A further 
modification, addition of a glycine to the amide was made (LWFB2_100E) and the C-
terminal carboxylate of this glycine moiety was observed to form a salt bridge with the 
R152 side chain and may explain its high affinity (Kd ~ 12 µM). This carboxylate group 
binds to the channel connecting the two subsites that would be occupied by consensus 
peptide residue -D3-. Thus the design further mimicked the peptide binding strategy by 
reproducing the binding orientation and key interactions. 
LWFB2_113D was designed based on LWFB2_100E to add additional features of 
the consensus peptide. LWFB2_113D contains a (D)-phenylalanine residue replacing 
the glycine residue in LWFB2_100E. The side chain of the (D)-phenylalanine residue 
reached the edge of subsite II, lying adjacent to the side chain of M362. Future 
optimization includes a screening of (D)-enantiomers of amino acids that can be 
incorporated into the lead molecule based on the structure of LWFB2_100E, and thus 
could result in a compound that binds to both subsites I and II. 
7.4 Future directions 
The optimal binding inhibitors LWFB2_100E and LWFB2_113D have Kd ~10 µM 
affinity with potential for further increases in affinity. Future developments will focus 
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on growing the best compounds so as to target subsite II by reproducing the critical H-
bond network of peptide ligands. The two small-molecule inhibitors possess ideal 
lipophilic ligand efficiency and are thus suitable for further modification with the aim of 
increasing affinity while maintaining a drug-like profile. 
Future work could include lead optimization as well as structural characterization to 
guide design. Functional assays (e.g. as described by Jergic and co-workers)140 will be 
valuable in correlating the inhibition of peptide binding by the FP assay to inhibition of 
in vitro DNA replication. Anti-bacterial testing will be used to measure the efficiency of 
those SC inhibitors as novel antibiotics. Once in vitro and/or in vivo efficacy was 
established for the developed compounds, further medicinal optimization may be 
carried out to improve ligand affinity and thus drug efficiency. 
The current work used the E. coli SC as the model target because it is easy to express, 
purify and crystallize, and it is structurally conserved across species. However, small 
differences may exist in the constitution of the SC binding pocket in different species. 
Investigation of inhibitors against a variety of bacterial strains and their isolated SC 
proteins may further our knowledge of the potential of SC inhibitors as broad-spectrum 
antibiotics.  
Successes in fragment-based drug design targeting protein-protein interactions are 
relatively few compared with enzymes. An example of success in this area was 
fragment-based screening of heat shock protein 90 (Hsp90) using NMR, ITC and X-ray 
crystallography.141,142 Hsp90 is a molecular chaperone for modulating protein stability 
and a key component in the heat shock response.143,144 Over-expression of Hsp90 is 
related to carcinogenesis and can be found in various cancer types.145-147 The inhibition 
of Hsp90 has been a popular area of research interests during the last decade and 
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progress had been made in diversifying inhibitor chemotypes.148 An aminopyrimidine 
fragment was found and the crystal structure of its complex with Hsp90 guided 
optimization toward leads with nanomolar potency and sound ligand efficiency. The 
development started with the fragment hit's complex crystal structure with Hsp90 by 
filling the proximal lipophilic pocket which was achieved by substitution on the upper 
phenyl ring with small groups. Ligand efficiency was monitored along the way to the 
finding of a potent lead, which adopts the same orientation of the starting fragment 
while the interactions are maintained. The work presented here used similar methods 
(i.e. X-ray crystallography) to identify the fragment hits, and a similar strategy in 
expanding the fragments to larger lead-like molecules, including monitoring and 
retaining LLE. Our design effort differed with respect to Hsp90 inhibitor development 
in the way that the E. coli SC binding pocket is separated into two subsites. This 
complicated the inhibitor development effort and demanded an in-depth investigation of 
the binding mechanism of peptides, which in turn guided the design of small-molecule 
inhibitors. 
Another example of the use of fragment screening in the development of PPI 
inhibitors was the development of compounds to block the interaction of interleukin-2 
(IL-2) with its receptor (IL-2R). This interaction stimulates T-cell proliferation, and is 
thus involved in the T-helper 1 (Th1) immune response.149,150 Arkin et al. discovered a 
small-molecule inhibitor of IL-2 and the structure of its complex with IL-2 served as the 
basis of fragment-based design.68 This compound underwent modification by 
substructure replacement and new lead series was subject to fragment tethering.151 In 
the tethering approach, a library of fragments containing sulfhydryl groups are screened 
against a protein target containing cysteine residues (usually introduced by  point 
mutantion). Under appropriate redox conditions, fragments with optimal interactions 
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with the target binding site will undergo disulfide exchange, forming mixed disulfides 
with the target, and may be detected by mass spectrometry. Hits against IL-2 were 
merged to the lead structure and resulted in 5-50-fold improvements in potency over the 
starting scaffold. The underlying principles of this strategy and efforts to extend the 
tetrahydrocarbazole scaffold to subsite II by derivatization on the indole NH group are 
similar: a single fragment is not enough for measurable binding to an obstructed or 
hidden pocket, which can be energetically unfavourable. Therefore, fusing them to 
either the residues near the expected binding pocket or an existing binder may overcome 
the energy barrier and produce net increased affinity.  
A tethering strategy could be used to improve our SC inhibitors. Specifically, a 
tetrahydrocarbazole scaffold similar to LWFB2_113D but with (D)-cysteine in place of 
(D)-phenylalanine (see Chapter 5), may serve as parent compound that is subject to 
disulfide exchange with sulfhydryl-containing fragments in order to find those that 
occupy subsite II as suggested by the binding pose of LWFB2_113D. 
In summary, the work presented here adds to the growing number of successful cases 
of inhibitor development against protein-protein interactions. Similar to the fragment-
based development of Hsp90 and IL-2 inhibitors, the affinity of the SC inhibitors was 
improved from millimolar to low-micromolar range. Expansion was used as the design 
strategy, but the idea of merging and tethering also inspired the design of P6B10 and the 
effort to target subsite II. A thermodynamic elucidation of the nature of LM/SC 
interaction was undertaken and the insights gained from this study guided the design of 
small-molecule inhibitors. Such strategies of mimicking the physiological protein-
protein/protein-ligand interaction with synthetic compounds should be applicable to 
medicinal design in general. 
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Appendix Table 1. The First-Pass Screen library from Zenobia Therapeutics chosen as the fragment library for screening (Plate 1). 
 
P1 1 2 3 4 5 6 7 8 9 10 11 12 
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Appendix Table 2. The First-Pass Screen library from Zenobia Therapeutics chosen as the fragment library for screening (Plate 2). 
P2 1 2 3 4 5 6 7 8 9 10 11 12 
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Appendix Table 3. The First-Pass Screen library from Zenobia Therapeutics chosen as the fragment library for screening (Plate 3). 
P3 1 2 3 4 5 6 7 8 9 10 11 12 
A 
54 
 
57 
 
173 
 
267 
 
212 
 
272 
 
273 
 
357 
 
358 
 
356 
 
370 
 
371 
 
B 
262 
 
265 
 
266 
 
312 
 
268 
 
305 
 
316 
 
441 
 
442 
 
443 
 
652 
 
582 
 
C 
303 
 
308 
 
435 
 
437 
 
438 
 
439 
 
440 
 
462 
 
463 
 
627 
 
628 
 
669 
 
D 
432 
 
434 
 
584 
 
585 
 
622 
 
623 
 
635 
 
625 
 
626 
 
680 
 
699 
 
686 
 
E 
546 
 
589 
 
600 
 
601 
 
633 
 
634 
 
693 
 
642 
 
696 
 
725 
 
701 
 
716 
 
F 
563 
 
609 
 
621 
 
630 
 
691 
 
692 
 
749 
 
695 
 
748 
 
740 
 
763 
 
764 
 
G 
687 
 
688 
 
689 
 
690 
 
757 
 
758 
 
759 
 
760 
 
761 
 
762 
 
785 
 
786 
 
H 
782 
 
784 
 
726 
 
791 
 
804 
 
805 
 
807 
 
808 
 
817 
 
818 
 
819 
 
820 
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 Appendix Table 4. The First-Pass Screen library from Zenobia Therapeutics chosen as the fragment library for screening (Plate 4). 
 
P4 1 2 3 4 5 6 7 8 9 10 11 12 
A 
372 
 
373 
 
478 
 
698 
 
723 
 
724 
 
739 
 
746 
 
N/A N/A N/A N/A 
B 
861 
 
647 
 
694 
 
705 
 
733 
 
738 
 
745 
 
747 
 
N/A N/A N/A N/A 
C 
703 
 
675 
 
708 
 
709 
 
742 
 
744 
 
765 
 
771 
 
N/A N/A N/A N/A 
D 
707 
 
718 
 
731 
 
732 
 
766 
 
769 
 
772 
 
773 
 
N/A N/A N/A N/A 
E 
729 
 
730 
 
754 
 
750 
 
796 
 
801 
 
802 
 
803 
 
N/A N/A N/A N/A 
F 
787 
 
788 
 
789 
 
790 
 
809 
 
863 
 
813 
 
814 
 
N/A N/A N/A N/A 
G 
792 
 
793 
 
794 
 
795 
 
827 
 
860 
 
834 
 
835 
 
N/A N/A N/A N/A 
H 
821 
 
823 
 
828 
 
826 
 
848 
 
850 
 
851 
 
852 
 
N/A N/A N/A N/A 
